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Summary 
 Liver transplantation has been a major scientific and clinical breakthrough in the 20
th
 
century for many patients with nonmalignant and malignant liver diseases. However, 
there is a worldwide shortage of available organs; and many patients therefore deterio-
rate or die while on the waiting list. One path-breaking solution to these problems is the 
development of extracorporeal bioartificial livers (EBALs) and BALs, which essentially 
are bioreactors with embedded hepatocytes (liver cells) that perform the functions of a 
normal liver. The purpose of EBAL devices is not to permanently replace liver func-
tions, but to serve as a supportive device, either allowing the liver to regenerate properly 
upon acute liver failure, or to bridge the individual's liver functions until a transplant is 
possible. Several types of BALs are being developed, including hollow fiber systems 
and flat membrane sheet systems with primary porcine hepatocytes, primary human 
hepatocytes, human hepatoblastoma (C3A), immortalized human cell lines and stem 
cells. However special attention needs to be paid to identifying a readily available and 
functional source of cells and to improving hepatocyte functionalities. Furthermore, 
bioreactor configurations that are not hollow-fiber based should be considered to 
improve both large-scale cell culture prior to therapy and mass transfers during treat-
ment.  
This thesis was a part of a EU project ‘NanoBio4Trans’, with the overall goal to 
combine induced pluripotent stem cells (iPSC), polymer hybrid bioactive scaffolds and 
biosensor technologies to develop BAL as an extracorporeal device and to perform 
biomedical research beyond the present state-of-the-art. One of the major challenges in 
producing large scale engineered tissue is the inability to create large, highly perfused 
scaffolds, in which cells can grow at high cell density and viability. In this project we 
explored several routes to create such large scaffolds with blood vessel-like networks. 
Such porous scaffold network helps the cells to adhere, proliferate and perform its 
biochemical functions for long periods. In fact we need to build two independent 
networks where one network will be "blood" while the other will take care of removing 
the waste. In nature, waste is collected and secreted into the intestine as bile, which 
essential means that the cells should be sandwiched between two fluidic networks. 
With the aim of developing a process which is scalable, compatible with cell 
culture, rapid, and inexpensive, we explored the capability of a commercial 3D filament 
printer for printing of polyvinyl alcohol (PVA) as a sacrificial mould and a polymer 
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casting process to generate various large scale tissue engineering constructs with single 
pore geometry with the desired mechanical stiffness and porosity. In addition, a new 
technique was developed to fabricate dual-pore scaffolds for various tissue-engineering 
applications where 3D printing of the PVA mould was combined with a salt leaching 
process. In this case, the sacrificial PVA mould, defining a structured network- architec-
ture of micro-channels, was filled with salt crystals to define random porous regions 
between the structured regions of the scaffold. The compatibility of fabrication methods 
were tested with various biocompatible synthetic polymers such as polydimethylsilox-
ane (silicone), poly(ϵ-caprolactone) and poly(2-hydroxyethyl methacrylate), but other 
natural and synthetic materials can also be adopted to this process. The in-vitro biocom-
patibility of the fabricated scaffolds was successfully tested with HepG2 cells. To 
demonstrate the potential of scaffolds to release drugs and hereby control the behavior 
of cells growing on its surface, the silicone elastomer based perfusable capillary net-
work scaffolds, generated from previous steps, was exposed to supercritical CO2 in the 
presence of a hydrogel to create an additional interpenetrating network (IPN) of hydro-
gel nanodeposits. Biocompatible IPNs of silicone elastomer with poly(2-hydroxyethyl 
methacrylate) (pHEMA) and Poly(ethylene glycol) methylether acrylate (PEGMEA) 
hydrogel 3D scaffolds were produced in this way. The model drug doxycycline was 
loaded into the hydrogel of the IPN materials, and the biological activity of released 
doxycycline was tested using a doxycycline regulated green fluorescent reporter gene 
expression assay in HeLa cells. Additionally, decellularized liver extracellular matrix 
(ECM) and natural silk protein materials have been developed and tested for enhancing 
the differentiation of hiPSC-derived hepatocytes and fabricating biodegradable scaffolds 
for in-vivo tissue engineering applications.  
Along with various scaffolds fabrication methods we finally presented an optimized 
study of hepatic differentiation of hiPSC-derived DE cells cultured for 25 days in a 3D 
perfusion bioreactor system with an array of 16 small-scale tissue-bioreactors with 
integrated dual-pore pore scaffolds and flow rates. Hepatic differentiation and function-
ality of hiPSC-derived hepatocytes were successfully assessed and compared against 
freshly obtained human precision-cut liver slices (hPCLS) as an ex vivo liver representa-
tive model as gold standard, developed by other project partners. 
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Resumé  
Udviklingen af levertransplantationer er et kæmpe videnskabeligt gennembrud, der har 
haft stor indflydelse på livskvaliteten og overlevelseschancerne for mange leverpatien-
ter. Donorlevere er desværre en mangelvare, og mange leverpatienter dør derfor inden 
en lever er tilgængelig. Én banebrydende løsning på dette problem er at udvikle og 
benytte en kunstig lever (bioartificial liver, BAL), der, forsimplet, er en bioreaktor 
bestående af hepatocytes (leverceller), der biologisk set fungerer som en rigtig lever. I 
tilfældet af en extracorporeal bioartificial liver (EBAL) er det ikke målet at erstatte en 
rigtig lever, men at stabilisere patienten indtil at patientens lever har kommet sig (akut 
leversvigt) eller til at en donorlever bliver tilgængelig.  
Dette projekt var en del af et EU-projekt, NanoBio4Trans, hvis overordnede mål var at 
kombinere stamceller med inducerede pluripotente stamceller (induced pluripotent stem 
cells, iPSC), bioaktive ”scaffold” af polymer, og teknologier fra biosensorer til at 
udvikle en ”extracorporeal” kunstig lever. En stor begrænsning for udviklingen af 
kunstige organer er at skabe store porøse ”scaffold” hvor celler kan trives i høj tæthed 
uden at opbygge affaldsstoffer eller løbe tør for næring. I projektet er kommercielle 3D 
filamentprintere blevet benyttet, da disse er hurtige, billige og fleksible. Specifikt er der 
i projektet blevet udviklet en 3-trins produktionsmetode, der involvere (1) 3D-print af 
vandopløselig polyvinyl alkohol (PVA) i den ønskede kanalgeometri, som derefter (2) 
fungerer som form for den færdige platform, der fx støbes i polydimethylsiloxane 
(PDMS). Herefter (3) opløses offermaterialet (PVA) og ”scaffolden” er færdig. For at 
opnå variationer i porøsitet blev der benyttet kombinationer af 3D-printet PVA og 
saltkrystaller som offermaterialer, hvor PVA-geometrien definerede ”scaffoldens” 
overordnede udformning, mens saltkrystallerne definerede områder med høj porøsitet 
og stokastisk natur. Ud over PDMS blev materialerne poly(ϵ-caprolactone) og poly(2-
hydroxyethyl methacrylate) testet som platforms-materiale, men andre naturlige og 
syntetiske materialer kan også anvendes. Specifikt er også blevet eksperimenteret med 
at støbe platformene i naturlige materialer så som cellefrit extracellular matrix (ECM) 
og silkeprotein. ”Scaffoldens” in-vitro biokompabilitet blev testet med HepG2 celler.  
For at styre cellernes vækst på de producerede ”scaffolds” blev der udført eksperimenter 
med absorption og desorption af medikamenter i og fra ”scaffolden”: De færdige 
”scaffold” blev eksponeret til superkritisk CO2 samt doxycyclin og en sekundær hy-
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drogel. Dette resulterede i at den oprindelige ”scaffold” blev gennemtrængt af strukturer 
bestående af den sekundære hydrogel og doxycyclin.  
Celler dyrket på disse ”scaffolds” er slutteligt blevet sammenlignet med virkelige 
leverprøver, og der er observeret stor lighed. 
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1.  CHAPTER 1. Introduction: Scope of the 
Thesis 
 
The loss or failure of an organ or tissue is one of the most frequent, devastating, and 
costly problems in human health care [1]. Organ transplantation has been a major 
scientific and clinical breakthrough in the 20
th
 century, in spite of many associated 
problems, such as lack of organ donors and/or rejection of the transplanted organs and 
life-long heavy medication with considerable side effects. To circumvent these prob-
lems, the innovative therapeutic approach of the 21th century is focusing on bioartificial 
organs using a multidisciplinary and complementary approach with the long-term goal 
of achieving better treatment Liver failure results from the liver’s inability to perform its 
normal functions. In acute liver failure (ALF) [2], liver function is normal 2–8 weeks 
before the onset of the disease. In acute-on-chronic liver failure (ACLF), liver function 
decreases abruptly in a patient already suffering from chronic liver insufficiency. 
Extracorporeal liver support system (LSS) have been developed to either bridge patients 
to liver transplantation or to allow the recovery of the native liver from injury. There are 
two types of LSSs: artificial livers (ALs) and bioartificial liver (BALs). AL devices use 
physical/chemical gradients and adsorption with anion- or cation-exchange columns or 
sorbent suspensions to cleanse the blood or plasma of its toxins. Detoxification alone is, 
however, not sufficient to replace liver function, as there are at least 500 different 
functions that the healthy liver organ performs. Therefore, extracorporeal BAL (EBAL) 
would be ideal for substitution of many physiologically relevant functions such as 
biosynthesis, metabolism, and detoxification. An EBAL is a cell-based system (a 
bioreactor) which performs most of the hepatic functions lacking in patients with liver 
failure (oxidative detoxification, biotransformation, excretion and synthesis). EBALs 
should be designed for the individual patient’s needs and long-term maintenance of 
hepatocyte differentiated functions in vitro. EBALs should be reproducible, automata-
ble, controllable, and compliant with clinical applications.  
1.1 Various extracorporeal liver support systems 
One of the technical challenges is ex vivo culturing of large masses of cells in a suitable 
environment while maintain all major cellular functions. Since hepatocytes are anchor-
age-dependent cells, various biomaterials for in vitro hepatocyte culture such as 
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membrane, microcarriers, polymeric matrix, or scaffold have been incorporated in 
EBAL design for cell attachment. There are mainly four different EBAL configurations 
under current investigation: (1) hollow fiber cartridges, (2) packed-bed systems, (3) 
encapsulation systems, and (4) flat plate systems, some of which are under clinical 
testing[3].  
Table 1. Summarizes bioreactor configurations and designs [4]. 
 
I. Hollow fiber systems[5,6] are most commonly used: generally, they consist of a 
cylindrical column with hundreds of thousands of hollow fibers aligned longitudinally 
through the column. Cells are cultured outside the hollow fiber while culture medium or 
patient’s blood/plasma is perfused in the fiber lumen along the hollow fiber.  
II. Packed bed systems: The matrix for hepatocyte attachment is filled into the reactor, 
which is perfused with medium or the patient’s blood/plasma. Various packing materi-
als for hepatocyte entrapment, such as microchanneled polyurethane foam [7], polyvinyl 
resin cubes [8], alginate beads [9], porous hydroxyapatite beads [10], and polyester 
fabric cell scaffold
 
[11]
 
have been explored.  
III. Encapsulation system: Hepatocytes are enveloped in a polymeric matrix to form a 
small capsule. The encapsulated hepatocytes are then packed into a chamber for perfu-
sion. Various materials have been used for hepatocyte encapsulation, including 
hydrogels [12], alginate [13], and copolymers such as hydroxyethyl methacrylate-
methyl methacrylate (HEMA-MMA) [14]. There is some evidence indicating that 
spheroids enhance cell-cell interaction [15] and facilitate the formation of bile-duct 
structure between cells, improving cell functions. In some of these systems, hepatocyte 
spheroids are thus formed before entrapment in a capsule [3].  
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IV. Flat-plate systems: Hepatocyte monolayer culture on a substrat such as collagen, 
laminin, fibronectin, or Matrigel is a common in vitro method. Overlay of a matrix gel 
layer on top of a monolayer culture, forming a sandwich configuration, stabilizes the 
hepatocytes’ cuboidal structure. The establishment of hepatocyte polarity and mainte-
nance of differentiated functions for several weeks can thus be achieved[16,17]. 
1.2 Sources of hepatocytes for large scale EBALs 
Hepatocytes are highly polarized cells that have a unique position as a barrier between 
the blood and the bile, and the substances trafficking between sinusoids and bile cana-
liculi predominantly rely on this cell polarity. The generation of hepatocyte polarity 
involves: (1) the establishment of cell-cell and cell-matrix interactions, (2) the organisa-
tion of cytoskeleton, and (3) the sorting and localisation of membrane proteins. The 
maintenance of normal liver function in a patient can be satisfied with about 20% of the 
whole liver mass, approximately 200 g (2 x 10
10 
hepatocytes). The LSS to date make 
use of cryopreserved or freshly isolated human or porcine-derived hepatocytes and cell 
lines at 100-600 g. 
1) Primary human hepatocytes are the ideal cells for EBAL with benefits including 
better biosafety and a satisfactory level of hepatic biofunctionality, particularly the 
ability to provide homologous biologically active substances[18]. Primary human 
hepatocytes, however, are scarce, do not proliferate in vitro, and normal functions 
cannot be maintained in vitro for longer than 1 or 2 weeks. Moreover, great variation in 
functional performance between different cell batches[19] has been seen, and there is 
also a risk for contamination with viruses, bacteria, and tumor cells[20]. 
2) Primary porcine hepatocytes are the preferred and the most widely used animal-
derived liver cells for EBALs due to their convenient availability, low cost, and well-
established isolation methods. However, there are a number of drawbacks, such as (1) 
they present xenogenic antigens to the human body and can thus cause immune re-
sponse during treatment; and (2) the potential danger of transfection with Pig 
endogenous retrovirus (PERV) common in pigs. 
3) Human liver cell lines, with the C3A cell line permitted for use in EBAL systems. 
Cell lines have the major advantage that they can be obtained in large amounts continu-
ously and reproducibly; however, there are some serious drawbacks. For example, 
compared to primary porcine hepatocytes, C3A has a lower metabolic capability partic-
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ularly with respect to ammonia, an important reason why some EBAL systems using 
C3A have not been able to obtain significant efficacy in clinical treatment. 
4) Co-cultures: In a normal liver tissue, the cell-cell, cell-extra-cellular matrix (ECM), 
and cell-microenvironment interactions have been widely explored and acknowledged 
for their major role in the maintenance of hepatic functions. Several studies have 
therefore aimed to simulate the physiological organization of liver tissue by recruitment 
of the non-parenchymal cells (NPC) into EBALs, and shown that the hepatic functions 
could be preserved for longer in the co-culture systems[21–24]. Ohno et al.[22,25] 
found that in the hepatocyte-endothelial cell sheets layered co-culture system, drug 
metabolism related gene expression is better preserved than in hepatocyt cultures alone, 
and the ECM molecular composition and cell-adhesion molecules changes in the system 
correlate with genes expression in a time-course pattern. The study suggested that the 
co-culture system can generate beneficial ECM to maintain the hepatic function in vitro. 
To ensure the availability of an EBAL at any desired time, cryopreserved hepatocytes 
have been suggested as first choice; however, the recovery of viability after thawing is 
still problematic. Hepatocytes are anchor-dependent cells and their maintenance de-
pends on the support from ECM and cell-cell communication[26]. Cryopreservation 
configurations such as monolayer collagen, sandwich collagen, microcarrier, and 
microcapsule stock of hepatocytes have shown better post-thawing viability and func-
tion than the suspension cell cryopreservation. 
However tissue engineering and stem cell biology have uncovered groundbreaking 
opportunities for cellular re-programming, i.e., some cell types can be changed into a 
pluripotent stem cell (PSC) by over-expressing key transcription factors. These, so 
called induced pluripotent stem cells (iPSC) [27] share the two key characteristics with 
embryonic stem cells (eSC): self-renewal and pluripotency (i.e. they can differentiate to 
form any cell type in the human body). Crucially they are generated from adult cells 
circumventing many ethical concerns associated with using human eSC. Therefore 
discovery of human iPSC (hiPSC) enables the growth of an almost unlimited supply of 
a patient´s own cells, potentially conferring the ability to grow and regenerate tissues 
and organs[28] from ‘self’, which is envisaged to resolve many organ rejection related 
issues[27,29]. Similarly, recent developments in material science and nanobiotechnolo-
gy have produced engineered materials and devices that can be manipulated to control 
the physical and chemical properties, resulting in unique functional or analytical proper-
ties. The fusion of these fields with resulting synergistic effects will open up yet 
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unexplored scientific possibilities. The NanoBio4Trans project is fully addressing the 
current needs related to the future of BAL developments, as recently stated by state-of-
the art scientific analysis [30]. 
1.3 EU project - NanoBio4Trans 
The Aim of NanoBio4Trans project was to create a new paradigm to engineer cutting 
edge scalable highly vascularised BAL/EBALs on the following hypotheses: 
1) The use of hiPSC as the starting material, is foreseen to enable the construction 
of personalized artificial organs from a patient´s own cells, which is expected to result 
in reduced organ rejection and increased availability of lifesaving organs for transplan-
tation. 
2) Growth and differentiation into in vivo-like BALs is possible if hiPSC-derived 
liver tissue is highly vascularized, i.e. penetrated with blood-vessel like channels lined 
with endothelial cells, and with immediate and nearby supply of the necessary growth 
factors and signaling molecules that support its growth and differentiation. 
3) Creation of novel scalable two-component perfusable hybrid scaffolds (PHSs) is 
possible using: (1) a primary highly dense and branched blood vessel-like channel 
network through which a heart-mimicking pulsating flow supplies nutrients and oxygen 
(thus resembling natural gradients), surrounded by (2) a secondary porous structure 
enclosing hydrogel micro deposits (HMDs) that contains necessary growth factors and 
signaling molecules.  
4) The use of integrated optical and electrical (bio)sensing systems for monitoring 
real time effects and changes during tissue growth will allow control and surveillance of 
BAL formation, with envisaged feed-back control. 
Major steps are: 
To explore different in vitro cellular systems for development of novel 3D cell/tissue 
culture systems starting from (a) existing endothelial cells and moving on to (b) hiPSCs, 
as they become available in the project, (c) using in a first instance miniaturized fluidic 
sensor array systems (BAL-on-a-Chips) for optimization of 3D culture and perfusion 
conditions, and (d) further adaption for up-scaling to a large size BAL support system to 
form BALs in the order of cm
3
 to dm
3
.  
To compare and validate the developed BAL system with fluidic tissue slice sensor 
array systems (Liver-on-a-chip), containing precision-cut liver slices obtained from 
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surgical waste from transplant. This reference system will be used as the gold standard 
to which the BAL systems will be compared. 
 
 
Figure 1. The NanoBio4Trans BAL support system´s development process: (A) The PHS with a primary 
highly branched perfusable channel network that allows flow through the material from one inlet to one 
outlet, and a secondary more arbitrary porous network (Fig. 1Aa), enclosing HMDs (in blue). (B) hiPSC 
derived endothelial and hepatocyte cells seeded and grown inside the primary capillary channel network, 
to closely mimic the in vivo situation of blood vessel lined with endothelial cells on top of which 
hepatocyte monolayers are formed (Fig. 1Bb). (C) A fully developed BAL support system, with integrat-
ed sensing and imaging tools for control of growth and viability and use as EBAL, with a final releasable 
BAL (Fig. 1Cc), potentially for  future transplantation.  
1.4 Motivation and Objective  
This thesis focuses on various aspects of liver tissue engineering such as scaffold design 
with controlled pore geometry, its mass fabrication, characterization and final integra-
tion into the perfusion bioreactor. The main goal is to create scalable (ranging from cm
3
 
to dm
3
) vascularized perfusable hybrid scaffolds (PHS) structures with (i) primary 
highly branched perfusable microchannel network (Fig. 1a) that allows flow through the 
material from one inlet to one outlet, and (ii) a secondary more arbitrary random 
microporous network that connects the structured channels (Fig. 2b), and (iii) a nanopo-
rous interpenetrating network (IPN) that encloses hydrogel deposits of e.g. drugs, 
extracellular matrix proteins, differentiation factors, promoting hepatocyte adhesion, 
growth, differentiation and function (Fig. 2c). The created PHS has the following 
requirements and functions, where it should: (a) serve as structural and mechanical 
support for growth and differentiation of the BAL, (b) be perfusable with extensive 
channel networks that enable growth of blood vessels and transport of O2 and nutrients 
to inner tissue and as a “nearby” source of important drugs and cell factors that sustains 
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the growth of cells into a final BAL, and (c) be biocompatible and potentially biode-
gradable. 
Finally developed 3D scaffolds has to be integrated into a perfusion based BAL-on-a-
Chip system incorporating pumps, sample reservoirs, bioreactors and different types of 
sensors for long-term growth and differentiation of hiPCS-derived DE cells into func-
tional 3D BALs. 
 
Figure 2. Illustration of PHS showing primary capillary network (a) and secondary porous HMDs, 
obtained in two different ways, throughout (b) and locally around the primary channels (c). 
Our concept to achieve this goal is based on developing new 3D microfabrication 
techniques to yield a multiple layered perfusable capillary network scaffold in silicone 
elastomer (Fig. 3a & b). The perfusable capillary network exposed to supercritical CO2 
in the presence of a second hydrogel in order to functionalize the network prior to cell 
seeding (IPN technology). The supercritical CO2 treatment leads to an expansion of the 
polymer structure, leaving space for inter-diffusion of hydrogel therein. When the 
supercritical CO2 pressure is released the polymer-blend structure is locked/frozen, 
leaving it interpenetrated with networks of hydrogel (Fig. 3c). In this way, HMDs, 
containing the necessary biomolecule and growth factors that support endothelial and 
heptocyte cell growth, are formed throughout the primary capillary network structure in 
a single step. With sufficient density, these HMDs will serve as islands for cell attach-
ment and further proliferation/spreading. 
a) b) c) 
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Figure 3. Illustration of the IPN scaffold concept, showing a) the base material, b) primary structured 
and/or random porous structure created within the base material, and c) a secondary IPN network within 
the PHS, enclosing hydrogel nano-deposits for in situ delivery of e.g. drugs, nutrients and growth factors. 
As the short term goal of the NanoBio4Trans project was to develop an extracorporeal 
liver device the scaffold fabrication materials were mainly focused on biocompatible, 
elastic and non-degradable synthetic polymer. However in the long run to be able to 
transplant the artificial tissues in vivo, stepwise degradation of the polymer scaffold has 
to be investigated to produce the bioartificial liver (BALs) that ideally results in a liver 
piece without any synthetic scaffold material left. At the end of my PhD I have tied to 
fabricate scaffolds from natural protein based polymeric scaffolds with programmable 
degradation properties. 
1.5 Thesis Outline 
This thesis is organized into seven chapters. Chapter 1 (this chapter) provides a general 
overview of the NanoBio4Trans project, with the aim to develop, optimize and validate 
a highly vascularised in-vivo-like bioartificial liver as an extracorporeal bioartificial 
liver. The main objective of the thesis is to develop new technologies for 3D microfab-
rication of scaffold structures that can be used for creating blood vessels and growing 
and perfusion of a bioartificial liver.  
Chapter 2 presents the current detailed literature overview of aspects in scaffold design 
parameters and various scaffold fabrication techniques. The fabrication methods are 
mainly categorized into three major types such as traditional fabrication methods to 
generate random pore scaffolds, modern additive manufacturing fabrication methods for 
scaffolds with structured pore architecture and finally, the next generation dual pore 
scaffolds obtained by combining both traditional and modern fabrication techniques.  
Different scaffolds fabrication techniques have been investigated which is rapid, inex-
pensive, scalable, and compatible with different polymers, making it suitable for 
engineering various large scale organs/tissues. In chapter 3 I present a scaffold fabrica-
tion technique, where a sacrificial water dissolvable PVA mold was 3D printed, 
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polymer casted around it, cured and subsequently the sacrificial mold was dissolved, 
leading to a structured porous scaffold.  
Similarly chapter 4 describes the fabrication of dual-pore scaffold by combining 3D 
filament printing of water soluble PVA sacrificial mold for primary structured pores (as 
explained in chapter 3 and patent A) combined with salt leaching to create random 
pores within the bulk scaffold. Using PDMS as the scaffold material, we have demon-
strated that the fabrication process is rapid and inexpensive as well as scalable for 
generation of scaffolds of a size, relevant for thick tissues. This method can also be used 
with different biodegradable natural polymers (e.g. gelatine and silk) combined with 
freeze-drying, to provide scaffolds with wide range of mechanical properties.  
Long term in-vitro studies of different types of scaffold were tested with human hepato-
blastoma (HepG2) cells. The dual-pore scaffolds with highly interconnected structured 
pores combined with the adjacent random pores were proven to be superior to the 
structured and random pore scaffolds.  
Along with scaffold fabrication techniques development of next generation “intelligent” 
instructive biomaterials that provide both physical support within a three dimensional 
(3D) microenvironment for controlling cell fate and direct cell differentiation through 
controlled drug release has attracted widespread attention in the field of tissue engineer-
ing. Chapter 5 deals with the fabrication of 3D printed porous silicone-poly(2-
hydroxyethyl methacrylate)-co-Poly(ethylene glycol) methyl ether acrylate (pHEMA-
co-PEGMEA) hydrogel inter penetrating network (IPN) scaffolds using indirect 3D 
printing and supercritical CO2 technology. The fabricated 3D IPN scaffolds were 
employed to support long-term growth of human mesenchymal stem cells (hMSC), 
resulting in well spread cell morphology with maintenance of high cell viability and 
metabolic activity. As a proof of concept, the biological activity of released doxycycline 
(DOX) from IPNs was confirmed using a tetracycline regulated green fluorescent 
reporter (GFP) gene expression assay with Hela cells.  
Similarly carbon based materials have shown previously can induce  the differentiation 
of hMSc and neuronal stem cells (NSC) into their respective lineages [31,32]. I have 
also developed some fabrication technique to fabricate 3D carbon scaffolds using 
pyrolysis presented in patent B and conference abstract (A&B). The presented 
fabrication method offers new opportunities to develop 3D conductive tissue engineer-
ing scaffolds with precise control of the pore architecture and interconnectivity, 
facilitating scalability.  
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Chapter 6 summarises the contributions of developed porous scaffolds into perfusion 
bioreactor development, sensors integration and hiPSC derived hepatocytes differentia-
tion during the NanoBio4Trans project. A tissue engineering bioreactor platform was 
developed, which integrates an array of 16 perfusable bioreactors that can be applied to 
culture cells in porous 3D scaffolds. The fabricated system was validated by culturing 
HepG2 hepatoblastoma cells in random porous 3D scaffolds. The developed bioreactor 
system has been integrated with impedance-based sensing technology along with 
perfusion for non-invasive real-time monitoring of cell proliferation in the 3D scaffolds. 
Next optimization study was carried out on hepatic differentiation of hiPSC-derived DE 
cells in the 3D perfusion bioreactor system with integrated random and dual pore 
scaffolds at two flow rates. Hepatic differentiation and functionality of hiPSC-derived 
hepatocytes are assessed using freshly obtained human liver as an ex vivo liver repre-
sentative model.  
Additionally for future work decellularized liver extracellular matrix (ECM) and natural 
silk protein materials have been developed and tested for enhancing the differentiation 
of hiPSC-derived hepatocytes and fabricating biodegradable scaffolds for in-vivo 
applications as described in chapter 7.  
Finally the key conclusions of my PhD thesis are summarized in chapter 8. To be able 
to utilize the scaffolds for clinical use some recommendations on a number of topics 
have to be explored in the future to improve and optimize the 3D scaffold as proposed 
in this thesis. 
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2.  CHAPTER 2. State of the art: Scaffold Design 
Parameter and Fabrication 
This work will be submitted as manuscript for a review paper to Journal of applied 
polymers: (2016). Fabrication of Scalable and Structured Tissue Engineering Scaffolds 
Using Water Dissolvable Sacrificial 3D Printed Moulds.  
2.1 Introduction 
Biomaterial porous scaffold plays a central role in modern regenerative medicine and 
tissue engineering as it offers a controlled biophysical and biochemical environment 
that can direct cellular behavior and function. In general, scaffold provides a tentative 
three-dimensional (3D) support to interact with cells to control their functionality, 
thereby guiding complex multicellular processes of tissue formation and regeneration 
[1]. Numerous scaffolds produced in various biomaterials using different fabrication 
techniques have been used to regenerate different tissues and organs[2]. Regardless of 
the tissue types, a number of parameters are important when designing or determining 
the suitability of a scaffold for use in tissue engineering. Fig. 1 illustrates some of the 
key requirements to be considered before developing smart 3D scaffolds for regenera-
tive medicine [3]. Primarily, the construct should be biocompatible and possibly 
biodegradable with desired surface properties for cell adhesion, migration and normal 
functionality. Secondly, since tissues of the human body have selective mechanical 
properties ranging from soft (brain, about 0.5 kPa), to moderately stiff (skin and mus-
cles, around 10 kPa) and stiff (precalcified bone, >30 kPa) [4], the scaffold construct 
must have desired mechanical strength and porosity to be able to integrate with the 
surrounding tissue. Moreover, the size of engineered scaffolds must be very similar to 
the area of the damaged tissue. In addition,  it has been shown that controlled delivery 
of biological signals from porous scaffolds, such as small drug molecule, growth factors 
and cytokines in vitro or in vivo, is crucial in the support and enhancement of tissue 
morphogenesis, viability and functionality [5–7], therefore, the design should consider 
the physico-chemical properties of scaffold materials so that they can release desired 
biomolecule to guide and regulate biological responses of the cells into specific tissue. 
New biomaterials are rapidly emerging, and in future, the research will be directed 
towards new fabrication methods, which will not only produce materials with various 
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physical properties, but also offer independent control over their physical, chemical and 
biological properties [8].  
 
Figure. 1 Schematics of general requirements for developing 3D smart scaffolds for 
tissue engineering and regenerative medicine [Modified from Ref. [9]] 
 
2.2 Scaffold fabrication methods 
Polymer scaffolds need to possess many key characteristics to be useful for tissue 
engineering, including high porosity and surface area, structural strength, and specific 3‐
D shapes. These characteristics are largely determined by the scaffold fabrication 
technique. Until now, various successful fabrication techniques have been developed to 
process different natural and synthetic biomaterials into 3D polymeric scaffolds for 
application in tissue engineering and regenerative medicine. The scaffolds fabrication 
technique can be classified into two major groups as shown in the Fig. 2, I) convention-
al fabrication techniques also named as “Non-designed controlled scaffold 
manufacturing” [10], which basically generate polymeric scaffolds with stochastic, 
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disordered or random microporous structures; and II) modern fabrication techniques 
named as rapid prototyping (RP) or Additive manufacturing (AM) or Solid Free-Form 
Fabrication (SFF) or “Design controlled scaffold manufacturing”[10], which enable the 
formation of channels/pores with precisely defined dimensions, location and geometry 
to generate 3D structured microporous scaffolds. Very recently, a new type of scaffolds 
fabrication has been generated by combining conventional and modern fabrication 
methods, which could be categorized as combined fabrication techniques [11–13]. This 
chapter will briefly highlight a few most commonly used scaffolds fabrication method. 
At the end special attention will be given to the method which combines of multiple 
fabrication techniques to design smarter scaffolds. 
 
Figure 2. Classification of scaffolds fabrication techniques. 
2.2.1 Random Porous Scaffold Fabrication: Using Conventional Methods 
Conventional techniques such as phase separation, gas foaming, freeze-drying, solvent 
casting, thermal processing, electrospinning and particulate leaching as well as combi-
nation of these techniques have been used in tissue engineering to generate engineered 
scaffolds with random foam-like internal structure (as shown in Fig. 3A) [14].  
 
 
Figure 3. Illustrations of two major types of porous scaffolds with A) random pores B) 
structured pores. 
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2.2.1.1 Particulate leaching  
Particulate leaching is the most commonly used scaffold fabrication method in tissue 
engineering and drug delivery applications [15–18]. Briefly, porogen particles (such as 
salt, sugar and wax, etc.) of desired dimensions were piled up into a mould and the 
polymer solution is casted into the mould. Subsequently the polymer solution is cross-
linked or hardened and the porogen particle was removed using a solvent. The size and 
the shape of the porogen particles are transferred as pores in the scaffold materials. The 
great advantages of this process include low cost, scalability of the scaffold size and the 
control over pore size by varying the size of the porogen particles [16,19]. However the 
scaffolds fabricated using this techniques has no control on inter pore connectivity and 
the pore architecture [19,20]. 
2.2.1.2 Emulsion and phase separation 
Another kind of fabrication technique to generate highly interconnected very fine 
random pore scaffolds is called liquid induced phase separation (LIPS) [21–23] or 
thermally induced phase separation (TIPS) [24,25]. In TIPS, the polymer is dissolved in 
a solvent (organic or aqueous) and subsequently cooled down until the polymer-solvent 
mixture freezes completely.  Finally the solvent is removed by freeze drying process to 
get the 3D porous scaffold. The method can generate scaffolds with very high porosity 
and different  pore sizes by varying freezing temperature [26,27], polymer material, 
polymer concentration and the type of organic solvent [28]. However, the main draw-
back is the small pore size (up to 100 µm) that can be reproducibly obtained by this 
process [28]. Moreover, the process mainly uses organic solvents and might leach some 
residues after processing and therefore it is always important to monitor the complete 
removal of the solvents before doing the biological studies. 
Similarly in emulsion freeze‐drying, mixture of polymer–solvent system and water 
leads to formation of an emulsion [29–32]. The emulsion mixture with a continuous 
phase (polymer rich phase) and a dispersed phase (water) is subsequently cooled down 
to completely freeze the mixture. The frozen mixture is freeze-dried to create pores 
through the removal of frozen solvent and water. Emulsion freeze‐drying can produce 
relatively thick scaffolds with large pores [30] compared to phase separation process. 
The method has been shown to generate scaffolds with porosity greater than 90%, and 
with medium (15 - 35 µm) and larger (greater than 200 µm) pore sizes [32,33].  
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2.2.1.3 Electrospinning  
Electrospinning (ES) is a scaffold fabrication techniques by which small diameter fibers 
(ranging from nanometer to micrometer) with large surface areas can be produced. The 
technology relied on charging of a polymer solution and subsequent ejecting from a 
capillary tip or needle. The jet coming from the needle draws continuously in a steady 
manner towards a collector due to an applied high electric field ranging from 10 to 30 
kV. Evaporation of the solvent from the jet after leaving the needle results in formation 
of a randomly accumulated, nonwoven mat of thin polymeric fibers on the collector 
[34–36]. 
The size of the nanofibers can be tuned by changing various parameters such as strength 
of the electric field, distance between the needle and collector, polymer concentration 
etc[37,38]. Electrospun nanofibers can also be orientated/ aligned either by using a 
rotating mandrel collector [39] or by inducing the electric field at the edges of the 
collector plates (Hall Effect) [40]. SEM image in Fig. 5C shows an example of electro-
spun silk scaffolds using the method described previously [41]. Nanofiber 3D scaffolds 
produced from the electrospinning process might be a possible option to mimic the real 
ECM fibers topography and size. Moreover, high surface area and high porosity of the 
spun fiber scaffold enhance the cell attachment and facilitate nutrient and waste ex-
change. In addition, the process is simple and inexpensive, and can provide tunable fine 
fiber resolution and controlled fiber alignment to induce cell and tissue alignment. 
However, in some solution spinning process the toxic organic solvents used during 
fabrication is not good for cells, but this can be partially solved by using melt spinning 
of some other polymers [42]. Another drawback of this method lies in limited control of 
pore structure. The pore size of electrospun scaffolds is dependent on the fiber diameter, 
and smaller diameter fibers will lead to smaller average pore sizes, which will in turn 
cause decreased cellular infiltration [43]. Therefore, there is great challenge to engineer 
3D scaffolds with complex pore geometry when using ES techniques. 
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Figure 5. SEM image of a A) salt leached porous scaffold [11]. B) Typical polystyrene-
based emulsion-templated (PolyHIPE) materials. [44]. C) Electrospun silk scaffold 
(unpublished). Scale bar: A = 500 µm, B= 20 mm and C= 10 µm. 
 
As described above, conventional fabrication techniques are quick, scalable and eco-
nomical, and advantageous in generating fine pore structures. However, they do not 
permit accurate control over the scaffold’s micro-architecture such as the pore size, 
shape, interconnections and spatial distribution of pores within the scaffold [45]. The 
tortuous (i.e. as the ratio of the actual length of the arbitrary pathway that a molecule 
has to cover to pass through a pore to the shortest linear distance) pathways created by 
the random porous scaffolds is another major limitation for nutrient supply, waste 
removal and effective release of biological signals [3]. Even though the random scaf-
folds has very large surface area for cell attachment and proliferation, their high pore 
tortuosity limits the cell viability normally to 0.5–1 mm into the scaffolds [46,47]. 
Furthermore it has also been shown that such random pore morphology is associated 
with drop in the oxygen concentration from the outside to the center of the scaffold 
[48,49]. 
 
2.2.2 Structured porous scaffold fabrication: using solid free-form fabrication / 
rapid prototyping (RP)  
To overcome the challenges of conventional scaffold fabrication techniques, various RP 
techniques recently have emerged arise where a 3D object is manufactured through 
layer by layer assembly process. The resulting scaffold (Fig. 3B) possesses tunable 
porosity, pore size and shape with complete interconnection of pores in all the direc-
tions, which improves the cell migration, proliferation and nutrient perfusion compared 
to scaffolds fabricated with conventional techniques.  
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Presently, computational techniques have allowed designing 3D anatomical porous 
scaffolds with balanced mass and oxygen transport properties. The philosophy of the 
method is to create objects by adding material layer-by-layer. It is therefore generally 
referred to as additive manufacture (AM) to distinguish it from conventional machining 
which removes material in a subtractive manner [14]. The basic principle for all current 
rapid prototyping techniques are mainly constructing a computer-aided design (CAD) 
model of a complex object, then converted into series of cross-sectional parallel layers 
(STL format). The RP machine manufactures the whole object by reproducing in a 
layer-by-layer fashion. The first layer of the physical object is created and then lowered 
by the thickness of the next layer. The process is repeated continuously until completion 
of the object. Finally the object is removed from the base platform of the machine.  
There are various ways to classify the fabrication techniques either based on the type of 
printing principle or on type of material used in the printer. Here, some of the most 
common fabrication techniques used in tissue engineering scaffolds fabrication based on 
different printing principle is classified in Fig. 6. 
 
Figure 6. Classification of various RP techniques used for fabricating tissue engineering 
scaffolds through laser-, nozzle-, and printer-based systems. [figure modified from 
reference [50]] 
2.2.2.1 Laser based system 
Stereolithography (SLA) is laser based RP technique which uses photo-curable resin 
in a layer-by-layer fashion to build 3D solid objects (Fig. 7A)[51–53]. A 2D layer of the 
designed pattern is traced with a laser on the surface of the resin reservoir and photo-
polymerizes the resin. After the first layer is cured, z-stage of the machine lowers the 
structure by few microns and a thin layer of uncured resin is spread on the surface of the 
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previously cured patterned layer. This process is repeated until the desired final solid 3D 
object is completed.  After being built, in the post-treatment steps the printed 3D object 
is washed in a chemical bath in order to remove excess resin and is further cured in an 
ultraviolet oven. The resolution of each layer is very much dependent on the elevator 
layer (z-step thickness) and the spot size of the laser. In µ-SLA, a single spot laser 
micro features with 10 μm resolution with a 1 μm z-step thickness can be produced [54], 
but  the fabrication time is significantly increased in order to achieve such high resolu-
tion. To reduce the fabrication time, the laser can be replaced with a digital photo mask 
[52] to cure each layer of the whole 3d object in one step. The method allows to fabri-
cate variety of 3D shapes with much higher resolution and surface smoothness 
compared to other RP techniques. However, SLA techniques usually  take longer time 
to fabricate a 3D structure and the printing materials are also more expensive. As 
material properties may vary over time, special care must be taken in handling printing 
materials.  
Similar to SLA, in selective laser sintering (SLS) technique, the laser selectively fuses 
powdered material by scanning cross-sections generated from a 3D digital description 
of the part on the surface of a powder bed. After each cross-section is scanned, the 
powder bed is lowered by one layer thickness, a new layer of material is applied on top, 
and the process is repeated until the part is completed. Such technique has been utilized 
mainly for creating bone tissue engineering constructs for example temporomandibular 
joint (TMJ). It provides a cost effective, efficient method to construct scaffolds to match 
the complex anatomical geometry of craniofacial or periodontal structures. Virtually 
any powdered biomaterial that will fuse but not decompose under a laser beam can be 
used to fabricate scaffold by SLS. [55]. However, limiting factors include the require-
ments of post-processing steps and the instability of the materials over time. 
Along with other 3D printing technologies, two-photon polymerization (TPP) microfab-
rication induced by a near-infrared femtosecond laser can fabricate arbitrary and 
ultraprecise 3D microstructures with high resolution not only on the microscopic scale 
but also on the nanoscale [56]. The TPP process is initiated by three-order nonlinear 
absorption within the focal region. 3D structures can be fabricated by moving the 
focused beam in photoresist according to a computer-designed 3D route with the 
resolution beyond the optical diffraction limit. Particularly, 3D hydrogels have been 
achieved by ongoing intense research activity due to their promising biomedical appli-
cations in tissue engineering and drug delivery. Many strategies have been developed to 
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improve the resolution of TPP to be less than 100 nm. In TPP, the spatial resolution is 
dominantly determined by laser power and exposure time, which largely depends on the 
efficiency of TPP initiators 
Even though laser based technique has produced various hard and soft scaffolds, the 
application of process in tissue engineering is very limited due to the lack of photo-
curable materials that are suitable for biomedical applications. 
2.2.2.2 Nozzle-based technique  
Another major group of fabrication techniques most widely used are nozzle-based 
system which process materials either thermally or chemically as it passes through the 
nozzle. Fused deposition modeling (FDM)[57,58] is type of nozzle-based RP tech-
nique where melted plastic filaments[59,60] or hydrogels[61,62] or biomaterial 
solutions [63,64] are deposited onto a build platform via a small temperature controlled 
extruder, layer by layer to make the 3D object (Fig. 7B). The base platform gets lowered 
at the end of each deposited layer so that subsequent layer can then be deposited. Each 
layer hardens as it is deposited and bonds to the previous layer. Elevated temperature is 
used in the inexpensive FDM based filament printing machines, which limits the type of 
biomaterials that can be employed. 
2.2.2.3 Printer based system 
3DP
TM
 is one of the printer based rapid prototyping techniques, where liquid binder is 
deposited on to sequential polymer powder layer as similar to ink‐jet printing tech-
niques. The process flow of the technique is described below in Fig. 7C. The position of 
the jet is controlled via a computer‐assisted design and manufacture (CAD/CAM) 
program. 3D objects can be made layer by layer with a resolution around 50–300 µm. 
The polymer powder can be mixed with the salt to generate pores for porous scaffold 
fabrication. Various materials such as ceramics, metal, metal-ceramics composite and 
polymers can be processed using this technique. Even though the resolution of the 
printer is determined by the jet size it is difficult to fabricate scaffolds with fine micro-
structures. 
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Figure 7. Schematic representations of different types of 3D printer systems. A) Stereolithography (SLA) 
system. An ultraviolet (UV) laser is used to solidify the model's cross-section while leaving the remaining 
areas in liquid form. The movable table is then lowered drops by a sufficient amount to cover the solid 
polymer with another layer of liquid resin. B) Fused deposition modeling (FDM) system. FDM uses a 
moving nozzle to extrude a fiber of melted polymeric material from which the physical model is built 
layer by layer. C) A typical 3DP
TM
 printer, a stream of adhesive droplets is expelled through an inkjet 
print head, selectively bonding a thin layer of powder particles to form a solid shape [ figure modified 
from reference  [55]]. 
Although RP techniques have currently gained an wide spread attention in the field of 
tissue engineering, each RP techniques discussed above has its own unique advantages 
and disadvantages in terms its capability to process different materials, printing resolu-
tions and the processing conditions, summarized in Table. 1[55]. 
 
Table 1. Classification of AM techniques on the basis of printing materials employed 
for the production of tissue-engineering scaffolds with pros and cons [45,65]. 
Technique Materials Resolution 
(µm) 
Advantages Disadvantages 
Powder-based techniques 
Stereolithogra-
phy (SLS) 
Polymer, 
ceramic or 
composites 
Ex. PEEK-
HA, 
Polycapro-
lactone 
(PCL) 
50–1000 No support 
material needed 
Laser intensity can 
induce polymer 
degradation; 
scaffolds generally 
present low me-
chanical properties, 
limited and high-
cost materials, 
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trapped non-
sintered material, 
poor control over 
surface topography 
Three dimen-
sional printing 
(3DP) 
Polymer, 
ceramic or 
composites 
Ex. PLGA, 
starch 
based 
polymer 
50–300 No materials 
heating involved 
in the fabrica-
tion process, no 
support material 
needed, high 
production rate, 
possibility of 
producing large 
size samples 
Structure shrinking 
upon sintering, 
trapped non-bound 
material, low 
scaffold mechanical 
properties, high 
roughness of 
scaffold surface 
Photosensitive polymer based techniques 
selective laser 
sintering (SLA) 
Polymers: 
PEG-DA, 
hydrogels: 
methacry-
lated-Gelatin, 
HEMA, 
mixture of 
methacry-
lated-Gelatin 
and hyaluron-
ic acid-
methacrylate  
14–150 Relatively easy to 
remove supports, 
possibility of encapsu-
lating cells 
Necessity of 
removing non-
polymerized 
resin, post-curing 
generally re-
quired, shrinkage 
of the scaffolds 
due to post-
processing steps, 
few suitable 
biocompatible 
and biodegrada-
ble materials 
μSLA methacry-
lated-
Gelatin, 
PEG-DA, 
0.5–10 High accuracy, small 
amount of photosensi-
tive material 
necessary 
Limited overall 
scaffold size 
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and alginate 
+ acrylated 
Two-photon 
μSLA 
Polymers: 
PEG-DA 
0.1–4 Possibility of produc-
ing scaffolds without 
layers superimposing, 
high accuracy 
Limited overall 
scaffold size, 
distortion and 
shrinkage can 
occur 
Melt–extrusion / thermoplastic based techniques 
(Fused deposi-
tion modeling 
(FDM), Preci-
sion extruding 
deposition 
(PED), Bioplot-
ter, Bioextruder 
and Bioscaf-
folder ) 
Polymer, 
composites 
Ex. PCL, 
PP-TCP, 
PCL-HA, 
PCL-TCP, 
PLLA-TCP 
100–500 Good mechanical 
properties, no 
materials trapped 
into the scaffold 
Possible thermal 
degradation of 
polymers, relative 
regular structure, 
supports needed for 
structure overhangs 
Solution/slurry extrusion-based techniques 
Pressure-
assisted mi-
crosyringe 
(PAM)/PAM2 
Polymers 
(PAM), 
hydrogels 
and cells 
(PAM2) 
10–1000 Possibility of 
producing hydrogel 
scaffolds encapsu-
lating cells (PAM2) 
Organic solvents 
(PAM) 
Low-
temperature 
deposition 
manufacturing 
(LDM) 
Composite 
slurries 
300–500 High accuracy on 
deposition of 
polymeric slurries, 
microporosity due 
to freeze drying 
Organic solvents 
Robocasting Ceramics or 
composites, 
Organic ink 
100–
1000 
Highly concentrated 
colloidal suspen-
sions can be used 
Sinterization 
necessary in most 
cases. Precise 
control of ink 
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properties 
is crucial 
Abbreviations: HA, hydroxyapatite; PCL, polycaprolactone; PEEK-HA, polyether-
etherketone-hydroxyapatite; PEGT-PBT, poly(ethylene glycol)-terephthalate-
poly(butylenes terephthalate; PLLA, poly-L-lactide; PP-TCP, polypropylene-tricalcium 
phosphate. 
2.2.2.4 Indirect RP fabrication method 
As discussed above, various RP methods have attracted a lot of attention for directly 
creating micro-scale porous structure scaffolds with desired complexities [14], but all of 
the RP technologies are very specialized due to the fact that each technique demands a 
specific form of printing material such as filament, powder, solid pellet or photocurable 
polymers [10,45,65]. Consequently, it is challenging to fabricate scaffolds using materi-
als which are not compatible with RP i.e, silicone elastomer, natural and synthetic 
hydrogels. One solution is to use indirect RP methods which first fabricate a sacrificial 
mould and then make a reverse structure using materials suitable for tissue engineering. 
Recently we have developed a multistep process (an example shown in Fig. 8) where 
the desired scaffolds material is casted around the sacrificial mould, crosslinked and the 
mould is removed by dissolving in appropriate solvent to yield the final scaffold. Such 
technique has the opportunity to control the scaffolds internal and external architecture 
with the desired materials of choice. A 3D microvascular network within polymer 
matrices has been fabricated by 3D printing of sacrificial wax moulds, casting of low 
viscosity epoxy around the moulds and subsequent removal of the moulds [66,67]. 
However, the use of wax (which has a melting temperature of about 60°C) limits the 
materials that can be cast around the mould since polymers requiring higher tempera-
tures for cross-linking cannot be employed. Furthermore, the complete removal of the 
sacrificial wax components (which may not be biocompatible) can be challenging, in 
particular  for large 3D structure with complex geometry.  
 
Perfusable 3D scaffolds have also been demonstrated in a similar manner by casting 
extracellular matrix (ECM) containing cells around a 3D printed sacrificial sugar glass 
lattice and subsequently dissolving the lattice to form vascular networks [68]. However, 
it is probably difficult to print large 3D structures in the very brittle sugar glass, and the 
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inter-filament distance (defined by the printing process) is limited to a minimum of 1 
mm. It may not be feasible to use this technique for creating dense vascular channels in 
large scale structures. Recently we have shown a new scalable approach involving 3D 
printing (using a commercially available filament based 3D printer) of a sacrificial 
polyvinyl alcohol (PVA) mould whose geometrical features are designed according to 
the required vascular channel network [69]. PVA is an ideal material because of its 
biocompatibility and water solubility. In addition, its high melting temperature (190°C) 
makes it robust for subsequent polymer casting and curing steps. 
 
Figure 8. Schematic illustration of the steps involved in the fabrication of SFF porous 
elastomeric scaffolds. A sacrificial 3D mould was printed in PVA (a, b). The printed 
PVA mould was transferred into a container containing pre-cured PDMS (c). Vacuum 
was applied to ensure complete filling of pre-cured PDMS into the pores of the mould 
(d). Following crosslinking of the PDMS, the sacrificial PVA mould was dissolved in 
water (e) leaving behind the structured PDMS scaffold (f). [from our result chapter 3 
[70]] 
 
In general, RP allows easy variation of the internal architecture of a scaffold, which in 
turn can lead to optimized specific surface area, scaffold mechanical response to exter-
nal stress, and flow resistance in a bioreactor [14]. The control of internal architecture of 
the scaffold can ultimately ensure the desired mechanical properties of the scaffold. 
Another main advantage of the technique is that the scaffolds can be tailored to match 
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the size of the damaged body parts. Organized pore structures of the RP scaffolds offer 
possibilities for regulation of efficient supply of nutrient and oxygen, which holds the 
promise for clinical applications.  
However, these techniques also present some drawbacks, in particular low resolution 
(around 200-500 µm). These techniques therefore only allow fabrication of scaffolds 
with large pore dimensions much larger than the sizes of a cell, which ultimately leads 
to non-uniform cell distribution around the scaffold and low cell seeding efficiencies 
around 25-40% [71]. In RP scaffolds, due to the large pore size, cells generally falls 
through the gaps of the scaffold. The attached cells on structured pore scaffolds forms 
2D monolayers on the surface of the printed layers, so the cell to cell communication is 
greatly reduced compared to 3D tissue organization.  
2.2.3 Next generation smart scaffolds: integration of multiple fabrication 
methods 
To overcome the disadvantages of conventional and RP methods, the third generation of 
scaffold fabrication techniques, so called combined fabrication methods (Fig. 4) have 
been proposed, which can generate scaffolds comprising structured pores (channels) in 
combination with local random porous regions. The structured pores help overcome the 
diffusion limitation, while the random pores provide a large surface area to accommo-
date high density of cells. By promoting rapid vascularization and improving nutrient 
and oxygen transport, the dual-pore scaffold can greatly enhance survival rate of the 
seeded cells. It is therefore a promising strategy to engineer large-scale artificial tissues 
or organs for regenerative medicine [13,72–77]. Recently it has been demonstrated that 
post-transplantation of a dual-porous scaffolds enabled more cells from the host tissue 
infiltrated into the scaffolds, hence, enhancing integration of blood vessels in the host 
tissue [78]. The dual-pore scaffold can be produced in several ways, such as combining 
conventional techniques with AM, microfabrication, or wire array molding process. 
 
 
 39 
 
Figure 4. A) Illustrations of dual-pore scaffolds and B) SEM image of and PCL dual-
pore scaffold, red circle shows the structured pore region and the random pore regions 
are present around it. 
2.2.3.1 Combined microfabrication with conventional techniques  
L. S. Wray et al. has shown a method of generating a dual pore scaffold where micro-
channels fabricated using microfabrication and soft lithography were integrated into a 
porous TE silk scaffold [79] to mimic the scaffold supporting co-culturing of two cell 
types in two different pore compartments. Incorporated porous microchannels supported 
endothelial cells for the development of vascular tube, while the microporous scaffolds 
surrounding the microchannels were loaded with human mesenchymal stem cells for 
supporting the tissue formation. The Schematic of the micropatterned porous silk 
scaffold fabrication is shown in the Fig. 14.  
 
Figure 14. Schematic of micropatterned porous silk scaffold fabrication. A) Microfluid-
ic channel patterns are transferred from a silicon wafer to polydimethyl siloxane 
(PDMS) using standard photolithography and soft lithography techniques. The PDMS 
mold is trimmed to the desired shape and size. B) A porous silk film is cast over the 
PDMS mold and crosslinked to induce β-sheet crystallinity. An aqueous-derived salt 
leached silk scaffold is assembled over the silk film. The scaffold is cured and removed 
from the PDMS mold. SEM images show patent microchannels on the surface of the 
scaffold and 100–350 μm diameter interconnected pores in the bulk of the scaffold. 
[Reproduced from reference [79]] 
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2.2.3.2 Combined wire array molding process with conventional techniques 
Similar to dual-pore scaffolds fabrication techniques using AM discussed above, 
indirect manual assembly fabrication approaches have been developed [12,13,78,80]. In 
such proposed technique dual-pore scaffolds were fabricated by combining both salt 
leaching using powder/freeze drying and wire array network molding. The basic fabri-
cation process flow as shown in Fig 15, a mould was fabricated with inserted various 
metallic wires which interns defines the structures linear pores in the final scaffold. For 
dual pore silk scaffold the liquid silk solution was poured into the mould and freeze 
dried using various temperatures depending up the required random pore size. After 
freeze drying the scaffold was crosslinked and the metallic wire was removed to yield 
the final dual-pore silk scaffold. However in case of combination of salt leaching 
process salt particle of desired size was mixed with the polymer materials such as PCL 
crystals and loaded in between the metallic wires of the mould and heated with required 
temperature to melt the PCL and the mould was pressed mechanically to fill the salt and 
polymer uniformly into the mould. Finally the mould was cooled down, both the 
metallic wire removed manually and salt particles were leached out in water. The salt 
crystals was therefore  replicated as random pores into the PCL scaffold.   
This simple fabrication technique offers a unique and versatile tool for engineering 
‘tailored’ scaffolds for a range of tissue engineering application. The process offers the 
possibility to scale the scaffolds from millimeters to centimeters to mimic the size of 
anatomical organs/tissues with the hollow channel arrays supporting localized and 
confluent endothelialization. However the published results have shown that freeze-
drying cannot yield as large a range of pore dimensions as salt leaching, which can 
utilise salt crystals of various dimensions depending on the requirements. Moreover 
metal wire based moulding process requires the choice of wire dimensions to achieve 
the desired pore dimension and time consuming by manual assembly of a number of 
wires.  
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Figure 15. Silk scaffolds with hollow channels. (a) Schematic of the fabrication process for building silk-
based porous scaffolds containing hollow channels using a linear wire array. (b) At each step in the 
process there are avenues for tuning the scaffold bulk properties (e.g. porosity, mechanical stiffness, and 
degradation rate) and the hollow channel properties (e.g. diameter, spacing, bioactive agent functionaliza-
tion and wall morphology). 
Dual-pore scaffolds comprising both global structured and local random pores, have 
shown tremendous potential towards engineering of complex tissues with better cell 
proliferation due to improved nutrient and oxygen transport [13,72–77]. This has also 
been demonstrated that upon transplantation of a dual-porous scaffolds into the mice, 
cells from the host tissue infiltrated rapidly into the scaffolds due to its smart global 
pore architecture compared to random porous scaffolds, hence, enhancing in-vivo 
integration of the scaffolds with host blood vessels [78]. The structured pores of the 
dual pore scaffold help overcome the diffusion limitation while the random pores 
provide a large surface area to accommodate a high density of cells. Therefore, dual-
pore scaffold design with perfusable channels serves as a promising strategy for engi-
neering of large-scale artificial tissues or organs for regenerative medicine by promoting 
rapid vascularization that enhances survival of the seeded cells. 
2.2.3.3 Combined AM with conventional Fabrication techniques 
Combination of AM with conventional scaffolding techniques such as ES, freeze-
drying, salt leaching, etc., offers new opportunities to generate porous scaffolds with 
nanotopography. 
Very recently S.M. Giannitelli et al. has summarized the advances in the combination of 
AM with other fabrication methods for the production of TE scaffolds  and classified 
various fabrication techniques into three major categories based on achieved level of 
integration: i) assembly level; ii) fabrication level; and  iii) technique level (Fig. 9)  
[81]. 
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Figure 9. Classification of combined additive manufacturing approaches, with the 
accent on the achieved level of integration. Major pros and cons each approach, together 
with the key scaffold architectural characteristics are presented. Combination of AM 
with ES has been chosen as a representative example for the illustration of manufactur-
ing equipment and obtained microstructures. [Reproduced with the permission from 
[81]] 
 
Assembly level: At this level, ‘‘multiphasic scaffolds” that contain two or more regions 
with different topologies are generated [34]. In the following example, a 3D porous 
biphasic scaffold was fabricated with two different techniques and joined manually 
together (Fig. 10A&D).  Firstly, PLGA/TCP skeleton wrapped in type I collagen was 
fabricated using the nozzle based rapid prototyping technique for the bone scaffold. The 
sponge-like chondral phase scaffold (Fig. 10C) was constructed using bovine cartilage 
extracellular matrix-derived scaffold by a modified TIPS conventional fabrication 
technique, as previously explained (Fig. 10B). Individual fabricated constructs were 
fused for each other to get the compact 3D scaffolds. 
Figure 10. A) Schematic diagram of the compact layer-free biphasic scaffold. SEM 
images of the biphasic scaffold with B) the chondral phase C) the bony phase and D) the 
fused compact biphasic scaffold. [Reproduced from reference [82]] 
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Recently we have developed a fabrication method for dual-pore scaffold with both 
defined structured and random pores microarchitectures using the sacrificial 3D printed 
structured porous PVA filament moulds filled with salt crystals in the inter-filamentous 
space (Fig. 11). The fabrication method is simple and involves casting of the desired 
polymer in the mould, which specifies the microarchitecture of pores within the result-
ing scaffold. The scaffolds generated through such combined indirect 3D printing and 
salt leaching process have structured pores distributed in x, y and z directions, and 
random pores placed in between the structured pores of the bulk scaffold. The detail 
fabrication method is discussed in chapter 4. 
 
 
Figure 11. Fabrication of dual-pore scaffolds: A sacrificial 3D mould was 3D printed in 
PVA (A) and packed with salt crystals (B). The salt-filled PVA mould was transferred 
into a container and PDMS was cast to cover it (C). Vacuum was applied to ensure 
complete filling of PDMS into the pores of the mould (D). Following crosslinking of the 
PDMS, the sacrificial PVA-salt mould was dissolved in water (E) releasing the dual-
pore PDMS scaffold (F) [11]. 
Fabrication level: ‘‘Bimodal scaffolds” that contain micro/nano-features inter- twined 
within the same architecture are generated at this level. As an example, a scaffold 
consisting of a microfibrous woodpile structure and nanofibrous matrices was intro-
duced to mimic the biophysical environment (Fig. 12) [77]. The scaffold was produced 
by a hybrid two-step process using two different polymer solutions as shown in Fig. 
12A. The woodpile-like structure was fabricated by a layer-by-layer direct polymer melt 
deposition (DPMD) approach. The polymeric nanofiber matrix was then spread onto the 
microfiber layer by ES. Subsequent microfiber layers combined with nanofiber matrices 
were repeatedly laminated onto the previously combined layers so that a 3D hybrid 
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structure was fabricated. While the DPMD process was carried out, a microfilament in a 
semi-molten state was extruded onto the prior unit layer. As it solidified for a few 
seconds, the microfilament adhered to a local region, where it came in contact with the 
prior unit layer. Every unit layer, therefore, was attached to the adjacent layers to form a 
complete 3D hybrid structure. This device was designed in such a way that the two 
processes could be carried out in an automated fashion. The structure fabricated (Fig. 
12B) by the DPMD process provides the mechanical support and overall shape of the 
resulting hybrid scaffold while nanofibrous structure of the scaffold mimics the natural 
extracellular matrix (ECM). 
 
Figure 12. A) The developed hybrid process. Hybrid scaffolds containing microfibers 
and nanofiber matrices could be built via a combined process of continuous DPMD and 
ES. B) (a) Photograph of the overall 3D woodpile structure with dimensions of 9 mm x 
9 mm x 3.5 mm; (b) the hybrid basic unit layer composed of microfibers and the elec-
trospun nanofibers matrix; (c and d) magnified images of (b). [Reproduced from 
reference [77]] 
 
Technique level: 
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Most recent works have tackled integration at the technique level by fusing the working 
principles of different fabrication techniques into a single, novel technology. In the 
following, we will refer to this last approach as ‘‘hybrid AM”. 
Doej et.al has produced a novel nanocomposite scaffold for bone tissue engineering 
which was made of chitosan (Chit) and nano-bioactive glass (nBG) and retained dual-
pore structure using a robocasting technique [83]. In this technique, composite solution 
was dispensed through a robot in a layer-by-layer fashion, and was rapidly solidified 
under a dry-ice cooled bath and freeze dried afterwards (Fig. 13A). The scaffold gener-
ated featured the pre-designed macro channeled (hundreds of micrometers) pore 
configuration due to the robotic dissension process and contained as well micropores (a 
few to 10 μm in size) throughout the framework as a result of the  freeze drying process 
(Fig. 13B). In this fabrication technique two different scaffold fabrication processes 
such as AM and conventional random porous scaffolds fabrication methods were 
assembled together to generate a dual-pore scaffold.   
 
 
Figure 13. A) Schematic drawing of the robocasting technique to produce Chit/nBG 
nanocomposite scaffold. Robotic dispensing of the composite solution (10% nBG) and 
 46 
 
layer-by-layer construction were possible by maintaining dry-ice cooled conditions. 
Optical image of the produced scaffold is also shown. B) SEM morphologies of the 
robotic-dispensed scaffolds; (a–c) Chit/nBG and (d,e) Chit, taken at different magnifica-
tions. Micropores were well in both types of scaffolds, through the rapid-solidification 
of ice crystals and the subsequent freeze-drying process. The existence of nBG was 
noticed in the nanocomposite scaffold (c). [Reproduced from reference [83]] 
2.3 Conclusions 
Recently in the field of tissue engineering, significant advances have been made in 
terms of scaffold biomaterials, smart scaffold design, and fabrication methods to control 
their in-vitro microenvironment, which has increased the hope for tissue engineering-
based treatment in clinics. This review discussed various scaffold design parameters and 
fabrication technologies. The challenge still remains to find a proper combination of 
desired biomaterials and fabrication techniques to meet the requirements for a success-
ful TE approach. Since past few years, a few of the dual pore fabricated scaffolds have 
shown tremendous potential in terms of in vitro and in vivo studies compared to random 
and structured porous scaffolds. In future significant efforts need to devote to the dual 
pore scaffold fabrication process, new types of biomaterials with desired mechanics and 
more tenability, as well as understanding of the cellular behaviors in different pore 
geometry of the scaffolds. 
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3.  CHAPTER 3. Fabrication of Scalable and 
Structured Tissue Engineering Scaffolds Using 
Water Dissolvable Sacrificial 3D Printed Moulds 
This work was previously published as: Mohanty, S., et al. (2015). Fabrication of 
Scalable and Structured Tissue Engineering Scaffolds Using Water Dissolvable Sacrifi-
cial 3D Printed Moulds. Materials Science Engineering C (55): 569-78. 
3.1 Introduction 
In recent years, there has been a great demand for the development of bioartificial 
organs/tissues in the field of organ transplantation and in vitro toxicological drug 
screening [1]. One of the primary challenges in translation of tissue engineering to 
clinical application is the difficulty in scaling up complex, biological effective tissues 
and organs to the size relevant for human [2]. Although small scale three-dimensional 
(3D) scaffold constructs has been achieved to mimic organs for e.g. in vitro drug testing 
[3], the applied fabrication approaches are not easily translated to constructs of human 
organ size. When engineering tissues in vitro, there is a requirement for structures or 
scaffolds that are able to support cell growth and at the same time mimicking the 
physiological environment including the geometrical, topographical and physical 
features of the targeted tissue. Specifically for the generation of thick 3D tissues, the 
development of highly dense vascular networks that can meet the nutrient and oxygen 
requirements of large masses of living cells remains a tissue engineering challenge. This 
often limits the size of engineered tissues to a few hundred micro meters [4]. The ideal 
tissue engineering scaffold supports the spatial distribution of cells in a three dimen-
sional structure, provides mechanical stability to the cells and enables optimum nutrient 
transport and metabolic waste removal [5,6]. Numerous approaches exist to create 3D 
highly vascularized engineered tissue scaffolds to accommodate a high density of cells 
in high surface to volume ratio structures [6,7]. One strategy has been to use highly 
porous structures with interconnected pores/microchannels that provide space for 
penetration and growth of cells and enable favourable mass transport characteristics 
[8]9]. The structural, mechanical and mass transport properties of such scaffolds are 
determined by parameters such as pore size, pore shape, porosity, pore interconnectivi-
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ty, permeability, scaffold surface area, scaffold effective stiffness and scaffold material 
[10]. 
Scaffolds consisting of stochastic, disordered or random micropores are one of the 
oldest and most widely used templates for tissue engineering [11,12]. Manufacturing 
techniques such as solvent casting-particulate leaching [13], phase separation [14], gas 
foaming [15], emulsion freeze drying [16] and fibre meshes [17] have been used to 
generate engineered scaffolds of foam-like internal structure with a random architecture 
and a limited control of scale [18]. Although such processing techniques are quick, 
scalable and economical, they do not enable accurate control of the microarchitectural 
details such as the pore size, geometry, their interconnections and distribution within the 
scaffold [19]. The possibility to control the inner architecture of scaffolds is desirable as 
it enables the control over its mechanical strength, the effective surface area for cell 
growth, and nutrient flow profiles within the scaffold [18]. To produce scaffolds with 
fine control over scaffold architecture in three dimensions, layer-by layer assembly 
techniques, where layers of polymers, patterned by moulding or embossing processes, 
are stacked, have been investigated by many researchers [20,21]. These techniques 
enable the formation of channels with precisely defined dimensions. However, the 
requirement for microfabricated master moulds and manual alignment of layers implies 
a slow and tedious process for achieving a multi-layered 3D construct [22].  
Recently there has been a move towards employing 3D printing [10,23,24] as a rapid 
prototyping technique to fabricate micro-scale porous structures of desired complexities, 
allowing a true engineering of the scaffold [18]. These methods involve the creation of 
3D objects using layer by layer deposition approch. Such techniques have successfully 
been employed in tissue engineering to develop scaffolds based on hard polymeric 
materials [25,26] and hydrogels [27,28]. The application of scaffolds made from soft 
polymers or elastomeric materials is desirable when engineering soft tissues [12,29,30]. 
For the fabrication of elastomeric scaffolds with microfluidic networks, micromoulding 
and individual layer-by layer assembly techniques have commonly been used [20,31]. 
However such techniques require the use of complex fabrication technologies and 
manual assembly for producing large scale structures. Thus the fabrication of 3D 
elastomeric scaffolds with defined microarchitectural details in cost-effective, scalable 
manner remains a challenge. 
Recently, processes combining 3D printing and moulding have been used for making 
structured 3D scaffolds. For example, 3D microvascular networks within polymer 
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matrices have been fabricated by 3D printing of sacrificial wax moulds, casting of low 
viscosity epoxy around the moulds and subsequent removal of the moulds [23,32]. 
However the use of wax (which has a melting temperature of about 60°C) limits the 
materials that can be cast around the mould to form the scaffold since polymers requir-
ing higher temperatures for cross-linking cannot be employed. Furthermore, the 
complete removal of the sacrificial wax components (which may not be biocompatible) 
can be challenging, in particular if you have a large 3D structure with complex geome-
try. Perfusable 3D scaffolds have also been demonstrated in a similar manner by casting 
extracellular matrix (ECM) containing cells around a 3D printed sacrificial sugar glass 
lattice and subsequently dissolving the lattice to form vascular networks [24]. However, 
it is probably difficult to print large 3D structures in the very brittle sugar glass, and the 
interfilament distance (defined by the printing process) is limited to a minimum of 1 
mm. It may therefore not be feasible to use this technique for creating dense vascular 
channels in large scale structures.  
This paper presents a new scalable and general approach for manufacturing structured 
pores/channels in 3D polymer based scaffolds. The method involves 3D printing (using 
a commercially available filament based 3D printer) of a sacrificial polyvinyl alcohol 
(PVA) mould whose geometrical features are designed according to the required 
vascular channel network. In addition to its biocompatibility, PVA is an ideal material 
because of its water solubility in combination with its high melting temperature (190°C) 
makes it robust for subsequent polymer casting and curing steps. A desired polymer is 
cast around the PVA mould, cross-linked and then the mould is dissolved, leaving 
behind a structured porous scaffold in the desired polymer material. The fabrication 
method was here demonstrated for two different polymers, the silicone elastomer 
polydimethylsiloxane (PDMS), and the syntetic hydrogel poly(2-hydroxyethyl methac-
rylate) (pHEMA). The scalability of the method was demonstrated by fabricating a 75 
cm
3
 large PDMS scaffold structure with 16,000 channels. Moreover, it was also shown 
that the PDMS scaffolds when properly pre-treated could support hepatocyte growth 
and proliferation for up to 12 days with high viability and proper function. 
3.2 Materials and Methods 
2.1 Fabrication of structured porous elastomeric scaffolds 
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The method used to fabricate elastomeric polymer scaffolds with structured channels is 
schematically presented in Figure 1. First, a commercial, low-cost 3D filament printer 
(MakerBot 2X) was used to print a sacrificial mould. A solid 3D cube of the specified 
length, width and height was designed using a computer aided design (CAD) software 
package (Solidworks 2013). The 3D CAD design was exported as .STL mesh file 
format for processing using the 3D printer software (Makerware 2.4.1, Makerbot). 
Commercially available water dissolvable polymer, Polyvinyl alcohol (PVA) (Mak-
erbot, USA) filaments were used to print the sacrificial mould. In the printing process a 
moving nozzle (x- and y-axis control) extrudes a heated polymer filament which then 
solidifies as it is deposited (Fig. 1(a)).  Following deposition of each layer, the mould is 
lowered (z-axis control) and the extrusion procedure is repeated such that successive 
layers are built on top of each other to form a 3D object (Fig. 1(b)). The printer settings 
used for printing PVA moulds are given in table 1. The extrusion temperature and feed-
rates were optimised for printing PVA. 
Table 1: 3D printing parameters used for fabricating sacrificial PVA mould 
3D printing parameters Settings 
Layer height 0.2 mm 
Infill pattern Woodpile or hexagonal 
Nozzle temperature 200 °C 
Build platform temperature 40 °C 
Feed-rate 20 mm/s 
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Figure 2: Schematic illustration of the steps involved in the fabrication of structured 
porous elastomeric scaffolds. A sacrificial 3D mould was printed in PVA (a, b). The 
printed PVA mould was transferred into a container containing pre-cured PDMS (c). 
Vacuum was applied to ensure complete filling of pre-cured PDMS into the pores of the 
mould (d). Following crosslinking of the PDMS, the sacrificial PVA mould was dis-
solved in water (e) leaving behind the structured PDMS scaffold (f). 
The printing infill density was varied to generate structures with varying porosity. The 
infill density is the parameter that defines the amount of material filled into the object 
and subsequently relates to the porosity of the 3D printed structure. The infill density 
can range from 0% to 100%, where 0% results in a completely hollow object and 100% 
infill results in a completely solid object. In order to generate structures with different 
porosities, moulds were printed with infill densities ranging from 20% to 80%. An 
illustration of the infill patterns and densities that were employed are shown in supple-
mentary Fig. 1.  
 
The 3D printed microvascular network of the PVA mould was replicated into elastomer-
ic structures of polydimethylsiloxane (PDMS): PDMS pre-polymer solution (Sylgard 
184, Dow Corning) was mixed with the curing agent in a 10:1 ratio (as per manufactur-
er’s guidelines). The mixture was degassed in vacuum and poured into a petri dish 
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containing the printed mould (Fig. 1(c)). PDMS fills the pores of the mould through 
capillary action and, in addition, vacuum was applied for 2-3 hours to ensure complete 
filling of the micro-channels of the mould with PDMS (Fig. 1(d)). PDMS was cured at a 
temperature of 60
°
C in an oven for 4 hours. Once cured, excess PDMS around the 
mould was removed to expose the PVA layer. This was done to assist the subsequent 
dissolution of PVA in water: The whole structure was immersed into a water bath (Fig. 
1(e)) until the PVA mould was completely dissolved (6 hours), and the elastomeric 
PDMS with microvascular network architecture was obtained (Fig. 1(f)).  
Cuboidal PVA moulds of 25 × 25 × 10 mm
3
 and 25 × 25 × 4 mm
3
 (length × width × 
height) were printed and used for casting PDMS scaffolds and these scaffolds were used 
for mechanical testing and cell culturing studies respectively.  
2.2 Characterizations of scaffolds 
2.2.1 Scanning electron microscopy (SEM) imaging  
The structural morphology and microstructure of the printed PVA mould as well as the 
resulting PDMS porous scaffolds were analysed using scanning electron microscopy 
(JEOL, Tokyo, Japan). Prior to SEM analysis, moulds and scaffolds were dried in an 
oven at 50°C overnight and sputter coated with gold. Samples were then analysed using 
12 kV of accelerating voltage. Pore sizes of the moulds and scaffolds were measured 
from SEM micrographs using Image J software. For each sample, ten measurements of 
pore dimensions were acquired. 
For cell-seeded scaffolds, samples were washed with PBS and fixed with 2.5% glutaral-
dehyde in PBS overnight. Next the samples were dehydrated in a series of ethanol 
solutions (50%, 70%, 90% and 100%), the samples were further air-dried and then the 
samples were ready for SEM observation. 
2.2.2 Porosity measurement 
The porosity of the PDMS scaffold was measured using equation (1) as described in the 
literature [33].  
Porosity (%) =
V−(
M
ρ
)
V
×  100%     (1)  
Where V is the volume of the scaffold, which is calculated using its outer dimension, M 
is the mass of the porous PDMS scaffold, and ρ is the density of PDMS (0.965 gm/cm3). 
Four scaffolds from each type of scaffold (with dimensions 23 × 23 × 6 mm
3
) were 
dried overnight at 80
°
C, and weighed to obtain the mass of the samples. The porosity 
was then calculated from the weight and the dimensions using equation 1. 
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2.2.3 Mechanical testing 
The mechanical properties of dry PDMS scaffolds (with dimensions of 25 × 25 × 10 
mm
3
) of varying porosity (20 - 80%) were tested by conducting uniaxial compression 
tests. A constant compression speed of 0.5 mm/min was applied to each sample using a 
tensile test machine with a 5 kN load cell (INSTRON Model 4301, Instron Engineering 
Corporation, Canton, MA, USA). The compressive modulus was estimated from the 
slope of the stress – strain curve in the elastic region, which was in the range of 12% - 
20% strain. The stress at 20% strain was obtained. The values reported were an average 
from four tested samples. 
2.2.4 Surface roughness 
The surface topography of the PVA mould and PDMS scaffold was visualized using 
SEM. PDMS scaffold surface roughness was measured using an optical measuring 
device (Alicona infinite focus). The parameters Ra and Rz were obtained from a stand-
ard spectrum of roughness. 
2.2.5 Wettability  
To assess wettability of the scaffolds, contact angle measurements were carried out on 
scaffolds before and after treatment with oxygen plasma. The contact angle was meas-
ured using the sessile drop method by depositing 3 µl of an ultrapure water drop on the 
scaffold. Three individual measurements were carried out on three independent scaf-
folds. 
2.2.6 Surface area calculation 
To estimate the surface area of the scaffolds, the dimensions of the filaments constitut-
ing the mould was acquired from SEM images of the mould. As previously described, 
the scaffold is formed by printing layers of filaments (with a height of 0.2 mm) organ-
ised in the xy axis. The surface area was calculated from the SEM images of a single 
layer and then multiplied by the number of layers.  
2.3. Culturing cells in scaffolds 
2.3.1 Cells 
Human hepatoblastoma (HepG2) cells were obtained from the German Collection of 
Microorganisms and Cell cultures (DMSZ, Braunschweig, Germany). The cells were 
maintained in Roswell Park Memorial Institute (RPMI) 1640 growth medium supple-
mented with 10% fetal bovine serum (FBS, Sigma-Aldrich Chemie GmbH, 
Switzerland) and 100 µg/ml penicillin and 10 µg/ml streptomycin in a humidified 
incubator at 37°C and 5% CO2. Cells were cultured to confluence in standard polysty-
 62 
 
rene cell culture flasks, and then released using 0.025% trypsin/EDTA solution. The cell 
suspension was centrifuged and the cell pellet was washed twice with phosphate buff-
ered saline (PBS) and then re-suspended in fresh growth medium. The cell density was 
measured using a haemocytometer and adjusted as required for the seeding on the 3D 
scaffolds. 
2.3.2 Scaffold preparation for cell culture  
PDMS scaffolds (fabricated with 80% infill moulds) were frozen in liquid nitrogen and 
punched into cylindrical scaffolds (having a diameter of 6 mm and height 4 mm) using a 
tissue puncher (Harris Uni-Core, USA). To render them hydrophilic, the scaffolds were 
modified with oxygen plasma using a 13.56 MHz RF generator equipped Atto Plasma 
System (Diener Electronic GmbH, Ebhausen, Germany). Initially the plasma chamber 
was evacuated to a pressure below 15 Pa, after which oxygen was introduced (pressure 
stabilization at 30 Pa) and the plasma was ignited (power 50 W) for a  duration of 2 min 
for each side of the scaffold.The treated scaffolds were transferred into an autoclavable 
glass vial containing sterile water and autoclaved at 120˚C for 20 minutes for sterilisa-
tion. To promote cell attachment to the scaffolds, the scaffolds were coated with 40 
µg/ml of Collagen I (Collagen I rat protein, Life Technologies, A1048301) at 4°C 
overnight. The scaffolds were washed twice with phosphate buffered saline (PBS) and 
excess collagen was removed by centrifugation of the samples at 1000 rpm. Finally, the 
scaffolds were placed in a petri dish containing RPMI medium and incubated inside a 
humidified incubator at 37°C and 5% CO2 for 2 hours prior to cell seeding. 
2.3.3 Cultivation of hepG2 cells inside the scaffolds 
HepG2 cells were cultured in the fabricated scaffolds to evaluate the ability of PDMS 
3D constructs to support cell adhesion, proliferation and spreading. For cell seeding a 
customised cell loading platform was developed as shown schematically in supplemen-
tary figure 2. A cell seeding plate with 16 cylindrical holes (having a diameter of 6 mm) 
and a rectangular support frame was fabricated in 6 mm thick Poly(methyl methacry-
late) (PMMA) using a CO2 laser cutter machine (Epilog Mini 18 Laser, CO 80403, 
USA). The seeding plate and frame were sterilized by immersion in 0.5 M sodium 
hydroxide solution for 2 hours followed by rinsing in sterile water. The frame and 
seeding plate were placed inside a sterile petri dish such that the seeding plate was 
raised and had no direct contact with the petri dish. The collagen coated scaffolds from 
the incubator were inserted into the holes in the seeding plate. A suspension containing 
250000 cells in 20 µl of media was prepared and loaded into each scaffold. After 
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seeding, the petri plate was incubated at 37 ˚C for 3 hours to allow the cells to attach to 
the scaffold. Every hour the loading plate was inverted upside down to enable better cell 
infiltration into the scaffold. Finally the scaffolds were removed from the seeding plate 
and transferred into a 24 well plate. 1 ml of cell culture medium was added to each well. 
The medium was refreshed every 2 days and old media was collected for cellular 
functionality assays. On day 4, 8 and 12 of the culture period, two scaffolds from each 
time point were sacrificed and used for live/dead staining.  
2.3.4 Biochemical assays 
Cell proliferation was estimated using the colorimetric indicator alamarBlue® assay 
(Life Technologies). The cell-scaffold constructs were transferred into a 24 well plate 
each containing 1 ml of RPMI and alamarBlue® solution (in a 10:1 ratio) and incubated 
for 2 hours in a humidified incubator at 37°C. The absorbance of the extracted dye, 
which is proportional to the number of cells attached to the scaffold, was measured 
spectrophotometrically using a microplate reader (PerkinElmer, USA) at wavelengths of 
570 nm. Three independent scaffolds were measured in triplicates, and the background 
(i.e. alamarBlue® absorbance measured at day 0) was subtracted.   
 
For the HepG2 functionality test, extracellular concentration of albumin secretion from 
the HepG2 cells was determined by using an enzyme-linked immunosorbent assay 
(ELISA) (Bethyl Laboratories, USA) according to the manufacturer`s instructions. All 
samples were measured in triplicates and the standard deviation (SD) of mean was 
determined from 3 independent scaffolds. The absorbance was measured at 450 nm 
using a spectrophotometer (PerkinElmer, USA).  
2.3.5 Cell Imaging 
To visualize cell viability in the scaffolds, a live/dead-assay was performed using a 
live/dead cell imaging kit (Life technologies LIVE/DEAD® Cell Imaging Kit), which is 
based on a cell-permeable dye for staining of live cells (excitation/emission 488 nm/515 
nm) and a cell-impermeable dye for staining of dead and dying cells (excita-
tion/emission 570nm/602 nm). Briefly, the cell-laden scaffolds were removed from the 
culture medium and gently washed with PBS. They were then incubated in the dye 
solution for 30 min at 37°C (as per manufacturer’s instructions). The scaffolds were 
imaged using a fluorescence microscope (Zeiss Axio Observer, ZI). 3D reconstructions 
were compiled from 20 imaged sections (each of 30 μm thickness). 
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To visualize the cell proliferation and distribution through the cross section of the 
scaffolds, cell-laden scaffolds were stained with cell-permeable nuclear stain Hoechst 
33342 (NucBlue® Live Ready Probes® Reagent, life technologies) for live cell nuclei 
and ethidium homodimer-1 (life technologies) for dead cell nucleus for 10 minute. The 
scaffolds were then dissected longitudinally using a sterile scalpel and each section was 
observed under a fluorescence microscope. 3D reconstructions were compiled from 20 
imaged sections (each of 30 μm thickness). 
 
An immunofluorescence study was performed to visualise the morphology of cells 
attached to the scaffold surface: After 12 days of cell growth, the cell-laden scaffolds 
were immunostained with beta-tubulin as cell cytoskeleton and nucleus. The construct 
was fixed (4% paraformaldehyde), permeabilized (30 min, 0.1% Triton-X in phosphate 
buffered saline (PBS)), and blocked (30 min, 0.1% Tween20 and 1% bovine serum 
albumin in PBS) for unspecific binding of the antibodies. The construct was stained 
with primary antibody as monoclonal Anti-α-Tubulin IgG1 (2 h, 1:200, Life Technolo-
gies) followed by TO-PRO-3 nuclear stain (1:1000, Life Technologies). The scaffold 
was then cut through the centre using a sterile scalpel and visualized under a Zeiss 
ApoTome fluorescence microscope. 3D reconstructions were compiled from 20 imaged 
sections (each having a thickness of 5 μm).  
3.3 Results 
3.1 Scaffold fabrication 
Scaffolds were fabricated by casting PDMS around sacrificial moulds printed using two 
different infill patterns (woodpile and hexagonal) and four different infill densities. 
Photographs and SEM images of the printed moulds and resulting PDMS scaffolds of 
the two different infill patterns are shown in Fig. 2. The scaffolds possessed well-
defined, porous structures. The square and hexagonal pore structure of both PVA 
moulds and PDMS scaffolds were observed to be uniform and consistent (Fig 2 (a, b, e, 
f)). The structural features of the PVA mould are faithfully replicated in the PDMS 
scaffold (Fig 2 (c, d, g, h)).  
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Figure 3: Photographs of moulds and scaffolds with hexagonal (a, e) and woodpile (b, f) 
infill patterns. SEM images of moulds and scaffolds with hexagonal (c, g) and woodpile 
(d, h) infill patterns. (i) optical image of a 50 layered (1 cm
3
 cube) and 150 layered (75 
cm
3
 cube) 3D printed PVA mould (j) optical image of 50 layered (1 cm
3
 cube) and 150 
layered (75 cm
3
 cube) PDMS scaffolds replicated from the mould (i). Scale bar in (i) 
and (j): 1 cm. 
The woodpile infill pattern results in structures comprising orthogonal arrays of fila-
ments with the centre-to-centre spacing between adjacent filaments differing based on 
the chosen infill density (Fig. 3). Infill densities of 20, 40, 60 and 80 % produces 
structures where filaments in a layer had a distances of 1482, 593, 253 and 78 µm 
respectively. As the infill density increases, the centre-to-centre spacing of the filaments 
in the PVA mould decreases (Fig. 3a-d). SEM images of the mould showed that the 
printed PVA filaments have an elliptical cross-section with a width of 400 µm and a 
height of 200 µm (supplementary fig). The channels in the resulting PDMS scaffold 
have an elliptical profile from a cross section view (width 344µm, height 190 µm) 
(shown in supplimentory fig 5) and a square profile (average side length 344 um) from 
the top view. The channels dimensions in the PDMS scaffold are slightly smaller than 
the dimension of the PVA filaments of the mould due to shrinkage of PDMS during the 
curing process. The channel to channel distance varied from 1.4 mm at 20 % infill 
density down to 78 µm at 80 % infill density of the printed mould. Thus the employed 
3D printing technique enables the layer by layer assembly of a different number of PVA 
filaments forming a porous 3D mould. To demonstrate the scalability of the fabrication 
process, a larger cubic mould (75 cm
3
) was fabricated and employed for generating a 
replica PDMS scaffold with the same dimensions. Fig, 2(i) shows an image of two cubic 
moulds of dimensions 1 cm
3
 and 75 cm
3
 printed using 80% infill settings and Fig. 2(j) 
shows the resulting PDMS scaffolds. Thus, as demonstrated in Fig. 2, the periodic 
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micro and macroscale structural patterns of the PVA mould were well replicated in the 
PDMS scaffolds.  
Figure 4: SEM micrographs of 3D printed PVA moulds of 20, 40, 60 and 80% infill 
densities (a-d) and corresponding PDMS scaffolds (e-h).  
3.2 Scaffold characterisation 
3.2.1 Porosity 
The experimentally determined porosity of fabricated scaffolds is presented in Fig. 4. 
The porosity of the scaffolds varied linearly as a function of the infill density of the 
printed mould from 19.9% porosity at 20% infill up to 81.2% porosity at 80% infill (Fig 
4(a)).  
3.2.2 Surface area 
The calculated surface areas of a 1 cm
3 
fabricated scaffolds of varying porosities are 
shown in Fig. 4 (b). As the infill density of the mould increases from 20 % to 80 %, 
there is also a corresponding increase (from 52.5 cm
2
/cm
3
 to 150.9 cm
2
/cm
3
, respective-
ly) in the surface area of the channels within the PDMS scaffold volume. As the infill 
density of the mould increases (Fig 3 (a-d) the density of channels also increases (Fig 3 
(e-h)), which results in a linear increase in the total surface area of the channels (Fig 4 
(b)). 
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Figure 4: Measured porosity (error bars = SD, n = 4) (a) and calculated surface to 
volume ratio (b) of scaffolds fabricated from mould with different infill density. 
 
3.2.3 Mechanical testing 
The assessment of the compressive characteristics of scaffolds is known to play a significant 
role in many tissue-engineering applications [34]. Compression tests of the scaffolds varying in 
porosity were performed to assess the stress-strain relationship and evaluate their compressive 
moduli (Fig. 5). The compressive modulus was determined as the slope of the initial linear 
portion of the stress vs. strain curve (12 – 20%). The compressive modulus were determined to 
be 1.84 ± 0.023, 0.84 ± 0.044, 0.36 ± 0.046 and 0.075 ± 0.047 MPa for the 20, 40, 60, and 80 % 
porosity scaffolds, respectively. Results showed that the energy absorption of the scaffolds is 
greatly reduced with increasing porosity. There is also a dramatic decrease in the compressive 
modulus and in the stress at 20% strain with increasing scaffold porosity 
 
 
Figure 5: (a) Stress–strain curves at 4N load for different scaffolds, (b) compressive 
moduli of different PDMS scaffolds (Error bars = standard deviation of 4 samples (n = 
4)). 
3.2.4 Surface roughness 
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The roughness of the 3D printed PVA mould and corresponding PDMS scaffold was 
assessed using SEM. As shown in Fig. 6 (a-d), the presence of features such as pillars 
and grooves visible on the PVA mould are faithfully replicated in the PDMS scaffolds. 
The roughness of the PDMS scaffold was measured using an optical profilometer. The 
relative height and surface roughness is shown in the surface profile image (Fig. 6(e)) 
and the roughness parameters Ra and Rz of the PDMS scaffold surface were measured to 
be approximately 1.036 μm and 1.32 μm, respectively. 
Figure 6: Surface roughness analysis: SEM images showing microfeatures in the PVA 
mould surface (a) and PDMS scaffold (b, c & d), Surface profile image of PDMS 
scaffold surface generated from optical profilometer (c) and zoom in of image c (d). 
3.3 Culturing cells in scaffold  
3.3.1 Preparing scaffold for cell culturing (surface treatment) 
To enable cell seeding and culturing within a porous scaffolds, it is important to render 
the scaffold surface hydrophilic [35]. This is required to ensure that the cell suspension 
and culture media can be absorbed within the scaffold pores. Oxygen plasma treatment 
was applied to the fabricated scaffolds to achieve this. Using this treatment, the contact 
angle of the scaffold surface decreased from 122° ± 3.5° to 0°
 
and media was able to 
infiltrate the pores of the scaffold (Supplementary Fig. 3).    
3.3.2 Cell proliferation, viability and function 
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Following the surface treatment, the scaffolds were prepared for cell culturing, seeded 
with cells, and incubated as described in materials and methods. Cell viability and 
proliferation in the PDMS scaffolds with 80 % porosity were investigated over a 12 
days culture period using biochemical assays and imaging techniques. Cell proliferation 
in the scaffold was quantified using the alamarBlue® assay. As shown in Fig. 7 (a), the 
fluorescence intensity increased linearly over the culture period, indicating increase in 
the number of cells in the scaffolds with time. The functionality of HepG2 cells cultured 
on the scaffolds was established by measuring the extracellular albumin production 
(Fig. 7 (b)). There was an increase in albumin production from day 1 to day 12 of the 
cultures which correlate with the increased cell density in the scaffolds.  
Figure 7: (a) Change in alamarBlue® florescence intensity of scaffolds over culture 
time. The fluorescence intensity is proportional to the amount of cells. (b) Albumin 
production of HepG2 cells grown in PDMS scaffolds over 12 days of culture. Error bars 
indicate standard deviation of 3, independent scaffolds. 
Live/dead staining of the cell-scaffold construct was carried out to assess the viability of 
cells cultured on the scaffolds. Fig. 8 shows the confocal microscopy images of stained 
HepG2 cells on day 4, 8 and 12 of the culture period. Through the culture period, the 
density of living cells (stained green) increased. On day 12 of the culture, a confluent 
layer of live cells was visible on the scaffolds. In all cases, no dead cells were observed, 
so close to 100 % cell viability was maintained throughout the 12 days culture period. 
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Figure 8: Live/dead staining of HepG2 cells grown on top and bottom part of the PDMS 
scaffold for 4, 8 and 12 days. Scale bars represent 1 mm. 
3.3.3 Cell infiltration and distribution within the scaffolds  
At different time points during the culture period, the infiltration and distribution of 
HepG2 cells within the PDMS scaffolds was investigated. This was done by staining the 
scaffolds with nuclear stain Hoechst 33342 (NucBlue® Live Ready Probes® Reagent, 
life technologies) for live cell nuclei and ethidium homodimer-1 (life technologies) for 
dead cell nucleus. To visualise cell distribution through the cross section of the scaffold, 
it was dissected along its central axis and imaged using fluorescence microscopy. Fig. 9 
shows live cell nuclei (stained blue) on the scaffold on day 4, 8 and 12 of the culture. 
Close to 100 % cell viability was observed (no dead cells could be seen) with cells 
present throughout the cross section of the scaffold by the end of the culture period. 
Scaffolds acquired from day 4 of the culture showed a higher density of cells closer to 
the top and bottom face of the scaffold and a sparse density of cells in the central 
regions of the scaffold. But with longer culture time, cells appeared to proliferate and 
are seen to be homogenously distributed throughout the channels of the scaffolds at day 
8 and 12.  
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Figure 9: Visualization of cell distribution through the central section of the scaffold 
stained with NucBlue® (live cells: blue) and ethidium Homodimer-1 (EthD-1) (dead 
stain: red) on day 4, 8 12 of HepG2 cell culturing. Scale bars 1 mm. 
Immunostaining of the scaffold was carried out to visualise the morphology of cells 
cultured on the scaffolds. Fig. 10 shows a homogeneous and confluent distribution of 
cells in the central region of the scaffold, highlighting the cytoskeleton beta-tubulin 
(green) and cell nucleus (red). After 12 days of cell culture the cells were uniformly 
distributed with high density of live cell in the centre of the scaffold. Immunofluores-
cence staining of the beta-tubulin demonstrated that the cells were well attached to the 
surface with a spread-out cell morphology. 
Figure 10: Hepg2 cell morphology and attachment to PDMS scaffold using immunostaining (a & b). Cell cytoskele-
ton beta tubulin (green) and nucleus (red). (a) Top surface of the scaffold. (b) Longitudinal cross section of the 
scaffold. Scale bar of image a) with 100 µm ,  b) with 1 mm. 
HepG2 cell adhesion on scaffold was also investigated through SEM as shown in the 
supplementary figure 5 (a, b & c). After 4 days of culture, the interaction between cells 
and the scaffold surface was examined. Cells cultured on PDMS scaffold formed a well 
spread morphology and exhibited excellent cell adhesion.  
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3.4 Discussion 
In this paper, a new scalable and reproducible technique for fabricating 3D polymer 
scaffolds with defined micro-architectures has been presented. The technique is simple 
and involves casting of a desired polymer material within a 3D printed water-soluble 
PVA mould, which defines the microarchitecture/geometry of pores or channels within 
the scaffold (Figs. 1-3). 3D printing parameters were optimised to enable the production 
of reproducible moulds with high yield. The technique was applied to fabricate ‘wood-
pile’ like scaffolds with regularly spaced aligned polymer filaments in the x and y 
directions. Scaffolds of porosities ranging from 20 – 80% and channel to channel 
distances ranging from 78µm to 1482µm were fabricated by specifying the infill density 
of the moulds. Scaffolds with hexagonal micro-features were also obtained by using 
moulds with hexagonal infill patterns. The dimensions of the channels formed in the 
PDMS replica scaffolds were ellipsoidal shaped with dimensions (344µm × 190µm) 
that were slightly smaller than that of the filaments in the printed mould (400µm × 
200µm), due to shrinkage during elastomer curing. 
We used the biocompatible elastiomeric polymer PDMS to demonstrate the ease of 
fabrication and scaling of scaffolds structure, and furthermore showed that it has 
potential as a scaffold for growth of liver cells. However, the method has general 
applicability, meaning that other mouldable materials can be structured in a similar 
manner. To prove this point, poly-2-hydroxyethyl methacrylate (pHEMA) hydrogel 
scaffolds were produced by monomer/crosslinker casting around PVA mould, photo-
crosslinking (supplementary Figure. 4, and material and method in supplementary 
section) and subsequent dissolution of the PVA mould. 
The silicone elastomer PDMS is optically clear, and, in general, inert, non-toxic, and 
non-flammable.  Its applications range from contact lenses and medical devices to 
additives in cosmetics and food products. PDMS is also widely used as a material for 
microfluidic cell culturing and the high number of publications using it indicates that it 
is a biocompatible material [36]. In general the effects of PDMS or silicones on cells 
need to be evaluated on a case by case situation, as PDMS in some situations have 
subtle effect on gene expression [37], but we clearly show here that the fabricated 
PDMS elastomer scaffold supports HepG2 growth and function (Figs. 7-10). This type 
of elastomer scaffold could be used as a part of a life support system (LSS), e.g., an 
extracorporeal liver [38]to temporarily relieve liver disease patients. In such application 
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PDMS offers several advantages: 1) It is easy to fabricate PDMS scaffold structures 
using the PVA sacrificial moulding method presented here 2) PDMS is a structurally 
strong material for building large meshes (figure 2J)  3) PDMS is easy to sterilise by 
autoclavation (in contrast to some hydrogels) 4) In contrast to hydrogels and many 
biodegradable materials PDMS does not shrink, swell or warp significantly with time 
meaning that rational fluidics optimisation can be done as well as robust fluidic connec-
tions for perfusions. 5) There are FDA approved medical grade silicone elastomers 
which should be compatible with the here described fabrication method. 
It is well recognised that in order to be of clinical relevance, tissue constructs must be 
scaled up to the macro scale, not only in length and width, but also in thickness [20]. 
The presented fabrication method overcomes existing challenges in creating thicker 
constructs in a simple and reproducible manner by using precision assembly technology 
to control the micro-architectural details. The scalability of the process was demonstrat-
ed by producing a 75 cm
3
 large scaffold structure with 16,000 channels with a channel 
to channel distance of only 78 µm (Fig. 2(j)). To our knowledge this is the largest 
scaffold ever to be produced with such small features sizes and with so many structured 
channels. Thus the process enables a more efficient scale up of scaffolds both in size 
and in throughput, while also allowing versatility in the implementation of 3D micro 
architectural designs. 
It is well established that the micro-roughness of a scaffold surface plays an important 
role in cell attachment and proliferation [39–42]. For this reason, the topological fea-
tures of the scaffold were analysed using SEM to measure the surface roughness. 
Geometrical and topological features of the 3D printed PVA mould (Fig. 6a and b) were 
well replicated in the PDMS scaffold (Fig. 6c and d), giving the scaffold micro- and 
nano-scale roughness. Such micro- and nano-scale roughness can be an advantage for 
cell attachment and proliferation [43]. Our results are in agreement with this: We 
observed confluent layer of well-attached cells with spread-out cell morphology (Fig. 
10). 
It is well known that cells respond to the material on which they grow, both in terms of 
cytoskeleton, cell morphology, cell differentiation and function [45,46]. The mechanical 
properties of the fabricated scaffolds of varying porosities were therefore characterised. 
The compressive modulus of the scaffolds were estimated to be 1.84, 0.84, 0.34, 0.075 
MPa for 20, 40, 60 and 80% porous scaffolds, respectively. The inverse relationship 
between scaffold porosity and compressive modulus is expected because scaffold with a 
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higher porosity have less material/mass to resist applied load and therefore have a lower 
compressive modulus. If the stiffness of the PDMS scaffold should be a problem it can 
be adjusted by changing the ratio of pre-polymer to curing agent [46] or by selecting 
hydrogel materials such as pHEMA (supplementary Fig. 4) could be used for casting the 
scaffold. 
A highly available surface area in a scaffold can provide high ligand density for initial 
cell attachment and proliferation [47]. We chose to use the scaffold with the highest 
porosity (80%) for culturing cells since it has the lowest compressive modulus, enables 
better mass transport, and has the highest specific surface area (Fig. 4b) for cell attach-
ment.  
Until now it has been a challenge to maintain viable cells within the inner cores of thick 
engineered tissue constructs due to insufficient oxygen and nutrient levels [33]. To 
regenerate artificial tissues a homogeneous cell distribution should be maintained inside 
the porous scaffold structure [48,49]. The scaffolds presented in this work were able to 
sustain cells with 100 % viability throughout the 12 day culture period. Metabolic 
assays and total cell DNA quantification assays do not give information on cell infiltra-
tion and distribution inside the scaffold. In order to visualise this aspect, the cell nucleus 
stained scaffolds were imaged at the top, bottom and cross sectional surfaces (Fig. 9). 
Cells were seen to be uniformly distributed throughout the channels of the scaffolds and 
along the cross sectional length of the scaffold. The achieved homogeneity can be 
attributed to the following: Firstly, the cell loading procedure employed ensures an even 
distribution of cells throughout the scaffolds. Secondly, the parallel and perpendicular 
structured channels in the scaffold allow sufficient oxygen and nutrient mass transport 
into the scaffold which promotes cell survival and proliferation. Thus at the end of the 
culture period, cells were seen to be uniformly distributed throughout the scaffolds and 
along the cross sectional length of the scaffold. Results from immunostaining clearly 
showed good HepG2 cell morphology and attachment to the scaffold surface (Fig. 10). 
Cell functionality was assessed by measuring albumin secretion of cells in scaffolds 
over time (Fig. 7b). The increase in albumin secretion through the culture period 
indicate that the cells were able to maintain their functionally while cultured in the 
presented 3D scaffold. 
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3.5 Conclusions 
In this study, we have demonstrated a new technique for fabricating scaffolds by 3D 
printing a sacrificial water dissolvable PVA mould, casting polymer around it and 
subsequently dissolving the sacrificial mould, leading to structured scaffolds. Different 
designs of PDMS scaffolds were successfully prepared, and the fabrication technique 
allowed the tuning of physical and mechanical properties by controlling the 3D printing 
parameter. By observing the biological activity of the hepatocytes in the scaffold we 
conforms that along with maintaining very high cellular viability the scaffold could also 
support high level of cellular albumin secretion throughout the cultivation period. After 
12 days of cell culturing we observed a very high density of cells, homogeneously 
distribution across the scaffold due to good mass and oxygen transport into the scaffold. 
The fabrication method can also be applied to other synthetic or natural polymers as 
demonstrated by fabricating scaffolds in the hydrogel pHEMA.  Furthermore, as we 
have demonstrated, the fabricated scaffold can be scaled up to sizes relevant for bioarti-
ficial organs. In conclusion, the described process is scalable, compatible with cell 
culture, rapid, and inexpensive. 
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Figure 1. Top and isometric view of different pore sized and designes of mould. A-E) 
top single layer and F-H) combined multiple layers of the 25 × 25 × 10 mm
3
 cube with 
woodpile and hexagonal design generated from respective g-code files using open 
source Repetier-Host V1 Beta1 software (http://www.repetier.com). 
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Figure 2. Schematic of cell seeding procedure. (A) Support frame, (B) Scaffolds (red) loaded in 
seeding plate (blue), (C) seeding plate placed on frame (D) cut through cross section of (C) BB’. 
Scaffolds are held raised within the holes of the tray and 20 µl of cell suspension are deposited 
on to each scaffold.  
 
 
 
Figure 3. Contact angle measurement and wettability on the PDMS scaffold before (A&C) and after 
plasma (B&D) of plasma treatment. 
Fabrication of structured porous pHEMA hydrogel scaffolds 
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Poly-2-hydroxyethyl methacrylate (pHEMA) hydrogel scaffolds were fabricated similar 
to the procedure for fabricating PDMS scaffolds with some modifications: 5 mL HEMA 
monomer (97% purity, Sigma-Aldrich Chemie Gmbh, Germany) , 0.125 mL (2.5%) of 
ethylene glycol dimethacrylate (EGDMA) co-monomer (98% purity, Sigma-Aldrich 
Chemie Gmbh, Germany), 1% (w/v) of azobisisobutyronitrile (AIBN) as photoinitiator 
(≥ 98 % (GC) purity, Fluka Analytical, Switzerland), and deionized water into a 50 
layered PVA mould (25 × 25 × 10 mm
3
) using vacuum. The mould with the polymer 
mixture was exposed to UV light (custom build apperatus) for ~20 min for the polymer-
ization of HEMA and soaked in deionized water for at least 24 h to remove the 
sacrificial PVA mould as well as any unreacted species. SEM images of 3D pHEMA 
scaffolds are taken with a JEOL, Tokyo, Japan after coating samples with gold. 
Results and discussion for pHEMA 
The fabrication of pHEMA scaffolds was very similar to the fabrication of PDMS 
scaffold with minor modifications as described above. The hydrogel scaffolds contain 
fully interconnected porous networks with mechanically stable structure for use as 
scaffold materials. The average pore diameter of pHEMA scaffold was around 400 µm. 
The zoom in image of the pHEMA scaffold (Fig. 10c) demonstrates the rough surface, 
which was replicated from the PVA mould. Fabrication of pHEMA scaffold with PVA 
molding approach confirms that the technique is also suitable for photocrosslinkable 
polymer fabrication.   
 
Figure 4. A, B & C) SEM micrographs of 3D pHEMA scaffolds casted from PVA molds with 40% in-fill density. 
The pHEMA scaffold is shown at different magnifications. The scale bare is 500 µm in A&B and 100 µm in C. 
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Figure 5. SEM images of cross-section views of PVA mould (A) and PDMS scaffold (B). The widths and heights 
were shown in red and yellow respectively. The scale bar for both A and B are 200 µm. 
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4. CHAPTER 4. Fabrication of scalable tissue 
engineering scaffolds with dual-pore 
microarchitecture by combining 3D printing and 
particle leaching 
This work was published as: Mohanty, S., et al. (2016). Fabrication of Scalable and 
Structured Tissue Engineering Scaffolds Using Water Dissolvable Sacrificial 3D 
Printed Moulds. Materials Science Engineering C (61): 180-189. 
4.1 Introduction 
In recent years, there has been a significant medical demand for the development of a 
functional engineered tissue constructs suitable for tissue/organ replacement. One of the 
primary challenges in translation of tissue engineering for clinical applications is the 
difficulty in scaling up complex, biologically effective tissues and organs to the size 
adequate for human therapy [1]. Generation of a thick 3D tissue requires development 
of highly dense vascular networks that can meet the nutrient and oxygen requirements 
of a bulk tissue composed of a large quantity of living cells [2]. Blood vessel formation 
within the bulk tissue construct does not occur within a sufficient time frame to supply 
the necessary amount of nutrients and oxygen, leading to necrosis in the formed tissue 
[3]. Therefore, there is a great demand for a smart scaffold designs for effective and 
efficient nutrient and oxygen transport throughout the bulk of thick engineered tissues.  
Polymeric tissue engineering scaffolds with disordered or random micropores  have 
traditionally been fabricated using various techniques, such as particle leaching, phase 
separation, and gas foaming [4–6]. Even though these techniques are scalable and 
economical, they do not allow accurate control of the scaffold microenvironment, 
determined by the pore architecture, mechanical strength, surface area and mass 
transport within the scaffold [7]. These techniques can only generate one type of pore 
geometry i.e. local/random in the scaffold. It has been shown that scaffolds consisting of 
only random pores can significantly limit cell penetration and uniformity of the cell 
distribution due to limited diffusion of culture medium into the centre of the scaffolds 
[8–10]. Therefore, there is a need for a second type of porous structure, which can 
efficiently interconnects local random pores of the scaffold for better generation of large 
tissues under in vitro and in vivo conditions. 
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Recently, studies using dual-pore scaffolds, comprising structured pores (channels) in 
combination with local random porous regions, have shown tremendous potential 
towards engineering of complex tissues with better cell proliferation due to improved 
nutrient and oxygen transport [3,11–16]. A recent report also demonstrated that after 
transplantation of dual-porous scaffolds more cells from the host tissue infiltrated into 
the scaffolds due to its smart global pore architecture compared to random porous 
scaffolds, hence, enhancing integration of blood vessels in the host tissue [17]. The 
structured pores help overcome the diffusion limitation while the random pores provide 
a large surface area to accommodate a high density of cells. Therefore, dual-pore 
scaffold design with perfusable channels serves as a promising strategy for engineering 
of large-scale artificial tissues or organs for regenerative medicine by promoting rapid 
vascularization that enhances survival of the seeded cells. 
Different approaches have been employed to fabricate dual-pore scaffolds for tissue 
engineering using both natural and synthetic polymers [3,11–15,18,19]. For controlling 
the size and degree of porosity of the random pores as well as the mechanical properties 
of the scaffolds, the two major fabrication techniques have been freeze-drying 
[3,11,13,14,20] and salt leaching [11,12,16] process. The published results have shown 
that freeze-drying cannot yield as large a range of pore dimensions as salt leaching, 
which can utilize salt crystals of various dimensions depending on the requirements. 
Currently various solid freeform (SFF) fabrication techniques such as stereolithography 
based printing have been reported to fabricate 3D porous scaffolds with well controlled 
pore size, porosity and mechanical properties using photo-crosslinkable materials [21]. 
Sacrificial moulds from SFF fabrication [11] or metallic wires [3,12,16,19] have been 
implemented for the generation of structured pores. Automated SFF fabricated moulds 
have several advantages compared to metal wire based moulds that require choice of 
wire dimensions and time consuming manual assembly of a number of wires. Hence, 
SFF based moulds are more reliable and rapid to use as well as provide easy upscaling 
of scaffold size. However, the SFF techniques presented by Kang et al. [11] required 
manual assembly of different stereolithographic printer parts and synthesis of photo 
curable inks for fabrication of the sacrificial mould. Moreover, fabrication of sacrificial 
moulds using stereolithography is a slow and expensive process requiring expensive 
commercial 3D printing equipment. Hence, there is an urgent need to develop SFF 
moulds using inexpensive 3D printing. 
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Recently, 3D printed poly(vinyl alcohol) (PVA) sacrificial moulds using 3D filament 
printer have been demonstrated to facilitate fabrication of porous polymeric scaffolds 
for various tissue engineering applications [22,23]. Ortega et al. and Jeffries et al. have 
proposed a new fabrication approach by encapsulating 3D printed single layered PVA 
channels using an inexpensive 3D filament printer in combination with electrospun 
nanofibers to create perfusable vascular networks [22,23]. However, the fabricated 
scaffolds only comprised a single layer of channels, hence, they didn´t generate a 
functional tissue/organ composed of multiple layers. Moreover, the random pores had 
dimensions of only a few nanometres, and were thus not able to facilitate cell penetra-
tion into the interior of the scaffolds. There is therefore a need to develop a new 
approach to fabricate multi-layered dual-pore scaffolds using a sacrificial mould that 
allows precise control over the geometry and dimensions of the structured and random 
pores. 
In this paper, we present a new method for fabrication of dual-porous scaffolds using 
the combination of 3D filament printing and salt leaching process to control the geome-
try and dimensions of the structured and random pores, respectively. The 3D printing of 
a sacrificial PVA mould allows generation of structured pores with a high degree of 
control over the inner architecture designed according to the requirements of an applica-
tion as we have described previously[24]. The parameters of the random pores, e.g., 
degree of porosity and pore size, are controlled by varying the size of the salt crystals 
used as the porogen. After casting the desired polymer in the mould and cross-linking it 
the PVA and salt are dissolved, leaving behind a dual-pore scaffold. The fabrication 
process is scalable and capable of generating scaffolds that are structurally and dimen-
sionally relevant for tissue engineering applications. We show the fabrication using 
polydimethylsiloxane (PDMS) and cultured human hepatoblastoma (HepG2) cells for 
16 days to demonstrate that the scaffolds could provide 3D microenvironment able to 
support cell growth and liver tissue functionality. The performance of the dual-pore 
scaffolds is compared with scaffolds having either only structured or only random pores 
fabricated using 3D printed PVA moulds or salt leaching, respectively. 
4.2 Materials and method 
4.2.1 Mould fabrication 
Sacrificial moulds for both structured and dual-pore scaffolds were 3D printed using a 
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Replicator 2X 3D filament deposition printer (MakerBot Industries, LLC, Brooklyn, 
NY, USA) as described previously [24]. In brief, a 3D cube (L 25 mm x W 25 mm x H 
10 mm) was designed using SolidWorks 2013 3D CAD design software (Dassault 
Systems, SolidWorks Corp., Waltham, MA, USA). The design was exported as STL 
format into the 3D printing software (Makerware 2.4.1) for G-code generation and 
mould printing. Water dissolvable poly(vinyl alcohol) (PVA) filaments (MakerBot, 
USA) were used to print the sacrificial moulds. The printing was performed at 200 
o
C as 
the nozzle temperature and 40
o 
C as the bed temperature. The PVA moulds printed with 
various porosities (infills) were used directly for fabrication of the structured pore 
scaffolds. For fabrication of the dual pore scaffolds (shown in Fig. 1 and summarised in 
Fig. S6), the PVA moulds were printed with 40 % infill as shown in Fig. 1A. 10 g of 
NaCl (Sigma-Aldrich Corporation, St. Louis, MO, USA) crystals (size 300 - 600 µm) 
was mixed with 1 ml of ultrapure water from a Milli-Q
®
 water purification system 
(Millipore Corporation, Billerica, MA, USA) and packed manually into the PVA mould 
(Fig. 1B). The salt filled moulds were dried in an oven at 60 
o
C for 1 h. The small 
amount of water was used to form the interconnections between the salt crystals as well 
as between the salt crystals and PVA filaments. Both the PVA moulds for the structured 
pore scaffolds and the salt-PVA moulds for the dual-pore scaffolds were replicated into 
polydimethylsiloxane (PDMS) (Sylgard 184 Elastomer kit, Dow Corning Corporation, 
Midland, MI, USA). The PDMS base was mixed thoroughly with the curing agent in a 
10:1 ratio and the mixture was degassed in a vacuum desiccator to remove air bubbles. 
The PDMS mixture was then cast into the mould (Fig. 1C). Then, the container with the 
mould covered with PDMS mixture was transferred into the vacuum desiccator for 2-3 
h to ensure complete infiltration of PDMS into the mould (Fig. 1D). The PDMS was 
cured at 60
°
C in an oven for 4-6 h. After curing, the excess PDMS around the moulds 
was removed to expose the PVA or salt-PVA structures. This was done to allow the 
subsequent dissolution of PVA and salt in water. The entire mould-PDMS structures 
were immersed into water (Fig. 1E) until the PVA and salt had been completely re-
moved (about 6-12 h), releasing the PDMS scaffolds with structured pore or dual-pore 
architecture (Fig. 1F). 
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Fig. 1 Fabrication of dual-pore scaffolds: A sacrificial 3D mould was 3D printed in 
PVA (A) and packed with salt crystals (B). The salt-filled PVA mould was transferred 
into a container and PDMS was cast to cover it (C). Vacuum was applied to ensure 
complete filling of PDMS into the pores of the mould (D). Following crosslinking of the 
PDMS, the sacrificial PVA-salt mould was dissolved in water (E) releasing the dual-
pore PDMS scaffold (F). 
The random pore scaffolds were fabricated using salt leaching process as described 
previously [9,12]. 10 g of NaCl was mixed with 1ml of water on a 100 mm plastic petri 
plate as described above. The mixture was placed in an oven at 60 
0
C to generate 
interconnections between the salt crystals and to evaporate the excess water. The 
hardened salt cube was cooled at room temperature. The PDMS mixture prepared as 
described above and cast on the petri plate containing the salt cube. The PDMS covered 
salt cube was placed in a vacuum desiccator for 1 h to let the PDMS infiltrate into the 
pores of the salt cube. The PDMS was cured in an oven at 60 
0
C for 4-6 h. Finally, 
excess PDMS was removed and the salt was dissolved in water, as described above, to 
release the random porous PDMS scaffolds. 
4.2.2 Characterizations of scaffolds 
The structural morphology and microstructures of the porous scaffolds were imaged 
using scanning electron microscopy (SEM) (JEOL, JSM 5500 LV, Tokyo, Japan). Prior 
to SEM imaging, the dried scaffolds were sputter coated with gold. The imaging was 
done using 12 kV accelerating voltage. To evaluate the complete removal of sacrificial 
moulding materials from the scaffolds, Fourier transform infrared (FTIR) spectroscopic 
characterisation of the moulding materials (salt and PVA) as well as the surfaces of the 
structured and dual- pore PDMS scaffolds (cross-sectional surfaces after cutting the 
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scaffolds, as shown in the Supplementary material Fig. S1) was performed using a 
spectrometer (Spectrum 100, Perkin Elmer Technologies, and Waltham, MA, USA) in 
transmission mode. The FTIR spectra of the samples were recorded by 20 scans in the 
range of 400–4000 cm−1 at a resolution of 2 cm−1 using air as background. 
The porosity of the PDMS scaffolds was determined using Eq 1 as described 
previously [12,16]. Four cylindrical scaffolds with structured, random and dual-pore 
architecture (Ø 6 mm, height 6 mm) were dried overnight at 60 
°
C, and weighed to 
obtain the mass of the samples. The porosity was then calculated based on the weight 
and the dimensions using Eq 1. 
Porosity (%) =
V−(
M
ρ
)
V
×  100%     (1) 
Where V is the volume of the scaffold, calculated based on its outer dimensions, M is 
the mass of the scaffold, and ρ is the density of PDMS (0.965 g/cm3). 
The compressive modulus of different scaffolds (L 25 mm × W 25 mm × H 10 mm) was 
determined by uniaxial compression tests using an Instron
®
 Tensile Tester 4301 (Instron 
Corporation, Norwood, MA, USA). The samples were compressed at a rate of 0.5 mm 
min
-1
. The compressive modulus was calculated as the slope of stress-strain curve from 
the linear range of the curve for each sample. The values reported were an average from 
testing of four independent scaffold of each type of porous scaffolds. 
To assess wettability of the scaffolds, contact angle measurements were carried out on 
scaffolds before and after oxygen plasma treatment. The contact angle was measured 
optically using an OCA 20 system (Dataphysics, Germany) by the sessile drop method 
by depositing a 3 µl drop of ultrapure water on the scaffold surface.  
4.2.3 Cell culture and assays in scaffolds 
4.2.3.1 Cells 
Human hepatoblastoma (HepG2) cells were obtained from the German Collection of 
Microorganisms and Cell cultures (DMSZ, Braunschweig, Germany). Cells were 
maintained in Roswell Park Memorial Institute medium (RPMI-1640) containing L-
glutamine and supplemented with 10% foetal bovine serum (FBS), both from Sigma-
Aldrich Corporation, St. Louis, MO, USA, and 1% penicillin/streptomycin (Life Tech-
nologies, Corporation, Paisley, UK) in a humidified incubator at 37°C and 5% CO2. 
Cell culture medium was exchanged completely every 2-3 days until the cells were fully 
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confluent. The cells were detached from the culture flask using 0.025% trypsin/EDTA 
solution (Life Technologies, Corporation, UK) and the cell number was determined 
using a haemocytometer and adjusted to the required number before seeding into the 3D 
scaffolds. 
4.2.3.2 Preparation of scaffolds for cell culture  
The scaffolds were prepared according to the protocol published previously [24]. In 
brief, cylindrical PDMS scaffolds of each type (Ø 6 mm, height 6 mm) were used in the 
experiments. Here, for cell studies control scaffolds with only structured pores, 80% 
porosity were used. To render the PDMS hydrophilic, scaffolds were treated with 
oxygen plasma for 1 min on both sides at a power of 50 W and pressure of 35 Pa using 
an Atto Plasma System (Diener Electronic GmbH, Ebhausen, Germany) equipped with 
a 13.56 MHz RF generator. The oxygen plasma treated scaffolds were autoclaved at 120 
˚C for 20 min followed by coating with 80 µg/ml of Collagen I (Collagen I rat protein, 
Life Technologies) at 4°C overnight. The scaffolds were washed twice with cell culture 
tested phosphate buffered saline (PBS) to remove excess collagen and then incubated in 
culture medium at 37˚C for 2 h until cell seeding. The cells were seeded into the scaf-
folds using a special 6 mm thick cell seeding tray with several holes (Ø 6 mm), 
fabricated of poly(methyl methacrylate) (PMMA) using a CO2 laser ablation machine 
(Epilog Mini 18 Laser, CO 80403, USA) as described previously [24]. The seeding tray 
was sterilized by washing with 0.5 M sodium hydroxide solution followed by rinsing 
with sterile water. Each scaffold was inserted into the hole in the seeding tray. 30 µl 
suspension of HepG2 cells in culture medium containing 250.000 cells were added on 
top of each scaffold and incubated at 37 ˚C for 3 h to achieve cell attachment. Every 
hour the tray was turned upside down for better cell infiltration into the scaffolds. 
Finally, each scaffold was transferred from the seeding tray into a well in a 24-well 
plate, and 1 ml of fresh culture medium was added in each well. Every 2 days the 
medium was collected for cellular functionality analysis and replaced with fresh medi-
um. On day 4, 8 and 12 of the culture period, two scaffolds were sacrificed and used for 
live/dead staining. Similarly, for determination of the total cell number, three scaffolds 
of each type were sacrificed at each time point (day 2, 4, 6, 8, 12, and 16).    
4.2.3.3 Biochemical assays 
Cell proliferation was determined based on the DNA content of cells cultured in the 
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scaffolds. The cells inside the scaffolds were lysed using 1 ml of lysis buffer (10 mM 
Tris pH 8, 1 mM EDTA and 0.2 % (v/v) Triton X-100). To ensure that the cells inside 
the scaffolds were totally lysed, the samples were stored on ice for 30 min and vortexed 
for 10 s every 5 min. The lysate from each scaffold was homogenised 5-10 times using 
a 21-guage needle. The DNA concentration in the lysates was quantified using 
PicoGreen DNA assay (Life Technologies Corporation, UK) according to the manufac-
turer’s protocol. A standard of DNA concentrations was prepared by isolating dsDNA 
from HepG2 cells (known number of cells) cultured in T25 flasks using the same 
protocol as for the scaffolds. The calibration curve was obtained by correlating the 
number of cells with the corresponding fluorescence intensity (shown in the Supple-
mentary material Fig. S4). 
The metabolic activity of the cells was measured using the alamarBlue® assay (Life 
Technologies Corporation, UK) as described previously [24]. In short, the scaffolds 
were rinsed with PBS and incubated in 1 ml of culture medium containing 10% alamar-
Blue® solution for 2 h in the incubator. Following incubation, 100-µl aliquots were 
placed into black 96 well plates and the fluorescence was quantified using a microplate 
reader (VICTOR3™ Multilabel Counter model 1420, PerkinElmer, USA) at the excita-
tion wavelength of 550 nm and emission wavelength of 590 nm. The background (i.e. 
alamarBlue® fluorescence at day 1) was subtracted from the value. 
 The concentration of albumin secretion from the cells in the scaffolds was deter-
mined using human albumin enzyme-linked immunosorbent assay (ELISA) 
Quantitation kit (Bethyl Laboratories, Inc., Montgomery, AL, USA) according to the 
manufacturer’s protocol. The absorbance was measured at 450 nm using a spectropho-
tometer (VICTOR3™ Multilabel Counter model 1420, PerkinElmer, USA). For all the 
biochemical assays, the tests were carried out in triplicate using 3 independent scaffolds 
of each type. The results are reported as average ± standard error of the mean (s.e.m). (n 
= 9).  
4.2.3.4 Live/dead cell staining 
Cell viability and distribution in the scaffolds were visualized using LIVE/DEAD® Cell 
Imaging Kit (Life Technologies Corporation, UK), containing a cell-permeable dye for 
staining live cells (excitation/emission 488 nm/515 nm) and a cell-impermeable dye for 
staining dead and dying cells (excitation/emission 570 nm/602 nm). The scaffolds were 
collected and gently washed with PBS followed by incubation in the dye solution for 30 
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min at 37°C according to the manufacturer’s protocol. The scaffolds were imaged using 
an Axio Observer fluorescence microscope (Zeiss Axio Observer.Z1, Carl Zeiss, 
Germany). The 3D reconstructions were compiled from 20 imaged sections (each 
having a thickness of 30 μm). 
4.3 Results and discussion 
Previously engineered dual-pore scaffolds with highly interconnected global (struc-
tured) and local (random) pores fabricated of both natural and synthetic biomaterials 
have shown promising results with improved cell proliferation in vitro and enhanced 
integration into the host tissue upon transplantation [3,12,17]. However, they had 
significant limitations in terms of mass fabrication and scalability due to the necessary 
manual assembly of the sacrificial mould components, as well as control of the dimen-
sions and number of structured pores introduced into the bulk scaffold. Thus, novel 
strategies can help develop mass fabrication of dual-pore scaffolds with control over 
physical and mechanical properties. With the goal of developing a simple, inexpensive 
and reproducible method for mass fabrication of dual-pore scaffolds with tuneable 
physical properties, we present a technique combining 3D filament printing of sacrifi-
cial moulds and salt leaching. Subsequently, to evaluate the dual- pore scaffolds in 
terms of physical properties and biological performance (cell loading, cell distribution 
and cellular functionality), two other types of scaffolds, i.e. the structured pore and 
random pore scaffolds were fabricated and used as controls. 
4.3.1 Scaffold fabrication 
3D filament printing is an inexpensive SFF technique that offers highly versatile ap-
proach to fabricate the sacrificial moulds, allowing to deposit PVA polymer layers with 
different geometries in the x and y directions, such as ‘woodpile’ or ‘hexagonal’ (as 
shown in the Supplementary material Fig. S2), that functions as vascular porous net-
works. As we have shown previously, PVA moulds could be fabricated with porosities 
in the range of 20 – 80 % depending on the infill of the mould, which were shown to 
correspond to channel distances ranging from 78 µm to 1482 µm [24]. Aside from 
effective control over channel dimensions and geometry, 3D filament printing allows to 
scale up the fabrication of tissue engineering scaffolds. Hence, to generate structured 
pores for dual-pore scaffolds, 3D printing of PVA filaments was an obvious choice for 
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our fabrication process presented here. In this work, 40 % infill was used to fabricate 
the PVA moulds for the dual-pore scaffolds, resulting in inter-filament distance of 800-
850 µm. Salt leaching as the source of random pores gives the possibility to control the 
pore sizes range by choosing the size distribution of the salt crystals to mimic the 
anatomical features of the tissues or organs required to be engineered [25]. In this study 
the NaCl crystals were used directly as provided by the supplier, sizes ranging from 300 
µm to 600 µm. 
 
Fig. 2 Sacrificial moulds and resulting fabricated porous PDMS scaffolds: A) 3D 
printed PVA mould (a) and replicated structured pore scaffold with pore size of 400 µm 
× 400 µm (b) and SEM magnification (c); B) photo of salt mould (a) and replicated 
random pore scaffold with pore size of 300-600 µm (b) and SEM magnification (c); C) 
photo of 3D printed PVA mould filled with salt (a) and replicated dual-pore scaffolds 
with structured pores of 400 µm × 400 µm and random pores of 300-600 µm (b) and 
SEM magnification (c). Scale bars: 1 mm in A, B and C (a & b); 400 µm in A, B and 
C(c). 
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The PDMS scaffolds with structured pores (Fig. 2Ab) were fabricated using 3D 
printed PVA filament moulds with woodpile pattern (Fig. 2Aa), while the random pore 
scaffolds (Fig. 2Bb) were derived from cylindrical salt disks (Fig 2Ba) using previously 
described methods [24,26,27]. As shown in the SEM image of the structured pore 
scaffold in Fig. 2Ac, the pores are square shaped with dimension of ~ 400 µm × 400 µm 
and well interconnected. In the random pore scaffolds, the salt leaching process gives 
pores with dimensions in the range of 300-600 µm (Fig. 2Bc), as determined by the size 
distribution of the used salt crystals. 
By combining both approaches, we fabricated dual-pore scaffolds (Fig. 2Cb) with both 
defined structured and random pore microarchitectures using the sacrificial 3D printed 
structured porous PVA filament moulds filled with salt crystals into the inter-
filamentous space (fig 2Ca). The method of fabrication is simple and involves casting of 
the desired polymer (in this study PDMS was used) in the mould which specifies the 
microarchitecture of pores within the resulting scaffold. Surface top view of the dual-
pore scaffold is shown in the SEM image (Fig. 2 Cc). The structured pores of dimension 
~400 µm × 400 µm are distributed in x, y and z directions, whereas the random pores 
with dimension of 300-600 µm are shown in between the structured pores of the bulk 
scaffold (Fig. 2 Cc). As shown in the SEM image of the top surface of a dual-pore 
scaffold (Fig. 3A and its zoom-in view Fig. 3B), the scaffolds had regular, well-
structured and highly interconnected structured pores in the z (yellow lines) and x-y (red 
lines) direction throughout the scaffold. In between the structured pores, the scaffolds 
had an array of square shaped random porous regions of 800 µm × 800 µm. The salt 
crystals of size 300-600 µm fused together and generated large interconnected pores. 
Fig. 3C and its zoom-in Fig. 3D, show SEM image of cross-sectional view (Supplemen-
tary material Fig. S1) of the interior of the scaffold. The channels in the scaffold have an 
elliptical cross-sectional profile, as the round PVA filament is flattened during printing 
of the mould, and the distance between two rows of structured pores is about 800 µm. 
The dimensions of the pores (width 344µm, height 190 µm) are slightly smaller than 
that of the filaments in the printed mould (400 μm × 200 μm), due to shrinkage during 
curing of the PDMS elastomer. A random pore region can be seen in the area between 
two rows of structured pores (blue dotted line). To demonstrate the possibility of 
controlling the size of the random pores, the previously described PVA mould was filled 
with smaller salt or sugar crystals, yielding scaffolds shown in the Supplementary 
material Fig. S4 (using 20-40 µm salt crystals) and Fig. S5 (using 100-200 µm sugar 
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crystals). The SEM images with different magnifications in Fig. S4 clearly show the 
highly interconnected small random pores (20-50 µm) along with the 400 µm × 400 µm 
structured pores. The inter-filament distance of a PVA mould has to be optimized 
according to the size of the salt or sugar crystals needed to generate the random pores. 
Using different size of porous mesh, it is possible to obtain salt or sugar crystals with 
different size distribution. If large crystals need to be used, the distance between the 
deposited PVA filaments has to be increased by reducing the porosity of PVA mould 
from 40 % infill to lower. 
 
 
Fig. 3 SEM images of fabricated dual-pore scaffolds (structured pore size 400 µm × 400 
µm, distance between structured pores 800 µm; random pore size 300-600 µm): A) top 
view showing structured pores and an array of random pores; B) magnification of the 
top view in (A); C) cross-sectional view of structured and random pores; (D) magnifica-
tion of the top view in (C). (Dashed lines: yellow – structured pores in z-direction; red - 
structured pores in x or y-direction; blue - random pores area) Scale bars: A) 1mm; B) 
and C) 500 µm; D) 250 µm. 
Here, we have shown the fabrication of dual pore scaffolds with dimensions of 25 mm × 
25 mm × 10 mm (length × width × height). However, the scalability of the PVA mould 
printing and the scaffold casting process that we have demonstrated in our previous 
work [24], mean that the method proposed in this paper can generate dual-pore scaffolds 
with dimension relevant for the size required for creating artificial organs. We used the 
biocompatible and non-biodegradable elastomeric PDMS, which is widely used in 
biological and medical applications [28,29], to demonstrate the ease of fabrication to 
obtain different porous scaffolds for tissue engineering applications. It has already been 
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shown that PDMS scaffolds have the potential to support long-term growth of liver cells 
[24]. However, this method can also be applied to other materials, providing the possi-
bility to fine-tune the properties of bulk scaffold by choosing a suitable biomaterial. To 
demonstrate this, poly(ϵ-caprolactone) (PCL), a FDA approved biodegradable polymer 
[30], was used to fabricate dual-pore PCL scaffolds (Supplementary material Fig. S5). 
Here we have shown the biocompatibility and functionality of HepG2 cells supported 
by various silicone scaffolds (Fig. 5-7) however this has to be tested with the type cells 
required to engineer the relevant tissue. Silicone based non-degradable scaffolds could 
be utilized to develop life support system (LSS) such as an extracorporeal liver [31] for 
the short term treatment of patients with liver failure. Utilizing silicone based highly 
porous scaffolds for extracorporeal liver device offers several benefits such as easy 
fabrication of scaffold structures with dual pores, structurally strong and elastic material 
for building large scale porous structures, easy sterilization method by autoclavation and 
without any shrinking or swelling properties allows robust fluidic perfusion into the 
scaffolds compared to some hydrogels [24]. Furthermore, FDA approved medical grade 
silicone elastomers are available, which should be compatible with the described 
fabrication method. 
4.3.2 Scaffold characterization 
4.3.2.1 Removal of the sacrificial materials (salt and PVA) from the scaffolds 
FTIR spectroscopy was used to monitor the complete removal of the sacrificial materi-
als (salt and PVA) from the scaffolds. Fig. 4A shows FTIR spectra of salt crystals 
(black), cross-linked PDMS (blue), 3D printed PVA filament (red) and PDMS dual-pore 
scaffold after removal of salt and PVA (green). In the spectrum for PVA, peaks were 
observed at 3400 cm
−1
 (–OH) and 1740 cm−1 (C=O), whereas salt crystals had a peak at 
3400 cm
−1
 (–OH). All of these peaks were absent in spectrum for cross-linked PDMS 
due to the different molecular structure [32,33]. The spectrum for the fabricated 3D 
scaffold (recorded from the interior regions as shown in the supplementary Fig. 1) 
completely resembles the one recorded for cross-linked PDMS, which clearly indicated 
that PVA and salts had been completely removed from the structure. Spectra were 
recorded from at least six different positions throughout the final scaffold to obtain a 
complete confirmation. Simultaneously, a basic visualization of the PVA removal was 
done. The PVA-salt-PDMS structures were transferred into a water beaker with a 
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magnetic stirrer to aid the faster dissolution of the PVA and salt. Initially, when immers-
ing the PVA-salt-PDMS structures into water, they sank to the bottom of the container. 
After complete removal of PVA and salt, the hydrophobic PDMS scaffold structures 
were floating on the surface. During the process of dissolution the water turned cloudy 
due to the release of PVA into the water, and water were replaced until it remained 
clear. 
4.3.2.2 Porosity 
The degree of porosity and pore size of the scaffold material both at the macroscopic 
and the microscopic level play a very important role in tissue regeneration [34]. The 
total porosity of the scaffolds, fabricated with the three different porous geometries was 
determined experimentally and presented in Fig. 4B. The porosity of the dual-pore 
scaffold was 64.8 ± 1.05% whereas in case of structured and random pore scaffolds the 
porosity was 39.5 ± 0.08 % and 68.02 ± 0.95%, respectively. The porosity of the dual-
pore scaffolds was higher compared to the structured pore scaffolds due to the presence 
of both structured and random pores. Previously, we have shown the possibilities to 
fabricate structured pore PDMS scaffolds with porosities ranging from 20 % to 80 % by 
varying the infill of the printed PVA mould from 20% to 80%. In this study, dual-pore 
scaffolds were fabricated using 40 % infill PVA moulds. For better comparison, the 
physical characterization of dual-pore scaffolds is compared with the structured pore 
scaffolds generated using 40 % infill PVA moulds. Previously published dual-pore 
fabrication methods have shown similar behaviour in terms of porosity, the total porosi-
ty of dual-pore scaffolds being always greater than the porosity of structured and 
random pore scaffolds [12,16]. In this study, the random pore scaffolds showed higher 
porosity (68.02 %) than the dual-pore scaffolds due to the larger size of the random 
pores in comparison with the size of the structured pores (Fig. 3). To achieve higher 
porosity in dual-pore scaffolds in comparison to random pore scaffolds, the size of the 
random pores has to be smaller than the structured pores. This concept was illustrated in 
the Supplementary material Fig. S4 and S5 where porosity of about 80% was achieved. 
The porosities of dual-pore scaffolds completely depend on the microstructure of 3D 
printed PVA mould and the size of the salt crystals filled in it. Hence, a desired range of 
pore dimensions can easily be optimized through this fabrication technique. 
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Fig. 4 A) FTIR spectra: salt crystals (black), cross-linked PDMS (blue), 3D printed 
PVA filament (red), and dual-pore PDMS scaffold after removal of salt and PVA 
(green). Mechanical characteristics of different scaffolds: B) porosity; C) stress–strain 
curves at 4 N load; D) compressive modulus. 
4.3.2.3 Mechanical testing 
The mechanical properties of tissue engineering scaffolds can modulate cell morpholo-
gy, proliferation, migration and differentiation [35–37],  and it is therefore important to 
control the mechanical properties of the bulk scaffold while engineering an artificial 
tissue. Mechanical compression tests were conducted with dry scaffolds with the 
different pore structures. Fig. 4C shows typical stress-strain curves of the different 
scaffolds at a constant compression rate of 0.5 mm min
-1
. The compressive modulus of 
structured, random and dual-pore scaffolds was determined to be 359 ± 16, 84 ± 10 and 
125 ± 35 kPa, respectively (Fig. 4D). Previously, it has been shown that the compres-
sive modulus of porous scaffolds reduces significantly as the porosity of the scaffolds 
increases [24,38,39]. For the same reason, the dual-pore scaffolds showed intermediate 
mechanical properties compared to structured and random pore scaffolds, indicating the 
expected relationship between porosity and the mechanical stiffness of the scaffolds. 
The compressive modulus of the structured pore scaffolds was similar to our previous 
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study presented with similar kind of scaffolds (about 360 kPa) [24]. Moreover, our 
mechanical tests on the different scaffolds showed similar trend as previously reported 
for structured, random and dual-pore scaffolds fabricated of PCL [12,16]. The result of 
the mechanical test indicates that the mechanical properties of the dual-pore scaffolds 
can be easily modified by the combination of random and structured pores. Since the 
elastic moduli of human organs and tissues are very diverse, the stiffness of fabricated 
dual-pore PDMS scaffolds can be tuned by changing the porosity of the scaffolds or the 
degree of cross-linking, i.e. the ratio between the PDMS base and the curing agent [36]. 
As mentioned above, the fabrication technique presented in this paper can be applied to 
other materials than PDMS, such as the biomaterial PCL (Supplementary material Fig. 
S5), which provides an additional route for fine-tuning scaffold stiffness according to 
the requirements of in vivo tissues. 
4.3.3 Cell proliferation and viability 
Although the proposed dual-pore scaffold fabrication technique can be used to control 
the physical and mechanical properties of the scaffolds, it is important to evaluate the 
cell behaviour in the scaffold architecture. As PDMS is a hydrophobic material, it is 
important to render the scaffold surfaces hydrophilic before seeding cells into the 
scaffolds. To achieve this, all the scaffolds were treated with oxygen plasma. The 
achieved hydrophilicity was confirmed by the decrease in contact angle from 120° ± 4° 
to below 10°.  
4.3.3.1 Biochemical assays of cell proliferation and functionality 
Proliferation and functionality of HepG2 cells in the different porous scaffolds was 
monitored during 16 days (Fig. 5). The proliferation of HepG2 cells within the scaffolds 
was determined based on both the total intra cellular DNA content using the Picogreen 
assay and cellular metabolic activity using alamarBlue
®
 assay. Along with cellular 
proliferation, the functionality of HepG2 cells was determined based on the extracellular 
albumin release as a liver-specific marker. 
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Fig. 5 HepG2 cell proliferation and functionality on different scaffolds: A) total cell 
number (Picogreen assay) during day 2-16 (B). B) Metabolic activity (alamarBlue
®
 
assay) over 1-16 days (D). C) Albumin secretion over 16 days (F). Data represents mean 
± s.e.m. (n = 6). 
As shown in Fig. 5A, from day 2 to day 4, the total cell number increased (proliferated) 
slowly in all three types of scaffolds, whereas after day 4 onwards the proliferation rate 
increased especially in the random and dual-pore scaffolds where the cell numbers 
increased at similar rates. However from day 9 the cellular proliferation rate in the dual-
pore scaffolds were higher in comparison to the two other types of scaffolds. From day 
12 the number of cells reached a steady state in both random and dual pore scaffolds 
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whereas the number of cells continued to increase in the structured pore scaffolds. At 
the same time the number of cells was lower in the structured pore scaffolds throughout 
the culture period in comparison with the random and the dual-pore scaffolds.  
Along with cell proliferation the metabolic activity of HepG2 cells in the three different 
types of scaffolds was determined using the alamarBlue® assay (Fig. 5B). From day 1 
to day 9, the metabolic activity increased steadily in all the different types of scaffolds 
(Fig. 5B) although the activity was lower in the structured pores scaffolds. Until day 9, 
the cells grown in the random pore and dual-pore scaffolds did not show any significant 
difference. However, after day 9, the metabolic activity in the random pore scaffolds 
started to decline whereas in dual- and structured pore scaffolds continued to increase 
until the end of the experiment.  
Fig. 5C shows the magnitude of albumin secretion from HepG2 cells cultured in the 
different types of scaffolds. Similar to the cell proliferation profiles (Fig. 5A), albumin 
production from HepG2 cells grown in all of the three different types of scaffolds 
increased for the first 12 days (Fig 5C). On day 12, the cells cultured in the dual-pore 
scaffolds produced the highest amount of albumin (375 ng/day/scaffold) compared to 
the cells cultured in the random and structured pore scaffolds (325 and 145 
ng/day/scaffold, respectively). However from day 12 to 16, the albumin secretion rate 
from cells in random scaffolds started to decline, whereas the rate remained constant for 
the cells grown in both the dual-pore and structured pore scaffolds.   
Both the random and dual pore scaffolds contain random pores, which increase the 
surface area compared to structured pore scaffolds. Therefore more cells could be 
trapped and adhere on these scaffolds and there were also more surface for cell prolifer-
ation. In the literature it has been shown that SFF fabricated structured pore scaffolds 
have lower cell adherence after seeding in comparison with random and dual-pore 
scaffolds [12,16], which clearly agrees with our result. From day 1 until day 9, the cells 
grown in random pores scaffolds or in the dual-pore scaffolds did not show any signifi-
cant difference in cell proliferation, metabolic activity and albumin secretion, whereas 
these parameters were considerable lower for the structured pores scaffolds, probably 
due to smaller surface area. The declining metabolic activity from day 9 or in albumin 
secretion from day 12 in the random pore scaffolds may be explained by insufficient 
nutrient and oxygen supply into the scaffold or by accumulation of cellular waste, due 
to limited mass transport in this type of scaffold. In summary,  the results clearly 
indicate that the cell proliferation, metabolic activity and albumin secretion from cells 
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growing in the dual-pore scaffolds showed better performance compared to the cells in 
the structured and random pore scaffolds due to high surface area of the random pores 
in combination with better nutrient and oxygen supply as well as waste removal through 
the structured pores. 
4.3.3.2 Cell distribution and viability within the scaffolds 
To visualize cell distribution and viability, in the different porous scaffolds, qualitative 
live/dead staining was carried out on day 2, 8 and 16 after cell seeding (Fig. 6). On day 
2, the number of live cells distributed on the surface of the random (Fig. 6Ba) and dual-
pore scaffolds (Fig. 6Ca) was higher compared to that on the structured pore scaffolds 
(Fig. 6Aa), which correlates well with the biochemical assays shown in Fig. 5. From 
day 2 to day 16, cells grow uniformly on the surface of all the different types of scaf-
folds (Fig. 6 A b, c and d; B b, c and d; C b, c and d). However on day 16, more dead 
cells could be observed on the surface of the random pore scaffolds (Fig. 6 Bd), whereas 
on the surface of the structured (Fig. 6Ad) and dual-pore (Fig. 6 Cd) scaffolds only very 
few dead cells could be observed. In dual-pore scaffolds, cell distribution was character-
ized by initial (from day 2 to 8) cell growth primarily in the structured pore regions 
(Fig. 6Ca and b). Later, when all the structured pores regions were completely covered, 
the cells migrated into the random pore regions of the scaffold as shown for day 16 (Fig. 
6Cc). 
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Fig. 6 Live/dead staining of HepG2 cells: Top view on A) structured, B) random, and 
C) dual-pore scaffolds on day a) 2, b) 8, and c) 16, as well as zoom-in of day 16. (green 
– live; red – dead) Scale bars: A, B & C (a,b,c)  1 mm; A,B,C (d) 350 µm. 
In Fig. 6, it was not possible to see the cell distribution in the central parts of the scaf-
folds, which are more critical due to the limitation of nutrient and oxygen supply. 
Therefore, the scaffolds were cut longitudinally through the centre (Supplementary 
material Fig. S1) and live/dead stained to visualise the cell distribution inside the 
scaffolds (Fig 7). The cells were distributed more uniformly inside the structured (Fig. 
7A) and dual-pore (Fig. 7C) scaffolds than inside the random pore scaffolds (Fig. 7B). 
On day 2, the cell distribution inside the different scaffolds was very low (Fig 7 Aa, Ba, 
Ca) but over time, the cell density in the structured and dual-pore scaffolds steadily 
increased (Fig 7 Aa-c, Ca-c). On day 16, the structured (Fig. 7Ac) and dual-pore (Fig. 
7Cc) scaffolds showed uniform cell distribution throughout, whereas the random pore 
scaffolds (Fig. 7Bc) had very low amount of cells distributed in the central regions. For 
this type of scaffold the cells appeared to be mainly proliferating on the outer surface, 
where there is direct contact with the culture medium, instead of migrating into the 
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centre of the scaffold. This difference in cell distribution can be explained by the 
presence of the structured pores that provide interconnections in x, y and z-direction 
throughout the structured and dual-pore scaffolds. Previously, similar kind of results 
have been reported, indicating that SFF fabricated scaffolds had more uniform cell 
distribution and penetration of cells into the scaffolds [16,24,40]. Moreover, more dead 
cells appeared over time inside the random pore scaffolds (Fig. 7Ba, b and c), which 
completely agrees with the biochemical assay that showed first a drop in metabolic 
activity (Fig 5B) and later in the albumin secretion (Fig 5C) from the cells grown in 
random pores scaffolds. Zhang et.el, have reported a similar phenomenon by creating 
PCL random pore scaffolds with a combination of different pore dimensions [9]. They 
also showed that after 14 days of cell culturing, the cell distribution in the random 
porous scaffolds was always on the outer edges which completely agrees with our 
result. Homogeneous cell distribution in the bulk scaffold prolongs the proliferation 
period, gives uniform tissue formation and better cell differentiation characteristics as 
shown in previous works[40–42]. The dual-pore scaffolds are superior to the two other 
types of scaffold as it combines high cell number (Fig 5A), metabolic activity (Fig 5B), 
and albumin secretion (Fig 5C) with uniform distributing of living cells both on (Fig 
6C) and into the scaffolds (Fig 7C). In future works, the effectiveness of dual-pore 
scaffolds will be tested for co-culturing of two different populations of cells: liver cells 
in the random pore region and endothelial cells as a lining of the structured pores. 
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Fig. 7 Live/dead staining of HepG2 cells: Cross-sectional view in the interior of A) 
structured, B) random, and C) dual-pore scaffolds on day a) 2, b) 8, and c) 16. (Green – 
live; red – dead) Scale bar: 1 mm. 
 
4.4 Conclusions 
We present a method to fabricate dual-pore scaffold by combining 3D filament printing 
of water soluble PVA sacrificial mould for primary structured pores and salt leaching to 
create random pores within the bulk scaffold. The method provides control over pore 
geometry and dimensions as well as mechanical stiffness of both the structured and 
random pores of the dual-pore scaffold. Using PDMS as the scaffold material, we have 
demonstrated that the fabrication process is rapid and inexpensive as well as scalable for 
generation of scaffolds of a size, relevant for thick tissues. The PVA printed sacrificial 
moulds can also be used with different biodegradable natural polymers (e.g. gelatine 
and silk) combined with freeze-drying, to provide scaffolds with wide range of mechan-
ical properties. Human hepatoblastoma (HepG2) cells were grown in different types of 
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scaffold for 16 days monitored with respect to attachment, distribution, proliferation, 
viability, metabolic activity, and albumin secretion and cells grown in dual-pore scaf-
folds with cells grown in only structured or only random pores scaffold. The dual-pore 
scaffolds with highly interconnected structured pores combined with the adjacent 
random pores was superior to the two other types of scaffold as it combines high cell 
number, metabolic activity, and albumin secretion with uniform distributing of living 
cells in the entire volume of the scaffold. In conclusion, the described fabrication 
technique is rapid, inexpensive, scalable, and compatible with different polymers, 
making it suitable for engineering various large scale organs/tissues. 
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Figure S1. Schematic of top view and cross-section view of the interior regions of the 
scaffolds. 
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Figure S2. Standard curve for total cell number quantification using the picogreen assay 
 
 
Figure S3. SEM image of hexagonal dual pore scaffolds (A) and zoom in into the 
random pore region of dual pore scaffold (B) (red: structured pore in x-y direction, 
yellow: structured pores in z direction and blue: random pore region). 
 
 
Figure S4. SEM images of dual pore scaffold with structured pore of dimension 400 µm 
and random pores of 20-40 µm. Scale bar: A) 1 mm, B) 500 µm and C) 50 µm. 
 
Fabrication of dual-pore PCL scaffolds 
Polycaprolactone (PCL) (average MW ~ 80,000) crystals and chloroform (99.0-99.4% 
(GC) purity) were purchased from Sigma-Aldrich Corporation, St. Louis, MO, USA. 
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PCL dual-pore scaffolds were fabricated in a similar manner as PDMS scaffolds using 
10% PCL solution in chloroform. PCL solution was prepared by dissolving PCL 
crystals in chloroform overnight. The sacrificial PVA mould was fabricated with 40% 
porosity and filled with salt crystals of size around 100-200 µm. The PVA-salt mould 
was covered with the PCL solution and kept in a vacuum desiccator for 1 hr to achieve 
proper filling of the mould. The mould with the polymer mixture was dried under fume 
hood overnight to completely evaporate chloroform from the mould. The dried PCL-
PVA-salt mould was soaked in deionized water for at least 24 h to remove the sacrificial 
PVA-salt mould. Porosity and the surface morphology of the 3D dual-pore PCL scaf-
folds were characterized using the methods described in the materials and methods 
section of the paper. 
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Figure. S5 A) Photographs of dual pore PCL scaffold casted from combined salt (parti-
cle size 100-200 μm) – PVA (40% porous) mould. B) Calculated porosity of the 
scaffold. C) SEM micrographs of 3D PCL scaffold’s top view with 400 μm of struc-
tured and 100-300 μm of random pore size. D) Zoom in of C. E) Side view from the 
center of the PCL dual pore scaffold. F) Zoom in of E. The scale bare is 1 mm in A and 
C, 500 μm for D and E and 200 μm for F. 
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Figure. S6 Schematics flowchart for the dual pore scaffold fabrication process, shown 
schematic in Fig 1.   
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5.1 Introduction 
Over the past decades, biomaterials have received increasing attention in the field of 
medical devices, diagnostics, sensors, drug delivery systems and tissue engineering 
applications.  However, the physicochemical and biological properties of some of these 
biomaterials either do not match with native tissues ore are not clinically approved. The 
ideal biomaterial for tissue engineering should enable 3D cell culturing and provide 
sufficient mechanical, biological and chemical support to guide cells in the desired 
direction. Therefore, the development of the next generation of instructive biomaterials 
should facilitate physical support within a three dimensional (3D) microenvironment for 
controlling cell fate and be able to direct cell differentiation through controlled release 
of cell-regulating factors[1–5]. Moreover, from a clinical perspective it is crucial to 
design porous scaffolds that match the morphological and anatomical structures of 
natural tissues[6]. Porous scaffolds with multiple functionalities have been fabricated 
from natural and/or synthetic polymers, metals, ceramics, and glasses that guide tissue 
regeneration through controlled release of tissue inductive factors[7,8]. However, 
several challenges still remain in fabricating dual 3D porous scaffolds from medically 
approved materials with high elasticity and durability to mechanical load similar to that 
of real tissue. 
In recent years, hydrogel-based materials have received increasing attention in 
regenerative medicine and tissue engineering due to their biocompatibility, viscoelastic 
properties and ease of fabrication. They have been applied as scaffolds that provide 
structural integrity to tissue constructs[9,10], support tissue in growth[11,12] and that 
can deliver drugs and proteins to targeted cells in a well-controlled manner[13–15]. 
Different microfabrication techniques have been developed to fabricate 3D natu-
ral/synthetic hydrogel scaffolds with defined macroscopic and microscopic features for 
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various tissue engineering applications [9,16–18]. Despite all their beneficial properties, 
there are still challenges to overcome for their clinical use. These challenges include 
none native-like mechanical characteristics[19] and fabrication of scalable 3D hydrogel-
based scaffolds. Additionally, hydrogels are not suitable for long-term controlled drug 
release due their inherent burst-release behavior, where most of the drugs are release in 
a short time period, lasting from a few minutes up to a few hours with almost no drug 
released beyond a week[20]. As an alternative to hydrogels, synthetic silicone elasto-
mer, a FDA approved biomaterial, is used in various medical implants due its high 
biocompatibility, optical transparency, oxygen permeability, and tunable degrees of 
stiffness to mimic mechanical properties of biological tissue[21,22]. However, it is not a 
suitable candidate in terms of drug release or to direct cells into native-like tissue 
structures[23]. This is primarily due to the hydrophobic and impermeable nature of 
silicone elastomers.  
Considerable attention has been given to generate silicone-hydrogel hybrid ma-
terials either by grafting the hydrogel materials on cross-linked silicone[24,25] or 
through mixing of silicone and hydrogel[26,27]. Despite the ease of fabrication of these 
materials, one drawback is the poor interfacial adhesion between the two phases. This 
can be improved by creating interpenetrating polymer networks (IPNs) consisting of 
silicone and hydrogel through various solvent based methods[27]. Several biocompati-
ble silicone-hydrogel IPNs have been generated with enhanced water uptake, improved 
mechanical stiffness, improved hydrophilicity and ability to load and release drugs 
compared to the base silicone[27–30]. However the formation of hydrogel networks in 
the described IPNs is completely dependent on the type of solvent. Most commonly, 
organic solvents are used for swelling the silicone materials and it is therefore challeng-
ing to load a drug during the IPN synthesis process due to the use of often toxic 
solvents. Moreover, the conventional IPN synthesis methods described above are time 
consuming. As an alternative to organic solvents and to reduce the time required for 
IPN processing, Steffensen et al developed 2-hydroxyethyl methacrylate (HEMA) based 
silicone IPN materials (pHEMA-IPN), using supercritical carbon dioxide (scCO2) as an 
auxiliary solvent for swelling the silicone[31,32]. scCO2 has many potential advantages 
over conventional solvents in terms of being nontoxic, nonflammable, economical, 
widely available, eco-friendly and having unique solvating properties[31,33].  
The pHEMA-IPN has been applied for controlled and sustainable drug release 
for various medical devices[31,32].
 
Due to the high glass transition temperature (Tg) of 
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pHEMA (90-100°C) compared to pristine silicone elastomer (-120°C), the resulting 
pHEMA-IPN becomes very hard and brittle[31]. However, the presence of PEG struc-
tural units with lower Tg (-67°C) has shown to dramatically lower the Tg value of a 
P[HEMA-co-(MeO-PEGMEA)] composite polymers[34], indicating that PEG can be 
used as a softener.  
Here a new microporous highly elastic and durable 3D IPN scaffold is present-
ed, which combines indirect 3D printing of a silicone scaffold (i.e. 3D printing of a 
sacrificial mould replicated into silicone[17,35]) with scCO2 based hydrogel impregna-
tion to create the 3D IPN scaffold. Moreover, a polyethyleneglycol monomethacrylate 
(PEGMEA) HEMA random-copolymer (pHEMA-co-PEGMEA) hydrogel is employed 
and its physical and mechanical properties compared to the previously reported pHE-
MA-IPN. Drug release profiles of doxycycline (DOX) from both the pHEMA- and 
pHEMA-co-PEGMEA IPN systems are evaluated and the ability for human mesem-
chymal stem cell (hMSC) adhesion and proliferation on 2D and 3D pHEMA-co-
PEGMEA IPN materials is investigated. Finally, the biological activity of DOX re-
leased from pHEMA-co-PEGMEA IPN is demonstrated using a DOX regulated green 
fluorescent reporter (GFP) gene expression assay in Hela cells. The proposed approach 
for directing cellular function through sustained release of drugs/biomolecules from IPN 
scaffolds may find use in engineering artificial tissue or regenerating damaged tissue. 
5.2 Experimental Section 
5.2.1 Materials 
Two-dimensional (2D) silicone elastomer substrate PE4062 cut into appropriate disc 
sizes (Ø 16mm x height 2mm), were purchased from LEBO Production AB, Skogås, 
Sweden. 3D silicon elastomer substrates were fabricated using commercial polydime-
thylsiloxane (PDMS) (Sylgard 184, Dow Corning). 0.2 M diethyl peroxydicarbonate 
(DEPDC) was used as initiator, prepared as described previously[36]. 97% 2-
hydroxyethyl methacrylate (HEMA) with 200-220 ppm monomethyl ether hydroqui-
none (MEHQ) used as inhibitor, and poly(ethylene glycol) methyl ether acrylate Mn 
480 (PEGMEA-480) with 100 ppm MEHQ and 100 ppm BHT used as inhibitor were 
supplied by Sigma Aldrich (USA). To remove any residual inhibitor, HEMA and 
PEGMEA-480 were individually passed through an inhibitor remover column, packed 
with De-Hibit 200 supplied by Polysciences (USA), according to instructions given in 
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the technical data sheet, and stored at 5°C. HEMA was furthermore purified by distilla-
tion at reduced pressure, and the fraction at 67°C and 4 mbar was collected and stored at 
5°C. 
 99.8% ethanol (EtOH), 98% ethylene glycol dimethacrylate (EGDMA), tetrahy-
drofuran (THF), NaOH pellets, 35% H2O2 and molecular sieves 4 Å (all from Sigma 
Aldrich, USA), 98% ethyl chloroformate (Fluka, Hungary), and anaerobic CO2 4.0 
(AGA, Denmark) were all used as received. Doxycycline (Clontech, USA) and Tetracy-
cline-Free fetal bovine serum were used for cell culture (Clontech, USA). 
5.2.2 Fabrication of 3D elastomer scaffolds 
Porous 3D silicone elastomer scaffolds with structured channels were fabricated in 
PDMS, using indirect polyvinyl alcohol (PVA) filament printing, as previously de-
scribed[17,35]. In brief, a water soluble PVA sacrificial 3D mould (dimension: 25 mm x 
25 mm x 10 mm of length, width and height) was designed and printed using PVA 
filament (Makerbot, USA) and a 3D filament printer (Makerware 2.4.1, Makerbot, 
USA). The PVA mould was printed with 80% porosity and then replicated into elasto-
meric structures by casting a mixture of PDMS pre-polymer and cross-linker at a ratio 
of 10:1, and cross-linked at 60 °C overnight. The PVA sacrificial mould was then 
dissolved in water for 12 h to achieve the final desired 3D porous PDMS scaffolds.  
5.2.3 Fabrication of IPNs 
pHEMA-based silicone hydrogel IPN production was based on the method previously 
described[31,32], with a few modifications. Since the initiator DEPDC is capable of 
initiating the polymerisation already at 40°C, the whole process was run at 40°C and 
300 bar for 16 h. The IPNs described in[31,32] had a relative limited water uptake with 
brittle mechanical properties due to the high Tg of PHEMA. In order to increase the 
water-uptake and to make the IPNs softer and more flexible, PEGMEA was added as a 
co-monomer in the synthesis. 
Silicone hydrogel IPN samples (2D and 3D) were prepared according to the fol-
lowing procedure: Silicone specimens (mass ~ 40-50 g) were organized in a stainless 
steel grid and placed in a one-litre reactor equipped with magnetic stirring (HiP, Penn-
sylvania, USA). A Thar P-50 electrical driven high-pressure pump (Thar Designs Inc., 
USA) was applied to assure the operational pressure. Solvents (70 ml EtOH and 70 ml 
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THF), monomers (100 ml HEMA and optionally 100 ml PEGMEA-480), cross-linker (6 
ml EDGMA) and initiator (50 ml 0.2M DEPDC) were mixed in a separate beaker for at 
least 10 min. The solution was added to the reactor and the reactor was closed and filled 
with CO2 to a pressure of 300 bar at 40° C. After a combined impregnation and 
polymerization step of 16 h the pressure was released during a 30 min period. Residual 
monomers and non-cross-linked polymers were removed from the samples by extraction 
in EtOH for one week. The hydrogel content of the IPNs was calculated according to 
eq. (1): 
 𝐻𝑦𝑑𝑟𝑜𝑔𝑒𝑙 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 =  
𝑚𝐼𝑃𝑁 − 𝑚𝑠𝑖𝑙𝑖𝑐𝑜𝑛𝑒
𝑚𝐼𝑃𝑁
∙ 100% (1) 
Where msilicone and mIPN represents the difference in mass of the silicone samples and 
when loaded with IPN, respectively. The structural morphology and microstructure of 
the 3D porous PDMS and corresponding IPN scaffolds were visualized using scanning 
electron microscopy (SEM) (JEOL, Tokyo, Japan). Prior to SEM analysis, the scaffolds 
were dried in an oven at 50°C overnight and sputter coated with gold. Samples were 
then analysed using 12 kV of accelerating voltage. Pore sizes of scaffolds were meas-
ured from SEM images using ImageJ software.  
5.2.4 Water uptake kinetics 
Five 2D IPN discs (Ø=16.2 mm), each containing 22% w/w of PHEMA or PHEMA-co-
PEGMEA, were tested for their ability to swell in water. To evaluate the water uptake 
on dry IPN discs, they were kept in a desiccator for at least 30 minutes after which they 
were weighed (W0) and placed in individual vials containing PBS (pH 7.4) (n = 5). At 
given time points the IPN discs were individually removed, wiped gently with tissue 
paper to remove excess water and weighed (Wt). The IPN discs were then transferred 
back into their respective vials. The water content of the IPN discs was calculated using 
eq. (2): 
 
 𝑊𝑎𝑡𝑒𝑟 𝑐𝑜𝑛𝑡𝑒𝑛𝑡(%) =  
𝑤𝑡 − 𝑤0
𝑤𝑡
∙ 100% (2) 
5.2.5 Surface characterization 
Attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR) was 
used to characterize the samples, using a FTIR spectrophotometer (Spectrum 100, 
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Perkin Elmer Technologies, USA). The average value after 40 scans at 4 cm
-1
 resolution 
was collected for each sample. ATR-FTIR spectra were taken of both dry and of fully 
water-swollen samples. 
To assess the wettability of IPN samples and their base silicone material, contact 
angle measurements were carried out on the 2D disc sample surfaces before and after 
treatment with oxygen plasma. The contact angle was measured using the sessile drop 
method by depositing a 3 μl ultra-pure water drop on the discs. Two individual meas-
urements were performed on five individual discs. 
5.2.6 Mechanical properties 
The mechanical properties of the silicone elastomer (PE4062) and its corresponding 
pHEMA-co-pEGMEA (PE4062|pHEMA-co-pEGMEA) IPNs were tested using uniaxial 
tensile stress tests with INSTRON Model 4301 (Instron Engineering Corporation, 
Canton, MA, USA). For this purpose, 5-7 dumbbell specimens (ASTM D638-5) of each 
sample were preconditioned in water at ambient temperature for 1 week. The tensile 
stress tests were carried out at 50 mm/min. 
5.2.7 In-vitro cell studies 
Human bone marrow derived mesenchymal stem cells (hMSCs)(PT-250, Lonza Biosci-
ence, DK) (passage no 3–4) were cultured in mesenchymal stem cell growth media 
(MSCGM)(Lonza Bioscience, DK) at 37°C and 5% CO2. The cell culture media was 
exchanged completely twice a week and cells were passaged at 80-90 % confluence. 
Before cell seeding 2D IPN discs (Ø 16mm, thickness: 2mm) and 3D porous IPN 
PDMS scaffolds (Ø 6 mm x height 4 mm) were treated with oxygen plasma for 1 min 
on both top and bottom surfaces. The samples were sterilized by autoclavation and then 
stored at room temperature for one week in sterile water for complete hydration of the 
hydrogel networks of IPNs. Before cell seeding, all IPN samples were coated with 80 
µg/ml collagen I (Life Technologies, A1048301) in sterile water overnight at 4 °C. To 
avoid cell migration from IPN discs and 3D IPN scaffolds onto the tissue culture plastic 
plate during long term culture, 12-well plates containing both IPN discs and scaffolds 
were coated with 5% w/v Pluronic®F127 (Sigma-Aldrich, USA) for at least three hours, 
then washed three times with sterile PBS and allowed to dry to avoid cell attachment to 
the plates. Cells cultured in tissue culture polystyrene (TCP) wells without any coatings 
were used as controls.  
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For 2D in-vitro cell culture, collagen coated IPNs were transferred into the previously 
prepared 12-well plate and 2 ml of cell culture media was added onto the IPN discs in 
each well. 20 μl of cell suspension containing 30000 hMSCs were seeded slowly on to 
the 2D IPN disc and TCP. The well plates containing IPN discs and the controls were 
transferred to an incubator at 37°C and 5% CO2 and cell culture media was exchanged 
every 3 days.  
For 3D cell culturing a special cell loading method was followed to ensure uni-
form cell distribution into the IPN scaffolds, as described previously[17]. In brief, a 6 
mm thick cell seeding tray with several holes (Ø 6 mm) was fabricated from 
poly(methyl methacrylate) (PMMA) using a CO2 laser ablation machine (Epilog Mini 
18 Laser, CO 80403, USA). The seeding tray was cleaned with 0.5 M sodium hydroxide 
solution followed by rinsing with sterile water for sterilization. Collagen coated 3D IPN 
scaffolds were inserted into the holes in the seeding tray. 100 µl of cell suspension 
media containing 250000 hMSCs were loaded on top of each scaffold and then trans-
ferred into an incubator (at 37 °C and 5% CO2) for 2 h to achieve cell attachment. Every 
hour the tray was turned upside down for uniform cell infiltration into the scaffolds. 
Finally, the 3D IPN scaffolds were transferred into a Pluronic®F127 treated 12-well 
plate containing 3 ml of fresh culture medium. To ensure efficient diffusion of media 
components into the interior of the scaffolds, they were rotated in the incubator (at 37 
°C/5% CO2) and the cell culture medium was refreshed every 3 days. 
Cell proliferation over the culture period was evaluated using the Alamar blue 
metabolic quantification assay (Life Technologies, USA) according to the manufactur-
er's instructions. Pristine silicone discs, 2D IPN and 3D IPN scaffolds without cells 
were used as negative controls to adjust for background fluorescence. Viability of cells 
was determined using a Live/Dead cell viability staining Kit (Life Technologies, USA), 
according to the manufacturer's instructions. Cells were incubated with calcein AM and 
ethidium homodimer-1 (EthD-1) for 30 min to stain live (green) and dead cells (red), 
respectively, for 30 min at 37 °C and 5% CO2. Following incubation, samples were 
washed twice with PBS and imaged using a fluorescence microscope (Zeiss Axio 
Observer, ZI) with excitation at 488 nm and emission at 515 nm for live cells and 
excitation at 570 nm and emission at 602 nm for dead cells. 
To investigate cell attachment and proliferation of hMSCs, actin filament and nuclei 
were stained and investigated by immunofluorescence, according to the following: At 
day 1 and 8 after cell seeding, cells were fixed with 4% paraformaldehyde (pH 7.4), 
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permeabilized (30 min, 0.1% Triton X-100 in PBS)), and blocked (30 min, 0.1% Tween 
20 and 1% bovine serum albumin in PBS) for unspecific binding of the antibodies. The 
cells were then stained with Alexa Fluor 555 conjugated phalloidin (1:200, Life Tech-
nologies) for actin filament visualization and counterstained with TOPRO-3 (1:1000, 
Life Technologies) for visualization of the nucleus. The cells were visualized with a 
confocal laser-scanning microscope (Leica microsystems, Germany). 
5.2.8 Doxycycline drug release studies 
IPN discs (Ø=10:2mm) containing 22% wt of pHEMA or pHEMA-co-PEGMEA 
hydrogel were loaded by soaking the IPN discs in 5 ml of 20 mg/ml of DOX solution 
(mixed in PBS) for one week at 4°C. The DOX loaded IPN discs were washed twice 
with Milli-Q water and dried at room temperature for 48 hr. For the drug release study 
IPN discs were immersed in closed dark-glass vials containing 5 ml PBS (pH 7.4), 
which was placed on a shaker at room temperature for 1 month. At regular time inter-
vals the concentration of drug released into the PBS supernatant was collected and the 
absorbance measured at 351 nm using UV-Visible spectrophotometer (UV-2600, 
SHIMADZU Corporation, USA). For each time interval and sample an UV-Vis spectra 
was recorded between 250 and 600 nm to determine the stability of DOX over time. 
After each measurement the whole volume of PBS and DOX mixture was replaced 
completely by fresh PBS. IPN discs, containing 22 % wt of pHEMA-co-PEGMEA 
hydrogel IPN, was used as a negative control. Three independent IPN discs were used 
for repeatability. 
5.2.9 Induction of gene expression of Hela Tet-On cells through doxycycline 
release from IPNs 
For biological assessment of drug-releasing IPNs, a DOX regulated green fluorescent 
reporter gene expression assay was used for HeLa cells as described in[37]. In sum-
mary, a pTRE-Tight-BI-DsRed-Express plasmid from Clontech, consisting of a 
bidirectional tetracycline sensitive promoter, which in one direction encodes the red 
fluorescent protein (RFP) reporter DsRed-Express, and in the other direction has a 
mutable cloning site (MCS) ZsGreen1-DR, encoding the green fluorescent protein 
(GFP) reporter, was inserted in-frame into this MCS. When this plasmid construct is 
transfected into HeLa Tet-On Advanced cells (631155, Clontech), which stably express 
the Tet-On trans-activator, gene expression of the fluorescent reporter proteins can be 
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induced by addition of DOX (a tetracycline analogue) to the cell culture medium in the 
range of 100-1000 ng/mL. Different concentrations of DOX (0, 0.00001, 0.001, 0.1, 10 
and 1000 µg/ml) were prepared in PBS, sterile filtered through 0.22 µm filter and stored 
at 4 °C. For drug-loading, sterilized pHEMA-co-PEGMEA IPN discs were transferred 
into solutions with different concentrations of DOX for one week. Following drug-
loading, IPN discs were removed, washed three times with sterile water and then coated 
with 80 µg/ml collagen I solution for 2 h at 37 °C for cell attachment. Finally, IPN discs 
were washed with sterile PBS and transferred into 24-well plates containing cell culture 
media (DMEM supplemented with 10% Tet System Approved Fetal Bovine Serum 
(FBS) (631106, Clontech), penicillin 100 U/mL, streptomycin 100 μg/mL (P4333, 
Sigma), and geneticin (G-418) 100 μg/mL (11811–023, GIBCO). HeLa Tet-On cells 
were trypsinized and 4 x 10
4
 cells were seeded on each IPN disc and cultured at 37 °C 
and 5% CO2. After culturing overnight the cell density was about 60-70% of conflu-
ence. For transfection of the reporter plasmid, a transfection solution was prepared by 
mixing 500 ng of plasmid DNA into 100 µL Opti-ME (31985, GIBCO) and 1.25 µL of 
Lipofectamine LTX (15338–100, Invitrogen). The solutions were mixed gently and 
incubated for 25 minutes at room temperature to form DNA-Lipofectamine complexes. 
The growth medium from each well was replaced with 0.5 mL of fresh medium. Cells 
grown on the IPN discs were transfected with the reporter plasmid by adding 100 µL of 
the solution containing DNA-Lipofectamine complexes. The cells were incubated at 37 
°C and 5% CO2. After 6 h of transfection, the cell culture medium containing DNA-
Lipofectamine complexes was removed, and cells were rinsed with PBS and added to 
0.6 mL of fresh medium. Finally, the transfected HeLa cells on the IPN discs were 
incubated at 37 °C and 5% CO2 for 18-24 h before assaying for fluorescent transgene 
expression. As a proof of concept for 3D IPN scaffolds, the same experimental proce-
dure was followed as described above for 2D IPN discs, but with some modifications. 
Only a single DOX concentration (1000 µg/ml) was tested and 2 x 10
5
 cells seeded into 
each scaffold. HeLa Tet-On cells grown on 2D IPN discs and 3D IPN scaffolds without 
DOX loading were utilized as negative controls. The cells on 2D IPN discs and 3D IPN 
scaffolds were imaged using a fluorescence microscope (Zeiss Axio Observer, ZI). 
5.2.10 Statistical analysis 
All the data presented are means and standard deviations of the experiments (n = 5 or 
6). Statistical analysis was carried out using OriginPro 9. The significant differences 
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between sample groups were determined using the nonparametric test, one-way analysis 
of variance (ANOVA), and Tukey's post-hoc analysis for pairwise mean comparisons. 
The statistical significance was defined as *p < 0.05, **p < 0.01, ***p < 0.005. 
5.3 Results and Discussion 
5.3.1 Fabrication of 3D IPN scaffolds 
Different geometries and porosities of scalable perfusable microporous 3D silicone 
elastomer scaffolds was recently realised by indirect 3D printing[17,35]. Here we have 
impregnated pHEMA-co-PEGMEA hydrogel into the 3D silicone scaffolds to fabricate 
3D IPN scaffold. Figure 1A shows a perfusable microporous 3D PDMS scaffolds (with 
80% porosity) impregnated with 82% wt of pHEMA-co-PEGMEA hydrogel using 
sCO2. SEM images of the top- (Figs. 1B a&b) and side view (Figs. 1B c&d) of the 
scaffolds show a highly interconnected square profile (average side length 350 um) with 
elliptical shaped channels (average width 400 μm, height 200 μm), respectively. The 
channel dimensions are slightly smaller than the dimension of the base 3D PDMS 
scaffold due to the swelling of the PDMS when impregnated with hydrogel. The ad-
vantage of using 3D printing to make 3D IPN scaffolds is that dimensions and 
geometries of the pores of the scaffolds are highly tuneable and controllable. Moreover, 
since the pores of the scaffolds are structured with interconnected channels they are 
easy to clean, removing any uncross-linked monomers or cross-linked hydrogels 
deposits connected around the porous scaffolds, by simple perfusion with water/buffer.  
Both pHEMA and pHEMA-co-PEGMEA impregnated 2D IPN discs and pHEMA-co-
PEGMEA impregnated 3D IPN scaffolds were investigated. 2D IPN discs with 22% 
(w/w) hydrogel were used for general comparison of physicochemical, mechanical and 
drug releasing properties. Finally the in-vitro hMSC studies and drug induced gene 
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expression of Hela cells were tested with 3D pHEMA-co-PEGMEA IPN scaffolds. 
 
Figure 1. (A) Schematic illustration of the process of producing a 3D IPN scaffold, starting from a 3D 
printed sacrificial water soluble PVA mould (a), via silicone elastomer casting around the PVA mould 
and its subsequent removal to form a 3D silicone scaffold replica (b), to its subsequent hydrogel impreg-
nation via sCO2, generating an 3D IPN scaffold (optical image) (c). Optical image of semi-transparent 
silicone (d) and 22% w/w pHEMA-co-PEGMEA (e) IPN discs.  (B) SEM images of 3D IPN scaffolds 
with 52% w/w pHEMA-co-PEGMEA with woodpile infill pattern from top (a & b) and cross sectional (c 
& d) view. Scale bars: 1 cm for A (d & e), 1 mm for B (a & c) and 400 µm for B (b & d). 
5.3.2  Physicochemical characteristics and mechanical properties of 2D IPNs. 
Figure 2 shows the physicochemical characteristics of 2D IPN discs and the base 
silicone elastomer. FTIR spectra of silicone (black line) and the corresponding IPNs 
with PHEMA (red line) and pHEMA-co-PEGMEA (blue line) are shown in Figure 2A. 
The characteristic absorption peaks observed at wavenumbers of 2962 cm
−1
 (C–H 
stretching in CH3), 1259 cm
−1
 (CH3 symmetric bending in Si–CH3), 1076 cm
−1
 and 
1018 cm
−1
 (Si–O–Si), identifies different functional groups present in silicone. The 
absorption peaks at around 1700 cm
-1
 and 3400 cm
-1
 are characteristic absorption peaks 
for carboxyl (C=O) and OH groups and were observed for both the IPNs, which clearly 
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demonstrates the presence of pHEMA and pHEMA-co-PEGMEA hydrogels in the bulk 
silicone elastomer of the IPNs. Water contact angle (CA) measurements (Figure 2B) 
revealed that pHEMA-co-PEGMEA IPN had a lower CA (of 84.5
O
)
 
than pHEMA IPN 
(92
O
) and the base silicone material (103
O
), indicating a decrease in CA with impregna-
tion with a more hydrophilic hydrogel. Water uptake kinetics for the two IPNs over a 
period of 22 days (Figure 2C) show an increase until day 5-6 after which the equilibri-
um-swelling ratio is reached; pHEMA-co-PEGMEA IPN clearly having a higher water 
uptake (11.56 %) than pHEMA IPN (8.25 %). The water uptake kinetics and total water 
uptake in the pHEMA IPN is very similar to what was previously reported[31]. While it 
has been shown that the water uptake capacity increases linearly with the weight of 
hydrogel content in IPN composites[28,29,31], the pHEMA-co-PEGMEA IPN had a 1.4 
fold higher water uptake compared to the pHEMA IPN in spite of containing the same 
amount of hydrogel (22% w/w). This is likely due to the fact, that PEG is more hydro-
philic than HEMA, giving the pHEMA-PEG conjugate an improved water uptake 
capacity compared to the corresponding pHEMA hydrogel[34,38–40]. Another reason 
can be that the porosity of the bulk cross-linked polymer network increases by incre-
ments in PEG concentration[38], also leading to a higher water uptake capacity of the  
pHEMA-co-PEGMEA. 
A hydrogel scaffold used as tissue matrix should be structurally stable to with-
stand in vivo mechanical stress while providing support to the ingrowing tissue[41,42]. 
Therefore, evaluation of mechanical properties of a biomaterial has an important role in 
design of an ideal tissue engineering scaffolds with desired stiffness equivalent to real 
anatomical tissues and organs[43].  The tensile properties of the base silicone and the 
two different hydrogel-IPNs were compared (Figure. 2D-F). Figure 2D clearly shows 
that the PHEMA-co-PEGMA-IPN behaves very similarly to the silicone elastomer 
while the pHEMA-IPN is softer and less robust with low strain at break. The tensile 
Young’s modulus (Figure 2E) of the bare silicone was higher (4.50 ± 0.12 MPa) com-
pared to pHEMA and pHEMA-PEGMEA IPNs (3.27 ± 0.10 and 3.38 ± 0.14 MPa, 
respectively), indicating that impregnation of hydrogels into the silicone significantly 
reduces the Young’s modulus in the IPN-based scaffolds. The ultimate stress sustained 
by pHEMA-PEGMEA IPN (8.95 ± 0.15 MPa) was slightly higher than for silicone 
(8.66 ± 0.26 MPa) and significantly higher than for pHEMA IPN (4.55 ± 0.18 MPa). 
Similarly, the ultimate tensile stress (Figure 2F) sustained by pHEMA-PEGMEA IPN 
was slightly higher than for silicon (796 ± 35% and 721 ± 24%, respectively) and 
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significantly higher than for pHEMA IPNs (105 ± 23%). Thus, the addition of pHEMA-
co-PEGMEA to silicone does not have a dramatic influence on the mechanical proper-
ties with only a slight increase in Young modulus, ultimate stress and tensile strain 
compared to base silicone material. Previously reported results have shown that   
brittleness of pHEMA IPN was due to the impregnation of  HEMA  molecules with 
high glass transition temperature (Tg)[32]. However, the introduction of PEGMEA with 
lower (Tg)[34] into the pHEMA IPN would have helped the base silicone to improve 
the mechanical properties of the IPN by enhancing the ultimate tensile stress and strain. 
The investigated pHEMA-co-PEGMEA IPN has a young’s modulus equivalent to that 
of cartilage (1-10 MPa)[44] with the mechanical properties tuneable by varying the 
hydrogel content as well as by controlling the level of crosslinking of the silicone 
material. 
 
Figure 2. Physicochemical characteristics of pHEMA IPN, pHEMA-co-PEGMEA IPN, each containing 
22% (w/w) of hydrogel, and the base silicone discs: (A) FTIR spectra, (B) contact angle- and (C) water 
uptake measurements.  Effect of hydrogel impregnation on the mechanical properties of IPN materials 
was determined using uniaxial tensile testing: (D) Stress–strain curves. (E) Young modulus, calculated 
from linear (10-20% strain) regions of stress-strain curve and the ultimate stress. (F) The comparison of 
ultimate tensile strain. The data represents mean± standard deviation (n=5). 
5.3.2 In-vitro cell studies on pHEMA-co-PEGMEA 2D and 3D IPN materials 
The ability of materials to support cell adhesion and proliferation plays a key role in 
tissue engineering applications. In the following study, we continued the work on the 
pHEMA-co-PEGMEA IPN since it proved to have better mechanical and physicochem-
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ical properties than pHEMA IPN. hMSCs were used to evaluate and compare cell-
matrix interactions on 2D pHEMA-co-PEGMEA IPN discs and conventional TCPs as a 
control, using quantitative Alamar blue assay and qualitative live/dead staining. PEG 
hydrogels have been shown not to promote cell adhesion, resulting in a round shaped 
cell morphology due to poor cell–matrix interactions[45]. hMSC attachment on IPNs 
coated with and without collage-I extra cellular matrix (ECM) was therefore investigat-
ed (Figure 3 and supplementary information Figure S1). The IPN without ECM showed 
similarly as before hMSC adhesion with aggregated cell morphology, whereas with 
ECM (Figure 3A) good adhesion was observed, although slightly lower than that on the 
TCP control surface. The proliferation rate on IPN discs was lower than on TCP over 21 
days of cell culture (Figure 3B), which might be due to a lower number of cells on IPN 
surface compared to TCP, the former having a lower surface area (2 and 1,767 cm
2
, 
respectively). Nevertheless, the cell proliferation rate followed the same pattern and was 
in the same order of magnitude on both surfaces. The fluorescence images of live/dead 
staining of cells (Figure 3C) gives additional evidence that until 14 days cells proliferat-
ed with 100% viability on the IPN discs. The corresponding images of hMSCs grown 
on TPC can be found in supplementary information, Figure S2. Moreover, confocal 
fluorescence images (Figure 3D) show well spread hMSC morphology and high prolif-
eration on the IPN surfaces over the 21-day culture period. Thus, cell–IPN interactions 
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can be promoted by providing adhesion sites through ECM coating of the IPN materials.
 
Figure 3. hMSCs growth on TCP and collagen-I coated pHEMA-co-PEGMEA IPN discs (22% (w/w)): 
Alamar blue assay was used to determine hMSC (A) attachment on IPN and TCP at day 1 post-seeding 
and (B) proliferation on IPN and TCP presented as fold change over a 21-day period compared to day 1. 
(C) Fluorescence images of live (green) and dead (red) staining of hMSC cells proliferating on IPN discs 
over a 14-day period (Scale bars = 200 μm). (D) Confocal fluorescence images of immunostained hMSCs 
proliferating on the IPN surface after 1, 7 and 14 days post cell seeding. The cytoskeletal F-actin fibres 
(red) and nuclei (blue) were stained with Alexa Fluor 555-labelled phalloidin and TO-PRO-3 iodide, 
respectively (Scale bars = 100 µm). 
 
A challenge with 3D scaffolds compared to 2D surfaces is to ensure that the scaffolds 
are highly porous with interconnected channels for cell attachment and efficient oxygen 
and nutrient supply as well as waste removal[46]. Moreover, the scaffold should support 
formation of tissue-like 3D cellular morphology and spreading across and into the 
material, as well as with cellular extensions across the voids of the porous 
scaffold[46,47]. The 3D IPN scaffolds were fabricated with 400 µm filament-to-
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filament distances with 80% porosity, subsequently loaded with 52% (w/w) pHEMA-
co-PEGMEA hydrogel. hMSCs were seeded into the scaffolds and examined over a 28-
day culture period and metabolic activity determined by the Alamar blue assay. Figure 
4A shows that the proliferation rate steadily increase over the 28 days. To visualise that 
cells were proliferating inside the scaffolds, the cell viability after 4 and 8 days were 
investigated by cutting the scaffolds through the centre, following live/dead staining 
(Figure 4BC). On day 4 the hMSCs were well spread all over the IPN scaffolds with 
100% viability (Figure 4B). On day 8 very similar viability was observed, however with 
a few dead cells (Figure 4C), which most likely was caused by insufficient diffusion of 
oxygen and nutrients into the interior of the scaffold. The morphology of the hMSCs on 
the IPN scaffolds was visualized using immunostaining of the cytoskeleton and nuclei 
on day 15 post cell seeding (Figs. 4D-G). hMSCs clearly proliferate nicely with well 
spread cell morphology within the IPN scaffolds (Figure 4E). Interestingly, the scaf-
folds seem to promote native-like 3D microtissue architecture with cells interconnected 
in between the 400 µm inter filament pore space of opposite filaments inside the IPN 
scaffold (highlighted with white dotted lines in Figure 4F and G). Overall our results 
show that the hMSCs proliferate with high viability inside the 3D IPN scaffolds, with a 
clear increase in metabolic rate over 28 days.  
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Figure 4. hMSCs cultured on pHEMA-co-PEGMEA 3D IPN scaffolds (52 % w/w): (A) hMSC prolifera-
tion inside 3D IPN scaffold over a 28 day period: Alamar blue metabolic assay presented as fold change 
in florescence compared to day 1 post seeding. (B-C) Fluorescent images of live (green) and dead (red) 
cells on day 4 (B) and 8 (C) cultured on 3D IPN scaffolds. (D-G) Confocal images of immunostained 
hMSCs cultured on 3D IPN scaffolds after 15 days post seeding: The cytoskeletal F-actin fibres (red) and 
nuclei (blue) were stained with Alexa Fluor 555-labeled phalloidin and TO-PRO-3 iodide, respectively. 
(D) Cells were visualized from the top surface of the scaffolds where (E) is a zoom in of (D). The centre 
of the scaffold is visualised in (F) and (G), showing that the IPN scaffold supports native-like 3D 
microtissue architecture. White dotted lines represent single layers of the IPN scaffold. Scale bars: 100 
µm for B-C and 200 µm for D-G. 
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5.3.3 DOX release studies from IPNs 
In a previous study it was demonstrated that it was possible to release antibiotics from 
pHEMA IPNs and that the release profile could be controlled by varying the hydrogel 
content as well as the concentration of drug loaded into the IPN[48]. Our hypothesis 
was that the introduction of a more hydrophilic PEGMEA network into the pHEMA 
IPN would improve the drug release profile compared to the previously synthesized 
pHEMA IPNs. Figure 5Aa compares the DOX release profile over a 7-day period from 
2D pHEMA and pHEMA-co-PEGMEA IPN discs containing equal amounts of hydro-
gel (22% w/w). The cumulative DOX release from pHEMA-co-PEGMEA IPNs was 
almost 2 fold higher compared to pHEMA IPNs. This was expected due to the more 
hydrophilic PEG network in the copolymer structures, resulting in a faster movement 
from DOX loaded IPNs [38,49] and is in good agreement with the water uptake data 
described in Figure 2Ac. Controlled and systematic long term delivery of bioactive 
molecules from biomaterials is required to minimize the release of the agent to non-
target sites[14,50] and to direct stem cells into a tissue-specific lineage[3]. The ability of 
long term release of the DOX from pHEMA-co-PEGMEA IPNs is shown in the Figure 
5Ab. A consistent release profile can be seen with a continuous release for 30 days after 
initial 5-days of burst release. The stability of the drug released into the surrounding 
PBS was examined regularly at different time points, using UV-Vis spectrophotometry. 
Figure 5Ac shows that the freshly made DOX solution (green line) and the DOX 
released from IPN (blue line) after 30 days of incubation had similar UV-Vis spectra 
with the same absorption maximum at 351 nm, indicating stability of the drug released 
from the IPN discs. Current observation is consistent with previous studies, reporting 
the short term stable release of DOX from various ceramic biomaterials[51,52]. The 
difference in absorbance peak height for DOX release from IPN and DOX standard 
solution is simply due to the different concentrations of DOX in the measured solutions. 
For negative control UV-Vis spectra (in black) was measured on a degraded DOX 
solution by exposing the solution to light during a week, which resulted in the disap-
pearance of the absorbance maximum at 351 nm, clearly confirming that the pHEMA-
co-PEGMEA IPN is a good drug delivery system maintaining the stability of DOX 
during long-term release.Delivery of DOX to cells from IPNs 
The biological activity of DOX released from pHEMA-co-PEGMEA IPNs was assessed 
using a DOX regulated GFP gene expression assay in HeLa Tet-On cells, expressing 
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GFP under the control of a tetracycline inducible promoter. DOX is a hydrophilic 
analogue of tetracycline, which upon contact with ZsGreen1-DR transfected cells 
activates GFP expression, which thus can be used to turn on the reporter gene [37]. We 
used this model system to demonstrate the release of DOX molecules from pHEMA-co-
PEGMEA IPN, activating gene expression of the HeLa Tet-On cells grown on the 
surface of the IPN materials (as shown schematically in Figure 5B). Different concen-
tration of DOX loaded pHEMA-co-PEGMEA IPN discs were first tested to determine 
the lowest concentration required for the induction of GFP expression. As shown in the 
Figure 5C, gene expression of ZsGreen1-DR was induced by the release of DOX at 
different concentration from the IPN discs into the culture medium. We found that 10 
µg/ml and 1000 µg/ml DOX induced strong GFP expression and that DOX concentra-
tions below 0.1 µg/ml did not result in any fluorescent signal. As a control, a similar 
experiment was performed on IPN discs loaded with 10 µg/ml DOX, but not transfected 
with ZsGreen1-DR plasmid, with no fluorescence observed after 24 h of cell culture 
(Supplementary Figure S3). Next, 3D pHEMA-co-PEGMEA IPN scaffolds, loaded with 
10 µg/ml of DOX, was tested and as shown in Fig 5D, a clear florescent signal can be 
observed after 24 hr of incubation, indicating that drug delivery form the 3D IPN 
scaffold is effective. In a future perspective this type of scaffold could be used for 
directed induction of stem cell differentiation. For instance dexamethanose, a small 
molecule with similar size and molecular weight as DOX that induces differentiation of 
hMSC to osteoblast over 21 days[3], could potentially be released from these types of 
IPN scaffolds for developing various bone and cartilage based tissue implants.
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 Figure 5. (A) In-vitro doxycycline release study: Amount of DOX released from: (a) pHEMA and 
pHEMA-co-PEGMEA IPN discs with 22% (w/w) hydrogel content over a 7-day period, (b) pHEMA-co-
PEGMEA IPN hydrogel over 30 days, and c) stability of released doxycycline from IPNs confirmed 
using UV-Vis absorbance spectra of the DOX solution in PBS (green line as positive control), DOX 
released from pHEMA-co-PEGMEA IPN into supernatant after 30 days (blue line) and degraded DOX 
solution in PBS by exposure to light for 1 week (black line as negative control). B) Schematics illustra-
tion of the induction of GFP expression in Hela-Tet-On cells through DOX release from IPNs. Different 
concentration of DOX loaded IPN discs (a & b) were seeded with Hela-Tet-On cells and cultured 
overnight (c). Then cells were transfected with plasmid for GFP expression and finally the cells grown on 
IPN surface was observed by green fluorescence after 24 hr of transfection (d). C) Fluorescent images of 
GFP-expressing Hela-Tet-On cells at different concentrations of DOX loaded 2D pHEMA-co-PEGMEA 
IPN discs (a). GFP-expressing Hela-Tet-On cells seeded and cultured on 3D IPN scaffolds loaded with 10 
ug/ml of DOX concentrations over night after which cells were transfected with plasmid for GFP 
expression and green fluorescence observed after 24 hr of transfection. Phase contrast channel (left), 
green fluorescence channel (middle), and an overlay of both channels (right) (b). Scale bar for all images 
in Fig. C (a & b) is 200 µm. 
5.4 Conclusions 
The present work demonstrates successful fabrication of microporous 3D silicone 
hydrogel IPN scaffolds using indirect 3D printing of silicone elastomer and subsequent 
impregnation with hydrogel IPN using supercritical carbon dioxide. Compared to the 
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existing p-HEMA IPN, the new p-HEMA-co-PEGMEA IPN appears to be better in both 
physicochemical and mechanical properties. The material is biocompatible and medical 
grade silicone materials can be applied with this process for in-vivo use. Moreover, in 
vitro cell studies demonstrated that the developed material could support long-term (21 
days) hMSC growth with very high metabolic activity and viability. Doxycycline was 
furthermore loaded into the IPN scaffolds and it’s in vitro release quantified over 30 
days, following confirmation of biological activation GFP expression in the Hela Tet-
on-cell model system. It is anticipated that the developed p-HEMA-co-PEGMEA IPN 
scaffolds potentially could be used as a long-term bioactive drug delivery system for 
various tissue-engineering applications. 
5.5 Associated Content 
Supporting Information 
 
Figure S1. Cell attachment and morphology visualization using Live (green)/dead (red) staining hMSCs 
grown with and without collagen-I coated pHEMA-co-PEGMEA  IPN surface. 
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Figure S2. Live (green)/Dead (red) staining of hMSCs grown on TPC over 14 days period. 
 
 
Figure S3. Negative control: pHEMA-co-PEGMEA IPN discs loaded with DOX, but not transfected with 
ZsGreen1-DR plasmid. No fluorescent signal was observed after 24 hour of Hela-Tet-On cells culture. 
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6.   CHAPTER 6: Application of 3D porous 
scaffolds in the NanoBio4Trans project for 
perfusion bioreactor array with integrated 
sensors and differentiation of iPSC into 
hepatocytes. 
This chapter summarises the use of the developed porous scaffolds into a perfu-
sion bioreactor with integrated bio-impedance sensors for differentiation of 
hiPSC derived hepatocytes during the NanoBio4Trans project. Two types of BAL 
support systems have been developed: (1) 16-bioreactor array intended for im-
proved throughput optimization experiments of cell culture and differentiation 
conditions. (2) 8-bioreactor array incorporating needle-electrodes for bioimped-
ance analysis of real time cell proliferation in 3D over time. Efficient operation of 
the BAL support system requires precise control of their key physical, chemical 
and physiological parameters. To implement this, advanced electrochemical 
sensors and assays have been developed and applied for monitoring hiPSC-
derived liver tissue. Finally the different scaffolds designs were integrated into 
the perfusion bioreactor and the hiPSC derived DE cells differentiation was 
optimized for BAL development. Various functions, such as metabolite secretion 
as well as expression of hepatic genes responsible for liver development, drug 
metabolism, synthesis and transport, were tested.  
6.1 Perfusion bioreactor array for tissue engineering applications 
Two versions of a perfusion bioreactor array platform – the BAL support sys-
tem - were developed. The first version (Fig. 1) is a 16-bioreactor array intended 
for optimimization  of cell culture conditions. The second version (Fig. 1Ab) is 
an 8-biorector array with integrated vertical needle electrodes for electrical 
impedance spectroscopy (EIS) analysis of cell proliferation over time. The main 
components of the BAL support system include: (1) an exchangeable bioreactor 
array chip (BAL-on-a-Chip) for performing cell culture in a 3D environment, and 
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(2) a mother board containing all necessary components such as vials and vial 
trays for storage of culture medium and waste and peristaltic pumps and motors 
for perfusion of cell culture medium. Fig. 1Ae schematically illustrates the 
perfusion culture system and fluidic/air circuit, which is the same for both plat-
forms. Four (Fig. 1Aa) or two 8-channel micropumps generate pulsatile flow and 
are controlled by motors and controllers from the Lego Mindstorm kit (Lego, 
Billund, Denmark). This allows culturing of cells at up to four different flow rates 
in a single experiment. The pumps allow flow rates from sub-µLmin-1 and up to 
approximately 90 µLmin-1. The fluidic circuit is formed by the pumps, bioreactor 
array and medium storage vials that are connected using PTFE tubing with inner 
diameter of 0.8 mm. Inlet and outlet vials are coupled with PTFE tubing and 
supplied with air supplemented with 5 % CO2 through a sterile 0.22 µm filter. All 
components are mounted onto a base platform for portability and easy handling. 
The entire system is placed in conventional cell culture incubators during the 
experiments. 
 
Figure 1. (A) Schematic design of a motherboard having an exchangeable bioreactor array with 
(a) 16 bioreactors (4  4 array) inserted and (b) an 8 bioreactor array  (4  2 array) with integrated 
needle electrodes for electrical impedance monitoring of cell proliferation over time. Schematic of 
the bioreactors in the (c) 4  4 array and (d) 4  2 array. (e) Schematic of fluidic circuit (blue 
arrows) and pressure circuit (red arrows). – (B) Assembled perfusion array platform with (a) 16 
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and (b) 8 bioreactors, the latter with (c) two integrated vertical needle electrodes in each bioreac-
tor. 
 
The bioreactor array allows cell culture in cylindrical 3D scaffolds having diameter of 6 
mm and height of 5 mm (Fig. 1Ac and 1Ad). Each bioreactor consists of an inlet port 
(at the bottom), a cylindrical chamber for housing a 3D scaffold and an outlet port (at 
the top). Silicone tubes (inner diameter of 1.8 mm and height of 10 mm) are press fitted 
to the ports of the bioreactor (inner and outer diameter of 1 mm of 2 mm, respectively) 
and serve as connectors between the bioreactor and the rest of the perfusion network. 
The bioreactor units are implemented into the arrays to enable parallel analysis. Fig. 
1Ac and 1Ad show the schematic of a single bioreactor in the case of the 16- and 8- 
bioreactor array, respectively. For the impedance measurements, two platinum (Pt) 
needle electrodes (diameter of 0.4 mm and height of 5 mm) were vertically placed at the 
opposite sidewalls of each bioreactor (Fig. 1Ad). Moreover, in the 8-biorector array an 
opening was introduced between the two rows of bioreactors to allow electrical connec-
tions to the electrodes via crocodile clips (Fig. 1Ab) 
6.2 Impedance based sensor integration and monitoring of cell 
growth in BAL support system 
We present the application of electrochemical impedance spectroscopy (EIS) as a 
method for discriminating between different polydimethylsiloxane (PDMS) 
scaffolds for three-dimensional (3D) cell cultures. The validity of EIS characteri-
sation for scaffolds having different degree of porosity (networks of structured or 
random channels) is discussed in relation to Archie’s law. The EIS based method 
was used to provide porosity information in physiological buffer that agrees well 
with a more conventional weight-based approach. Different frequency ranges 
have been proposed that may serve as means of single-frequency measurements 
for fast scaffold characterization combined with in vitro monitoring of 3D cell 
cultures (Published in paper 4). Table 1 shows the values of porosity determined 
for random and structured scaffolds (20 - 80% infill) using both EIS- and weight-
based techniques. The obtained porosity values using the two approaches are 
comparable. The weight-based method shows a higher standard deviation, which 
may be due to errors in the weighing, whereas EIS measurements provide a 
higher precision for the obtained porosity values reflected by the small standard 
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deviations. Nevertheless, the porosity values determined using the more conven-
tional weight-based technique were considered as guidelines for validation of the 
EIS-based technique.  
Table 1. Porosity values (%) for random and structured scaffolds (20 - 80% infill) 
determined using the weight-based method [13] and EIS measurements in PBS. 
Values are reported as mean ± standard deviation (n = 3) with suitable frequency 
ranges for EIS analysis. 
Scaffold 
type 
Porosity (%): 
weight-
based 
method 
Porosity 
(%): EIS
a
 
Frequency 
range (kHz) for 
EIS analysis 
Random 64 ± 1 67.75 ± 0.01 50 - 70 
Structured 
20% 
19.5 ± 0.5 23.47 ± 0.01 50 - 70 
40% 38.89 ± 0.07 45.80 ± 0.04 50 - 70 
60% 60.5 ± 0.5 60.99 ± 0.03 50 - 70 
80% 81 ± 1 89.17 ± 0.05 50 - 70 
[a] In porosity calculation involving Eq. 1 and 2, the following parameters are used: m = 1 for structured 
scaffolds and m = 2 for random scaffolds; C = 1 for all scaffolds and σ0 = 1.35 S/m. 
Using the BAL support system in Fig. 1Bb, impedance monitoring of cell growth 
in the porous 3D scaffolds over a 19-day period was performed after loading of 
cells using a suspension with density of 2  106 Heg2 cells in 30 µL. Fig. 2A 
shows the measured impedance magnitude at 10 kHz over time. A drop in imped-
ance was observed during the first three days of culture, which was unexpected. 
However, we reasoned that this most likely was due to a loss of non-adherent 
cells when perfusion was turned on, moreover calculations on the theoretically 
predicted number of cells that could be housed in the scaffolds was determined to 
be much lower than the number of cells that were loaded/seeded (see task 4.3 for 
calculations). After an initial decrease of impedance during the first three days, 
the impedance started to continuously increase over time. To understand these 
results, the cell number was determined based on the dsDNA content of cells in 
the scaffolds, using the PicoGreen assay. In fact the number of cells at the end of 
the 19 days cell culture period was found to be lower than the number of cells 
seeded into the scaffolds at the start of the experiment. This is also indicated by 
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the impedance spectra of Fig. 2A, showing a lower impedance magnitude at the 
end of the culture period compared with the magnitude at the beginning. Fig. 2B 
shows correlation between the measured impedance at day 19 (evaluated at 10 
kHz)
 
and the determined dsDNA quantity (day 19) in the different scaffolds. A 
parallel experiment was performed where scaffolds were loaded with 2  106 
cells and then perfused with medium in the bioreactors. After 24 hours, we found 
that only 0.9 (± 0.2)  106 cells (mean ± SD, n = 4) remained in the scaffolds, 
confirming the initial loss of cells and thus the decrease in impedance. 
 
 
 
Figure 2. (A) Dynamic measurement of |Z| over 19 days of perfusion culture with HepG2 loaded 
bioreactors. (B) Linear correlation between the cell number found at day 19 and |Z| at 10 kHz (R
2
 
= 0.982). 
6.3 Assessment of hiPSC derived BAL function at different conditions 
6.3.1 Distribution, attachment and differentiated morphology of hiPSC-derived DE 
cells 
The distribution, attachment and differentiated cell morphology of hiPSCs-derived DE 
cells were evaluated by imaging of the middle of a cross-sectioned scaffold after 22 
days of culture at 1 µL/min flow rate in differentiation medium in the 16-bioreactor 
array system in Fig. 1Ba.  
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As shown in Fig. 3A and B of Höchst stained cell nuclei, the cells are uniformly distrib-
uted throughout the entire scaffold, but residing in populations in the cavities of the 
porous scaffold. A close-up image of live-stained cells in Fig. 3C displays proper cell 
attachment and morphology. Moreover, in Fig. 4, images of DE cells, differentiated on 
PDMS and on a polystyrene reference show that DE cells obtain identical morphology 
on PDMS.  
The effect of scaffold design- and flow rate on hepatic differentiation, metabolic activity 
and function of the BAL was further investigated. 
  
Figure 4. Optical images of the morphology of DE cells differentiated in 2D PDMS sheets (using 
Cellartis ECM coating), compared to a 2D static reference culture on polystyrene (using Cellartis ECM 
coating): Both images represent differentiated cells at day 19 of differentiation after the DE stage. Left: 
Reference culture. Right: PDMS sheets. Scale bars=60 µm. 
   
Figure 3. Microscopy imaging of hiPSC-derived DE cells cultured and hepatically differentiated inside a 
porous 3D scaffold at perfusion conditions: Image at day 22 after cell seeding of the middle of a cross-
sectioned scaffold. A) Scan of entire cross-sectioned scaffold showing cell distribution. Höchst stained cell 
nuclei in blue color. B) Close-up view of cell distribution with Höchst stained cell nuclei. The fluorescence 
image is merged with a phase contrast image of the scaffold. C) Calcein-AM live-stained cells in green.  
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6.3.2 Analysis of hiPSC-derived BAL at different conditions in comparison to 
PCLSs 
Several BAL versions were created during the Nanaobio4Trans, using hiPSCs differen-
tiated to the DE stage by Cellartis. The DE cells were produced from hiPSC by Cellartis 
and delivered to DTU. Scaffolds were prepared and loaded with hiPSC-derived DE cells 
and cultured for 25 days in the BAL support system with 16-bioreactor array at DTU. 
Two different scaffold designs (hexagonal and random) were tested and two flow rates 
(1 and 5 µL/min). The hepatic differentiation and functionality of hiPSC-derived 
hepatocytes were assessed at RUG using freshly obtained human PCLS as an ex vivo 
liver reference model. PCLS were incubated under static conditions in 12-well plates 
and in the liver-on-a-chip with a flow rate of 10 µL/min. Cells and slices were incubated 
in Cellartis hepatocyte maintenance culture medium. 
The characteristics of these cells were determined with a palette of assays (metabolism, 
function, viability, and gene expression) developed by RUG. Human PCLS were 
cultured under static and flow conditions, using Cellartis hepatocyte maintenance 
medium. The same palette of assays was performed on the PCLS, static cultures and 
hiPSC-derived BALs. As the variation in liver function in the human population is well 
known to be large, the individual data of 3-9 human livers is given with the median 
value. The degree of hepatic differentiation in the BALs after 25 days of culture in 
Cellartis medium was analysed by gene expression of liver markers, albumin secretion 
and drug metabolism by phase I- and phase II activity.  
An often used marker for hepatocyte function is albumin secreted into the medium. The 
medium from the respective BAL was collected and analysed using an ELISA kit. In 
regards to albumin, a similar or higher gene expression level (Fig. 5) was observed 
compared to the static references from Cellartis (dark blue bar) and DTU (yellow bar), 
which correlates with a lower expression of alpha-fetoprotein, i.e., the foetal form of 
albumin and should go from high to low during differentiation and maturation. The 
highest level of albumin expression was, however, seen for cultures in the Hex scaffold 
at a flow rate of 5 µL/min. The gene expression data for albumin were supported by a 
similar pattern in secretion level of albumin (Fig. 6) per scaffold for duplicate bioreac-
tors and different conditions. Noteworthy is that the albumin secretion was increasing 
over time from day 21 to day 25.  
 
 148 
 
The results show that albumin can be detected in the medium that passes through the 
BAL with the general trend that albumin secretion increases with time during the last 
day of differentiation, which is what should be expected.  
 
 
 
Figure 5. Effect of scaffold design and flow rate on gene expression of hepatocyte specific markers: 
hiPSC-derived DE cells were cultured and hepatic differentiated inside a 3D random porous scaffold 
(Ran) or a combined structured/random porous scaffold (Hex) at perfusion conditions at a flow rate of 1 
µL/min or 5 µL/min for 25 days. Each culture condition was performed in duplicate and is shown in the 
diagrams as separate bars to easily visualize variation between parallel cultures at the same condition and 
easy comparison of gene expression of the same bioreactor culture to albumin secretion (Fig. 4.23) and 
phase I and phase II activity (Fig. 7), which are all shown in the same order in the diagrams. Gene 
expression was analyzed by qRT-PCR using Taqman® assays for the genes: Albumin (ALB), alpha-
fetoprotein (AFP), CYP3A4, CYP3A5, CYP3A7, and constitutive androstane receptor (CAR). Gene 
expression is normalized to expression of CREB-binding protein. Two 2D static references are included: 
One based on cDNA from cells cultured at Cellartis (Ref Cellartis) and another based on cells cultured at 
DTU for 21 days in a standard 6 well plate (Static 6 well). 
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Figure 6. Effect of scaffold design and flow rate on albumin secretion: hiPSC-derived DE cells were 
cultured and hepatic differentiated inside a 3D random porous scaffold (Ran) or a combined struc-
tured/random porous scaffold (Hex) at perfusion conditions at a flow rate of 1 µL/min or 5 µL/min for 25 
days. Each culture condition was performed in duplicate and is shown in the diagrams as separate bars to 
easily visualize variation between parallel cultures at the same condition and easy comparison of albumin 
secretion of the same bioreactor culture to gene expression and phase I and phase II activity (Fig. 4.24), 
which are all shown in the same order in the diagrams. Medium from the BAL outlets were collected at 
day 21, day 23, and day 25 and analyzed for albumin by ELISA (E80-129, Bethyl Laboratories).  
 
A very important test for BAL function is the ability to metabolise drugs. This was done 
by adding test substrates to the perfusion medium and measuring the metabolite using 
HPLC or mass spectrometry. The BAL was first matured and then perfused with 7-
ethoxycoumarin (phase I and II metabolism) or 7-hydroxycoumarin (phase II metabo-
lism). The medium for the respective BALs was collected after the BAL was filled with 
medium containing the respective forms of coumarin. The medium was then frozen and 
shipped to P5 for HPLC analysis. The results are shown in Fig. 7 where addition of the 
coumarin substrates showed the highest metabolic activity with respect to glucuronida-
tion and sulfation at the highest flow rate, 5 µL/min, and at a level similar or higher than 
for liver slice cultures. Furthermore the glucuronidation activity was, as expected, 
higher than the sulfation activity.  
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Figure 7. Effect of scaffold design and flow rate on phase I- and Phase II activity: hiPSC-derived DE 
cells were cultured and hepatic differentiated inside a 3D random porous scaffold (Ran) or a combined 
structured/random porous scaffold (Hex) at perfusion conditions at a flow rate of 1 µL/min or 5 µL/min 
for 25 days. Each culture condition was performed in duplicate and is shown in the diagrams as separate 
bars to easily visualize variation between parallel cultures at the same condition and easy comparison of 
phase I and phase II activity of the same bioreactor culture to gene expression (Fig. 5) and albumin 
secretion (Fig. 6), which are all shown in the same order in the diagrams. For the activity experiments, the 
scaffolds were removed from the flow bioreactor and placed in a 48 well plate in 1 mL medium with the 
added specific substrate(s). The scaffolds were then incubated for 2½ hours at 37°C/5% CO2 and medium 
collected and stored at -20 °C for later analysis of metabolites by HPLC. A) For phase I and phase II 
activity measurements, the medium was added 500 µM 7-ethoxycoumarin and analyzed for the metabo-
lites Gluc: 7-hydroxycoumarin glucuronide, Hc: 7-hydroxycoumarin, and Sulf: 7-hydroxycoumarin 
sulphate. B) In case no phase I activity would take place, 500 µM 7-hydroxycoumarin (product in phase I, 
and substrate for phase II activity) was added to the medium in another experiment, but to the same 
scaffolds. The medium was analyzed for the metabolites Gluc: 7-hydroxycoumarin glucuronide and Sulf: 
7-hydroxycoumarin sulphate. 
 
Expression of different hepatic genes responsible for liver development, synthesis, 
metabolism and membrane transport in hiPSC-derived BAL differentiated under 
different conditions were compared. The expression of the foetal liver marker AFP was 
lower in hiPSC-derived BAL cultured under flow compared to static cultures, but was 
higher than in PCLS, where it was nearly absent. This indicates the beneficial effect of 
flow on hepatocyte maturation. Expression of CYP3A7 (also mainly expressed in foetal 
liver) was low and similar to PCLS in all cell culture conditions. Expression of hepatic 
nuclear factor, HNF4α (liver differentiation marker), and nuclear receptor, CAR, which 
both regulate the expression of various hepatic genes, showed different expression 
patterns. HNF4α showed good expression levels, whereas CAR was poorly expressed 
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hiPSC-derived BALs cultured under all conditions compared to liver slices. Different 
CYP enzymes showed different expression levels. For example, CYP3A5 was ex-
pressed more in hiPSC compared to PCLS, on average 4-to 5-fold higher for hiPSC 
cultured at 5µL/min flow, and 9- to 12-fold higher in hiPSC cultured under static 
condition. On the other hand, CYP3A4 and CYP2B6 had low expression in hiPSC-
derived BAL compared to hPCLS.  
Overall the data indicates that hiPSC-derived BAL differentiate under flow into both 
hepatic and biliary directions, as epithelial biliary cell markers, such as CK7 and BGP, 
were well expressed in cell cultures. 
6.4 Conclusions 
Overall the achievements of BAL support system developed during NanoBio4Trans 
project demonstrates that function of hiPSC-derived hepatocytes or BALs is similar to 
fresh human liver tissue. Moreover, it reveals that these hiPSC-derived hepatocytes, 
cultured on the developed 3D scaffolds under perfusion into a BAL, show as yet unri-
valled functionality, with excellent comparability of liver functions with human liver 
tissue. The differentiation of hiPSC-derived hepatocytes under flow conditions in the 
scaffolds was similar to that in normal cultures, which generates a unique possibility to 
differentiate and mature cells directly in a perfusion based support system.  
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7.  CHAPTER 7. Biodegradable scaffold 
containing native extracellular matrix (ECM) for 
hiPSC derived liver tissue engineering 
In previous chapters various synthetic scaffolds fabrication techniques have been 
explored for the differentiation and maturation of hiPSC derived hepatocytes. At the 
beginning the major goal of the project was to develop a platform for an extracorporeal 
device so synthetic polymer scaffolds coated with commercial ECM was suitable. The 
ECM used in standard hepatocytes cultures is mainly either collagen or fibronectin or a 
mixture of both which is highly expensive. However the mammalian liver tissue is 
composed of two major components: cells (Various liver cell types) and ECM compo-
nent that provides structural support to the tissue’s geometric shape. The tissue ECM is 
a complex mixture of proteins and polysaccharides such as collagen, elastin, hyaluronic 
acid, proteoglycans and glycosaminoglycans [1,2]. So to develop a better organ model 
much attention has to be paid to choose the right kind of ECM to specific cell types and 
at the same time the materials has to be economically viable. Secondly to be able to use 
the scaffolds for in-vivo tissue engineering applications the scaffolds has to be biode-
gradable [3,4] and the degradation time of the material should match the healing or 
regeneration process [5]. This chapter presents some preliminary findings carried out at 
the end of my PhD where I have tried to isolate decellularied native porcine liver ECM 
and tested the influence of native ECM on maturation of hiPSC derived hepatocytes. 
Silk fibroin, obtained from silkworms, demonstrates great biocompatibility along with 
outstanding mechanical properties and proteolytic degradation making it suitable for 
extensive use in multiple types of tissue engineering scaffolds [6]. I have therefore tried 
to fabricate silk protein based porous scaffolds using previously developed techniques 
in chapter 4 and also some bioinspired liver scaffold design. 
7.1 Decellularized liver extracellular matrix (L-ECM): coating 
materials on to biodegradable scaffolds 
In the field of liver tissue engineering, In-vitro culture of iPSC derived hepatocytes with 
better differentiation; improvement in hepatocyte-specific functions such as albumin 
secretion, hepatic transport activity, and ammonia metabolism; and loss of hepatocyte 
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polarity is a major challenge. Identification of new extracellular matrix (ECM) compo-
nent that can maintain a functional hepatocyte differentiation profile would represent an 
advantage towards the development of an engineered liver tissue [2,7,8]. Individual 
extracellular matrix (ECM) components or combinations of desired ECM components 
have been used as substrates for hepatocyte culture systems for several decades [10]. 
Conventional in vitro culture models for hepatocytes include the use of sandwich 
configuration in which hepatocytes are either placed between two layers of type-I 
collagen and Matrigel (MG) or cultured on type-I collagen single layer. It has already 
been shown that ECM derived from the liver and type-I collagen are useful substrates 
for hepatocyte culture [8], [11]. However, ECM gels are not suitable for scaling up into 
3D organs and cannot sustain long term cultureing: Firstly it is challenging to design 
porous scaffolds from those natural ECM due to their low mechanical strength and the 
second major problem is associated with the faster degradation of such natural ECM. So 
the idea of the project was to fabricate mechanically stiff (close to stiffness of liver) 
porous scaffolds containing liver specific ECM components and which could be pro-
gramed for biodegradation over periods from months till years. The hypothesis was that 
silk fibroin scaffold with ECM could be a solution to the problems associated with pure 
ECM mentioned above. The main advantage of the natural silk fibroin was expected to 
be to provide the mechanical stiffness required and it can provide programed degrada-
tion of the scaffold.  
In this study the first focus was to develop biomimetic ECM materials from decellular-
ized porcine liver tissues and test this L-ECM coating material in comparison to 
commercially developed ECM commercially available by Cellartics (C-ECM) in terms 
of maintenance of hepatic phenotype, functions and hepatocyte survival of matured 
hepatocytes derived from hiPSC in vitro. Such ECM materials could subsequently be 
used to coat or embed into a biodegradable 3D silk scaffold. In the second part of the 
study the fabrication of two types of dual-pore silk scaffolds were investigated.  
7.1.1 Materials and methods 
Preparation of L-ECM  
Adult porcine liver were obtained from the local abattoir. The liver tissue was decellu-
larized and prepared as previously described [2]. Briefly, the chopped liver tissue was 
cut into small rectangular pieces, rinsed in phosphate buffered saline (PBS), and decel-
lularized using 1% sodium dodecyl sulfate (SDS), until the tissue was white. The 
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resulting decellularized L-ECM was then rinsed with DI water overnight, lyophilized, 
and milled into a fine powder using a 40 mm mesh strainer and small tissue mill. The 
resulting milled powder was then solubilized by a pepsin-based enzymatic digestion in 
0.1 M HCl for at least 48 h. The solubilized L-ECM was adjusted to pH 7.4 with NaOH. 
The final concentration of L-ECM solution was adjusted to 10 mg/mL and further 
diluted with PBS if necessary. 
 
Figure 1: Schematic illustration of liver extracellular matrix (L-ECM) preparation. Native porcine 
liver was washed with a decellularizing solution (1% sodium dodecyl sulfate (SDS)) to remove 
cellular components in the liver tissue. The LEM was lyophilized and ground into powder. The 
powder was solubilized with 10% (w/w) pepsin in 0.1 M HCl. Ultimately LEM solution was used 
to prepare a 2D coating for hepatocyte culture. 
 
Figure 2: showing the cut liver pieces washing with 1% SDS (A&B) and lyophi-
lized (C) and ground into powder (D). 
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Growing cells on ECM 
Matured hepatocyte derived from human pluripotent stem cell (hiPSC) (Cellartis®, Cat. 
No. Y10050) (after 21 days of differentiation) were used in this work. The cell culture 
treated 24-well polystyrene plates 100 µg/cm
2
 C-ECM or different concentrations of L-
ECM overnight and air-dried in a sterile laminar air flow (LAF) cabinet. In an initial 
experiment maturated hepatocytes were seeded into the well plates according to the 
company protocol and cultured for 11 days period and the cell attachment and morphol-
ogy was observed under the microscope to determine the minimum concentration 
required for future experiments. In a subsequent experiment 100 µg/cm
2 
of L-ECM or 
C-ECM was coated in the wells of 24-well plates as described above and the mature 
hepatocytes were seeded into the wells and cultured for 16 days. On day 7, 12 and 16 
the hepatocytes grown on the two different ECMs were analyzed and compared. Visual 
microscopy observation, liver specific biochemical assays, and quantitative reverse-
transcription PCR (qRT-PCR) of liver specific gene markers were performed to evalu-
ate the two different ECM coating materials on maturation of hepatocytes derived from 
hiPSC as described below.  
 
Analyzing cells grown on ECM 
The cells were lysed used lysis buffer provided by Fisher BioReagents™ SurePrep™ 
RNA/DNA/Protein Purification Kit (Fisher scientific, USA Cat no: BP280250). The 
protein content of cell lysates were measured by the Pierce® BCA Protein Assay Kit 
(cat. no. 23227) according to the manufacturer’s microplate protocol. The absorbance 
was read at 570 nm and protein calculated based on a standard curve made with known 
concentration of bovine serum albumin. 
Urea and albumin concentrations secreted from the hepatocytes into the medium 
were measured using albumin ELISA (Bethyl, USA) and Urea Assay Kits (Abnova, 
Germany) according to supplier’s instruction. 
Total cellular RNA was isolated using the Fisher BioReagents™ SurePrep™ 
RNA/DNA/Protein Purification Kit (Fisher scientific, USA Cat no: BP280250). Differ-
entiated cells were lysed using the lysis buffer provided in the Fisher BioReagents kit. 
The lysate was collected in microtubes and processed according to manufacturer’s 
instructions. The RNA was converted to cDNA using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, 4374966). Quantitative real time PCR (qPCR) 
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was conducted using the TaqMan® Gene Expression Assays (Applied Biosystems 
4331182, ALB (albumin) ID: Hs00910225_m1, AFP (alpha-fetoprotein) ID: 
Hs00173490_m1, CYP2B6 ID: Hs04183483_g1, CYP3A4 ID: Hs00604506_m1, 
CYP3A5 ID: Hs00241417_m1, CYP3A7 ID: Hs00426361_m1, HNF4A (hepatocyte 
nuclear factor-4-alpha) ID: Hs00230853_m1, NR1I3 (CAR, constitutive androstane 
receptor) ID: Hs00231959_m1, ABCB11 (BSEP, Bile Salt Export Pump) ID: 
Hs00184824_m1, ABCB1 (Pgp, permeability glycoprotein) ID: Hs00184500_m1,  and 
KRT7 (cytokeratin-7) ID: Hs00559840_m1), TaqMan® Gene Expression Master mix 
(Applied Biosystems, 4370048) and RNase-free water according to the manufacturer’s 
instructions (Applied Biosystems 11/2010). The Ct values obtained after analysis in the 
real time PCR thermocycling machine (MJ Research, the thermocycling program was 
50ºC for 2 minutes, 95 ºC for 10 minutes and 40 cycles of 15 sec at 95 ºC and 1 minute 
at 60 ºC) were normalized to the Ct value of housekeeping gene CREBBP (CREB-
binding protein) ID: Hs00231733_m1 (e.g. ∆Ct(ALB) = Ct(ALB)-Ct(CREBBP). The 
gene expression is presented as individual data points using the formula: 2
-∆Ct
. 
7.1.2 Results 
Figure 3 show the adhesion and morphology of hiPSC derived hepatocytes cells grown 
for 11 days on polystyrene (PS) well plates coated with either ?? µg/cm
2
 C-ECM or 
different concentrations of L-ECM. In wells coated with only 50 g/cm2 L-ECM the 
cells started to delaminate from the edges of the well plate. However, at higher concen-
tration of L-ECM as well as for the C-ECM coating no significant cell delamination 
were observed. So 100 g/cm2 was chosen as the optimal concentration for further 
studies. 
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Figure. 3 Comparison of cell adhesion and morphology of hiPSC derived hepatocytes cell grown on 
polystyrene surfaces coated with either ?? µg/cm2 C-ECM or different concentrations of L-ECM. Phase-
contrast images taken after 11 days of culture period.  
In the next phase we compared mature hepatocytes derived from hiPSC, grown on 
either L-ECM or C-ECM coated surfaces (figure 4). On day 7 no significant difference 
in morphology regarding “bile-canaliculi like” structures and poly-nucleated cells were 
observed. However on day 12 cells grown on C-ECM coated surface started to detach 
and by day 18 some area without any cells can clearly be seen. The company instruction 
was to grow cells only until day 11 or 12 and they have also confirmed that cells lose 
their liver-like function after 12 days of growth. In contrast, for the cells grown on L-
ECM coated surfaces cells were very strongly adhered to the surface even till the end of 
the experiment after18 days. 
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Figure. 4 Microscope imiges of hiPSCderived hepatocytes morphology, cultured on PS surface coated 
with either 100 µg/cm2 L-ECM coating or C-ECM (commercial cellartics ECM) over 16 days period.   
Albumin and Urea production: 
The changes in albumin and urea production rate from hepatocytes grown on both the 
surfaces were compared after 6, 12 and 18 days of growth, respectively, as shown in 
figure 5. The albumin secretion from hepatocytes grown on L-ECM surfaces was 
always higher compared to cells grown on C-ECM coated surfaces. On day 18 the 
hepatocyte cells grown on L-ECM surface produced just as high amount of albumin as 
on day 12 indicating the maintenance of maturation period. In contrast for the cells 
grown on C-ECM coating the amount of albumin produced was below the detection 
limit. This might be due to the loss of maturation (and herby loss of liver specific 
metabolic activity) as well as a higher number of cell detachment form the C-ECM 
coated compared to L-ECM as shown in the figure 4. In case of urea synthesis on day 6 
and 12, from hepatocytes grown on both surfaces showed similar level, although it was 
a little higher from cells grown on C-ECM coated surface compared to cells grown on 
L-ECM coating. Similar to albumin secretion on day 18 cells grown on L-ECM surface 
produced significantly higher amount of urea compared to cells on C-ECM coatings. 
Throughout the culture period hepatocyts grown on L-ECM coated surface maintained 
almost constant level of urea production.  
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Figure 5. Measurement of (A) Albumin and (B) Urea secretion over 18 days period by matured hepato-
cytes derived from hiPSC. 
Gene expression studies: 
We have also compared various up and down regulating liver specific gene from hiPSC 
derived matured hepatocytes cultured on both  C-ECM and L-ECM coating conditions 
on day 6, 12 and 18 (figure 6). From the figure 6 this was clear  that in case of upregu-
lating genes hepatocytes grown on L-ECM coated surface has shown better 
performance compared to C-ECM coated surface, except for HNF4A. For HNF4A both 
the surfaces have shown almost similar level of expression. The expression of albumin 
specific gene are in agreement with the albumin protein release assay shown in figure 
5A. However for downregulating genes a mix level of expression was observed.  For 
example in case of AFP expression on day 6 the level of expression was almost similar 
but on day 12 the expression lever was higher for cells grown on L-ECM compared to 
C-ECM coated surface. Again on day 18 the effect was quit opposite to day 12. For 
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KRT cells on L-ECM performed better compared to cells grown on C-ECM coated 
surface.  
 
 
Figure 6. Time resolved gene expression of hepatocyte specific markers during differentiation: Gene 
expression at cc and L-ECM 2D coating  conditions is shown at 6, 12, and 18 days of growth. The error 
bars are based on results from 6 independent chambers from 3 independent experiments. 
This comparison clearly shows that the hepatocytes grown on L-ECM coated surface 
performed better than on C-ECM coated surface. So in future L-ECM can be utilized as 
better ECM material for maintaining hiPSC derived functional human hepatocytes in 
3D porous scaffolds. 
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7.2 Fabrication of silk scaffold material for tissue engineering 
The first use of silk in medicine began in ancient times for suturing. Silk makes an 
exceptional suture material due to its robust mechanical properties, biocompatibility, 
and programmable degradation profile with time[11]. Centuries later this unique protein 
is still being explored for its application in the biomedical field. However, its applica-
tion range has broadened from its use as raw fiber sutures to aqueous and organic 
solvent-based silk solutions, sponges, foams, films, powders, particles, hydrogels, 
nanospheres, electrospun regenerated fibers, and aerogels. Currently, these formats are 
being applied to a wide variety of tissue engineering applications including regeneration 
of bone, cartilage, kidney, muscle, ligament, lung, skin, cornea, heart, nervous tissue, 
and intestine[12]. Our goal was to explore the fabrication of 3D silk scaffolds with 
various pore architectures for liver tissue engineering.  
7.2.1 Materials and methods 
Preparation of silk fibrion fiber from B. mori (Bombyx mori) cocoon 
Figure 7 illustrates all the steps in silk extraction. For silk fibroin extraction, silkeworm 
cocoons were opened, the silkworms were discarded, and the cocoons were cut into 
small pieces. Only cocoons that looked undamaged were used. Then 3 liters of ultrapure 
water was boiled in a glass beaker and 6.36g of sodium carbonate (Na2CO3) (Sigma 
Aldrich, USA) was added to the boiling water and dissolved in order to prepare a 0.02M 
solution of Na2CO3. Then 7.5g of cocoon pieces were added to the boiling Na2CO3 
solution and cooked for 30 minutes. In order to disperse the cocoons, they were stirred 
with a spatula every 10 minutes. The silk fibers were removed with a spatula, squeezed 
and cooled in 2L of cold ultrapure water in a beaker. Then the silk fibroin was rinsed in 
ultrapure water for 30 min . After rinsing, the fibers were removed from the water and 
squeezed and spread on a piece of aluminum foil and left to dry in a fume hood over-
night.  
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Figure 7. Aqueous-based processing of silk fibroin. Silk protein from B. mori silkworm cocoons was 
extracted by first boiling the cut cocoons in 0.02 M sodium carbonate, rinsing the boiled silk fibers in 
deionized water, and drying the fibers. The fibers were then dissolved in a 9.3M lithium bromide solution 
and the lithium bromide salt was subsequently dialyzed out of solution leaving behind the aqueous silk 
protein [ From reference [12]]. 
Preparation of B. mori silk fibroin solution 
The dry silk fibers were dissolved in a 9.3 M lithium bromide (LiBr) (Sigma Aldrich, 
USA) solution (25% wt/v) at 60°C for 4 to 6 hours, and the resulting solution was 
dialyzed with deionized water using 3500 Dalton molecular weight cut off dialysis 
tubing (Thermoscientific, USA) to remove the lithium bromide. The solubilized silk 
protein solution was then centrifuged twice (9700 RPM, 20 min, 4 °C) to remove 
insoluble particulates. The concentration of the silk solution was determined by drying a 
known volume of the solution and weighing the remaining solids. This protocol resulted 
in a 6–8% wtv−1 silk solution. Silk solutions were stored at 4 °C for a maximum of 
3weeks. 
Fabrication of dual-pore silk 3D scaffolds 
Sacrificial moulds for dual-pore silk scaffolds were 3D printed using a Replicator 2X 
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3D filament deposition printer (MakerBot Industries, LLC, Brooklyn, NY, USA) as 
described previously[13]. In brief, a 3D cylindrical cube (W 20 mm x H 6 mm) was 
designed using SolidWorks 2013 3D CAD design software (Dassault Systèmes Solid-
Works Corp., Waltham, MA, USA). The design was exported as STL format into the 
3D printing software (Makerware 2.4.1) for G-code generation and mould printing. 
Water dissolvable poly(vinyl alcohol) (PVA) filaments (MakerBot, USA) were used to 
print the sacrificial moulds. The printing was performed at 200°C as the nozzle tempera-
ture and 40°C as the bed temperature. The PVA moulds were loaded into a 20 ml plastic 
syringe and the 6% silk solution was injected into the mould and transferred into a -20 
or a -70 
0
C freezer and kept there overnight. The freezing temperature mainly controls 
the size of the random pore of the scaffold through the crystal formation of different 
sizes. At lower temperature the random pore size also decreases. Accordingly -20 
0
C 
was used for hexagonal PVA mould (generated microporous lamellar structure) and -70 
0
C for woodpile PVA mould different type of random pore generation. After freezing 
overnight the silk-PVA mould was freeze dried for one day. The silk was made insolu-
ble by water annealing (this the process of crosslinking the silk) at room temperature for 
24 hr to induce β-sheet formation. Scaffolds were cut into desired size and rehydrated in 
miliQ water for 24 hr to remove the PVA completely from the silk. Fresh miliQ water 
was exchanged very 2-3 hr. 
7.2.2 Results of silk scaffold fabrication 
Figure 8 shows a photograph of the dual-pore silk fibroin scaffold.. The woodpile silk 
scaffolds with dual pores were fabricated using 3D printed PVA filament moulds. As 
shown in the SEM image of the scaffold in figure 9, the pores have a round geometry 
with diameter of about 400 µm. In the random pore regions of the scaffolds, the number 
of random pores generated was very high with small dimension ranging from ~50-100 
µm due to the low temperature used for freezing (-70 
0
C), but the pore size can easily be 
controlled by changing the freezing temperature. 
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Figure 8. Photograph of porous silk fibroin scaffold. 
  
Figure 9. SEM images of woodpile designed dual-pore silk fibroin scaffold with top and bottom view. 
However we have also tried to fabricate dual pore scaffolds with lamellar random pores 
using a similar approach by using a hexagonal PVA mould as shown in the figure 10. 
From the SEM figure it this is clear that the structural integrity of lamellar pores were 
well maintained and intact into the bulk scaffold.  
 
Figure 10. A) SEM images of Hexagonal dual-pore silk scaffolds for liver tissue engineering. B) is the 
zoom in into the structured pore region of A. round red lines:structured pores and in between red lines  are 
the lamellar porous random pore region.  
7.3 Future work: Next generation biomimetic scaffold design for liver tissue 
engineering 
In future work to design silk scaffolds with microvascular network similar to real liver it 
is important to understand the internal ECM microarchitecture of it. As shown in figure 
11, the ECM of liver hexagonal lobule resembles some plate like arrangement. The 
blood flows through small blood vessel such as hepatic artery (12-35 µm diameter) to 
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the central vain of diameter of 70 µm. In liver lobule, hepatocytes are always attached 
on a 1-2 µm 2D planer ECM structure arranged in 3D. 
 
Figure 11. Liver Histology left: SEM of liver lobule of liver ECM (Baker, W. Morrant & Harris, Vincent 
Dormer Kirkes' Hand-book of Physiology, 13th ed. (P. Blakiston's Son & Co., 1892) 370), middle: 
schematics of arranged liver lobule and the blood flow into it (courses.stu.qmul.ac.uk), right: illustration 
of microfluidic blood flow into the cross-section of liver lobule. 
To design this kind of channel morphology directional freezing silk scaffold technique 
has been used to fabricate the scaffold as shown in figure 12. Lower concentrations of 
silk and higher freezing temperature (-20°C) were used to make soft scaffolds with large 
pores (of diameter = 200 µm). 
 
Figure 12. Fabrication of lamellar scaffolds. top and bottom left: Methods of fabricated which is adapted 
from the literature. Bottom right: SEM image of generated lamelar scaffolds with different concentration 
of silk protein (a,b,c) and scaffolds without directional freezing (d). [From reference [14]] 
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Figure 13 illustrates the possibility to design scaffolds with complex pore networks, 
which could simulate the suitable nutrient flow conditions closely similar to microenvi-
ronment of liver micro-lobule. The central large pore (2-3mm in diameter) will act as 
central vain and the directional pores of diameter bellow 200 µm will act as portal vain 
or hepatic artery. 
 
Figure 13. Multidirectional freezing scaffold.  In the current design of the scaffold 200 µm cappilaris are 
connected into the center where it was punched to be able to use as inlet or outlet of the flow. 
We have also tried to fabricate dual pore scaffolds with lamellar random pores using a 
similar approach (illustratd in fig 13)  by using a hexagonal PVA mould as shown in the 
figure  
7.4 Conclusion 
In this chapter we have shown that L-ECM derived from decellularized native liver can 
serve as functional ECM surface for hepatocytes derived from hiPSC as compared to C-
ECM supplied by the hiPSC company. Similarly we have also shown that biodegradable 
silk materials can be utilized to generate 3D dual-pore scaffolds by combining 3D PVA 
printing with freeze drying. More novel biomimetic approach can be adapted into the 
current fabrication techniques to generate more smart scaffolds materials. Finally such 
3D dual-pore scaffolds can be coated or embedded with L-ECM as functional surface to 
induce better maturation of hiPSCs for BAL generation. 
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8.  CHAPTER 8. Conclusion and Outlook 
In my PhD research work, I established the scientific and engineering foundation for the 
development of extracorporeal bio-artificial livers. New 3D scaffold fabrication tech-
niques were developed and shown to be highly scalable, reproducible and economical. 
A wide range of materials were screened for their applicability to make scaffolds or to 
form interpenetrating networks (IPNs) inside the 3D scaffolds. . The potential of using 
the fabricated 3D scaffolds for tissue engineering was demonstrated by culturing 
hepatocytes in integrated BAL support systems. The principle findings are summarized 
below:  
1) Novel fabrication strategies that combine 3D filament printing of sacrificial moulds, 
polymer casting and sugar/salt leaching procedures were developed to realize woodpile 
and hexagonal scaffold 3D scaffold architecture.  Microporous structures, random, and 
combined structures/random channel network architecture have been achieved. 
For structured scaffolds fabrication, we explored 3D printed polyvinyl alcohol (PVA) as 
a sacrificial mould in a polymer casting process. The PVA mould network defines the 
channels and is dissolved after curing the polymer casted around it. It was possible to 
achieve 80% porosity corresponding to about 150 cm
2
/cm
3
 surface to volume ratio. The 
process is easily scalable as demonstrated by fabricating a 75 cm
3
 scaffold with about 
16,000 interconnected channels (about 1 m
2
 surface area) and with a channel-to-channel 
distance of only 78 μm. To our knowledge, this is the largest scaffold ever to be pro-
duced with such small feature sizes and with so many structured channels.  
For dual-pore scaffolds architecture, we innovatively combined 3D printing of PVA 
mould with salt leaching process. In this technique, the sacrificial PVA mould, which 
determines the structured pore architecture, was filled with salt crystals to define the 
random pore regions of the scaffold. The technique has a number of advantages over the 
methods reported in literature, such as automated assembly of the sacrificial mould, and 
precise control over pore architecture/dimensions by 3D printing parameters. The 
fabricated dual-pore scaffolds could support high cell density , and at the same time, 
provide uniform cell distribution throughout the scaffold. Higher cell proliferation and 
viability have been achieved attributed  to efficient nutrient/oxygen transport through 
the structured pores.  
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2)  New materials were explored, either as fabrication material to construct 3D scaffold 
or as coating material to form network inside the 3D scaffold.  
Silk was investigated as an alternative to conventional materials for scaffold fabrication. 
Natural silks possess excellent tunable mechanical and elastic properties, and moreover, 
they exhibit characteristics that are interesting for medical applications such as the 
induction of no or very low immune response, low bacterial adherence and inherent 
biodegradability. We have demonstrated the fabrication of dual-pore silk scaffolds by 
modifying the previously developed 3D printing techniques with freeze-drying process. 
Similarly we have also shown that decellularized liver ECM (L-ECM) can serve as 
better ECM surface for hiPSC derived functional human hepatocytes compared to 
commercial ECM.In addition to scaffold fabrication, different combinations of materials 
have been produced and tested to form hydrogel-based nanostructured IPNs inside the 
3D scaffolds. The hydrogels would make it possible to deliver drugs that can specifical-
ly activate gene expression from cells in the interior of the 3D scaffolds. The 
combination of silicone and a PEGylated acrylate, poly(ethylene glycol) methacrylate 
(pHEMA-PEGMEA)) has shown tunable physicochemical and drug releasing proper-
ties.  We have proved that the IPN materials were able to release small molecule which 
could potentially induce biological response in the cells. 
3) The fabricated 3D scaffolds were integrated in the BAL support systems and hepato-
cytes were successfully cultured in the porous scaffold. 
BAL support systems under perfusion control were developed by incorporating pumps, 
sample reservoirs, bioreactors, 3D scaffolds and different types of sensors. Using the 
BAL support system, impedance monitoring of cell growth in the porous 3D scaffolds 
over a 19-day period was performed. The systems were successfully tested for their 
ability for long-term growth and differentiation of hiPCS-derived DE cells into func-
tional 3D BALs. Moreover, it reveals that these hiPSC-derived hepatocytes, cultured on 
the developed 3D scaffolds under perfusion into a BAL, show as yet unrivalled func-
tionality, with excellent comparability of liver functions with fresh liver tissue. 
Perspectives 
1) Fabrication techniques. 
Even though the described fabrication techniques are rapid, inexpensive, compatible 
with different polymers and allow scaling up, the major challenges we currently face 
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include: (1) developing scaffolds with biomimetic microvascular networks and desired 
mechanical stiffness similar to biological organs/tissues, (2) using biodegradable and 
bioactive functional materials for long-term maintenance of mature hepatocyte’s 
morphology and functionality, (3) advanced approaches for forming three-dimensional 
fully functional tissues and/or organs by controlling vascularization process. The ability 
to create biomimetic microvascular networks in three-dimensional designs should be the 
ultimate goal which would undoubtedly have in tissue engineering applications. To 
date, few fabrication methods exist that are capable of emulating hierarchical and 
branching channel designs, especially in 3D. Fabrication techniques of potential interest 
including direct-ink writing, soft lithography, direct-laser ablation, stereo-lithography, 
2-photon polymerization, bioprinting, and electrostatic discharge have to be integrated 
together to achieve the scaffolds with biomimetic microvascular networks. One of the 
recombination as described in chapter 7 is to resemble the structural morphology liver 
hexagonal lobule ECM using plate like arrangement. The blood flows through small 
blood vessel such as hepatic artery to the central vain with diameter of 70 µm. In liver 
lobule, hepatocytes are always attached on a 2D planer ECM structure arranged in 3D. 
To design such kind of channel morphology, directional freezing silk scaffold technique 
can be used to achieve the anatomical morphology and dimension close to liver lobule. 
Such lamellar structure may be created inside a 3D printed hexagonal PVA mould with 
lamellar local pores for hepatocyte attachment and structured global pores generated 
from PVA for nutrient/oxygen transport in the bulk scaffold. Next goal would be to 
fabricate biodegradable composite polymer scaffolds from the mixture of L-ECM and 
silk protein for generating bioartifical liver tissue by growing stem cell derived func-
tional human hepatocytes. In future combination of biomimetic/bio-inspired scaffold 
design and materials derived from nature can create the functional tissue for in-vivo 
application. 
2) IPN for drug release 
Even though we have shown that the IPN materials can release small molecule, the 
loading and release of large biological molecules such as proteins and growth factors 
has to be tested to determine the real potential of developed IPN scaffolds. 
3) Cell culture in the BAL system 
As the ultimate goal of the BAL technology is to bring the technology to the 
clinics to save patient’s lives, there are various factors that have to be considered 
and evaluated in future as described below. 
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i. Scaffold design, which will influence the flow profile through the tissue and thereby 
the applied shear stress and optimized nutrient supply with the differentiation signal-
ling factors. 
ii. The optimal flow rate, which is a balance between shear forces on the cells and to 
ensure sufficient supply of oxygen and nutrients as well as removal of cellular waste 
products.  
iii. Long term non-invasive online monitoring of viability and metabolic activity of the 
BAL system. 
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COMPONENT INVOLVING USE OF A 
DISSOLVABLE, SACRIFICIAL MATERIAL 
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Published on: 21 Jan 2015. 
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9.1 ABSTRACT 
 
The present invention relates to a method of manufacturing a porous polymer compo-
nent 1 with structured and/or random pores 4 and/or channels 5. The method comprises 
arranging a dissolvable, sacrificial material 2 in a geometrical arrangement correspond-
ing to an inner structure to be obtained in the polymer component 1. A component 
material 3, which is to form the final component 1, is arranged so that it surrounds at 
least a majority of the sacrificial material 2, and subsequently the sacrificial material 2 
is dissolved and removed from the component material 3. The sacrificial material 2 and 
thereby the resulting inner structure of the component 1 is arranged in a controlled and 
reproducible manner. The sacrificial material 2 and possibly also the component materi-
al 3 may e.g. be arranged by use of a 3D-printer or manually. The method may e.g. be 
used to manufacture a three-dimensional scaffold for tissue engineering. 
 
 
 
 
 
9.2 FIELD OF THE INVENTION 
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The present invention relates to the manufacturing of a porous polymer component, and 
in particular to methods involving arrangement of a sacrificial material which is subse-
quently dissolved and removed from a component material in order to form the cavities 
in the inner structure of the component.  
 
9.3 BACKGROUND OF THE INVENTION 
 
Porous polymers are used for a very large number of applications for years including as 
different ones as: core materials in lightweight engineering structures, thermal insula-
tion, packaging and various products for personal care. The microstructure of the porous 
polymers is typically random, and the main purpose of the material typically relates to 
the “build-in” air bubbles being formed as part of the manufacturing process. However, 
for some applications it would be desirable to be able to control the microstructure of 
the polymer, e.g. to ensure that a fluid can pass through the material in a controllable 
manner. 
 
In the field of tissue engineering, there is a requirement for porous material scaffolds 
that can be used to integrate biological cells or molecules to regenerate tissues. Such 
scaffolds support the spatial distribution of cells in a three dimensional structure, 
provide mechanical stability to the cells and should enable optimum nutrient transport. 
The desired scaffold would be highly porous and have interconnected pores. Thus, there 
is a need for reproducible and fabricatable scaffolds with controlled porosity.  
 
Attempts have been made to make a porous polymer material by use of a sacrificial 
material constituting what are to become cavities in the final product when the sacrifi-
cial material is removed after moulding a polymer around it. US 6,900,055 discloses a 
method of manufacturing a porous silicone rubber for growing cells or living tissue. A 
silicone rubber precursor is contacted with biologically acceptable sacrificial filler; this 
filler is described as a ground inorganic salt. The inner structure of the porous polymer 
thus reproduces the structure of the filler and can only be selected by choosing the best 
available sacrificial filler material for a given application. 
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Hence, an improved method of manufacturing a porous polymer component would be 
advantageous. 
 
9.4 OBJECT OF THE INVENTION 
 
It is an object of the present invention to provide a method of manufacturing a porous 
polymer component with which it is possible to obtain a controlled and reproducible 
inner structure of the component. This may include a manufacturing which results in an 
inner structure that varies through the thickness of the component in a controlled 
manner. 
 
It is another object of the present invention to provide a method of manufacturing a 
porous polymer component which removes the need for cleanroom facilities necessary 
for many known methods. 
 
It is another object of the present invention to provide a method of manufacturing a 
porous polymer component with which it is easy to scale the dimensions of both the 
outer geometry of the component and the inner pores or channels to a desired size for a 
given application. 
 
It is an object of at least some embodiments of the present invention to provide a 
method of manufacturing a porous polymer component having a structured inner 
structure through the thickness of the component. 
 
It is another object at least some embodiments of the present invention to provide a 
method of manufacturing a porous polymer component which are more simple and 
efficient than known methods and which may therefore be advantageous especially for 
components to be produced fast or in low numbers. 
 
It is a further object of the present invention to provide an alternative to the prior art. 
9.5 SUMMARY OF THE INVENTION 
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The above described object and several other objects are intended to be obtained in a 
first aspect of the invention by providing a method of manufacturing a porous polymer 
component with structured and/or random pores and/or channels, the method compris-
ing the steps of: 
arranging a dissolvable, sacrificial material in a geometrical arrangement corresponding 
to an inner structure to be obtained in the polymer component,  
arranging a component material so that it surrounds at least a majority of the sacrificial 
material, and 
dissolving and removing the sacrificial material from the component material, 
wherein the step of arranging the sacrificial material and thereby the resulting inner 
structure of the component is done in a controlled and reproducible manner. 
 
By “porous component” is preferably meant that the component has a lot of very small 
holes in it so that a fluid, such as air or water, can pass through it.  
 
By “pores” is preferably meant small openings or holes in a solid substance. 
 
By “channel” is preferably meant a passageway along which something, in the present 
application typically a fluid, may pass or interconnected pores making such passage 
possible.  
 
By “structured” is preferably meant that the pores or channels are arranged in an orderly 
and definable manner with respect to physical characteristics, such as dimensions or 
orientations. 
 
By “random” is preferably meant that some characterising parameters relating to the 
geometrical arrangement in the inner structure, typically including the spatial orienta-
tion of the cavities, is not controllable. The inner structure of the component is still 
controlled in the sense that at least one parameter has been controlled to an extent so 
that it can be reproduced in a controlled manner. Such a parameter may e.g. be an 
average diameter of the pores or channels.  
By “controlled” is preferably meant that at least some of the parameters which can be 
used to describe the porous structure are controllable and thereby also reproducible. 
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Such parameters can e.g. be the volume fraction of solid material, an average size of the 
pores, or an average orientation of channels.  
 
In some embodiments of the invention, the above-mentioned steps take place one at a 
time and in the order in which they are mentioned. In other embodiments some of the 
steps happen concurrently as will be explained below. 
 
The method may further comprise the step of curing the component material before the 
sacrificial material is removed. This will be the case for materials which need curing 
before being in their final form and ready for handling. This will be explained in further 
details below. The sacrificial material may also be cured. 
 
In some embodiments of the invention, the inner structure of the component is con-
trolled to be random substantially throughout the component. Careful design of a 
random structure can be used to increase the surface-to-volume-ratio which will be 
advantageous for some applications of the invention. It is e.g. considered to be advanta-
geous for applications within environmental engineering, such as for spongy material 
used to soak-up oil spill, or other applications exploiting the effect of surface tension. 
 
The inner structure of the component may alternatively or in combination therewith be 
controlled to have a predefined geometrical configuration with orderly arranged pores 
and/or channels.  
 
An example of an advantage of having both random and structured regions in a compo-
nent is that in order to maximise mass transport in e.g. tissue engineering scaffolds, 
bigger channels enable rapid transport of fluid or nutrients while the smaller pores 
provide a larger functional surface area e.g. for cell growth, catalytic reactions, and 
adsorption or absorption or release of components over time. To summarise, having 
pores in combination with larger channels would enable access to a larger volume of the 
component. 
 
An advantage of the possibility of controlling the sacrificial material so that structured 
channels are obtained is that it is possible to make the channels continue towards the 
centre of the component. This can e.g. be used in tissue engineering to make sure that 
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also cells located at the centre are supplied with oxygen. The channels do not necessari-
ly have the same size throughout the thickness of the component, but may resemble the 
decrease in size down to capillary in natural organs. 
 
The inner structure of the component may be so that it comprises pores and/or channels 
of predefined dimensions through the thickness of the component. 
 
The pores and/or channels may be of varying dimensions through the thickness of the 
component. The dimensions may e.g. vary from an outer surface of the component 
towards an inner region. Such a structure may e.g. find use within tissue engineering for 
the manufacturing of artificial organs. A graded structure in the form of a decreasing 
diameter of the channels towards the middle of the component can resemble the veins, 
arteries and/or blood vessels in a natural organ and be used to ensure that oxygen can be 
transported to and from a central region. It will also be possible to have one substantial-
ly constant value of a characteristic parameter, such as the average diameter, at some 
regions, such as near the surface, and another substantially constant value of the charac-
teristic parameter at other regions, such as at the middle of the component. 
 
In some embodiments of the invention the sacrificial material may be arranged by use of 
3D-printing. 3D-printing is at present a quickly developing technology which can be 
used to precisely manufacture highly specialized structures. The obtainable dimensions 
and precision will depend on the 3D-printing technology used. At present it is in the 
order of micrometres and upwards. Hereby complex geometries of what are to become 
the network of porous and channels can be made in an easily controllable manner. In 
principle any printable and dissolvable material can be used; some examples will be 
mentioned below. The choice will depend both on the application of the final compo-
nent and on the manufacturing method used. 
 
By use of 3D-printing it is possible to make components in a wide range of dimensions. 
This technology is highly advantageous over the presently used methods as it is rapid 
and flexible with respect to both sizes and materials used. A further advantage is that the 
process can easily be automated. 
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In some embodiments of the invention, the sacrificial material and the component 
material are arranged concurrently by a use of 3D-printing. Hereby complex geometries 
can be built including some where part of the material for the final component needs to 
be supported by the sacrificial material during manufacturing until it is in a stable and 
self-supporting form.  
 
In the embodiments of the invention including the use of 3D-printing, fused deposition 
technology may be used.  
 
In the method as described above, two or more sacrificial materials may be arranged at 
different regions of the component being manufactured, the two or more sacrificial 
materials being dissolvable by use of different solvents, the method further comprising 
the step of sequentially dissolving and removing the two or more sacrificial materials 
from the component material. Hereby it will be possible to form more complex inner 
structures or outer geometries of the component.  
 
The method may further comprise a subsequent step of pyrolyzing the component 
provided that a material which can be pyrolyzed is used. Examples of materials with 
which this step is possible are polymers such as polydimethyl siloxane (PDMS), poly-
styrene, block copolymers and different photo-curable carbon containing polymers. The 
pyrolyzed scaffold is a hard material which is suitable as a scaffold material for tissue 
engineering tissues, such as bone.  
 
The component may be pyrolyzed so that an electrically conductive component is 
obtained. Such a component may e.g. be used for scaffolds for tissue engineering so that 
the conductivity allows the monitoring of cell growth and the potential for stimulating 
cells by electrical methods. Parameters that are relevant to control during the pyrolysis 
process are the temperature ramping speed, maximum temperature, time and combina-
tion of gases. 
For some applications of the invention, an alternative to using 3D-printing for the 
manufacturing will be a method in which the sacrificial material is arranged manually 
with respect to a template adapted to assist in holding the filaments in a desired ar-
rangement during manufacturing of the component. Such a manual arrangement of the 
sacrificial material may e.g. be winding of one or more filaments around the template. 
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The filaments may e.g. be made by 3D-printing or by extrusion. This method can e.g. be 
used for the manufacturing of microfluidic lab-on–a-chip as will be shown in relation to 
the figures. With this method it is possible to make any type of geometrical features, 
such as channels with a circular cross section, which are difficult to make with other 
methods, including 3D-printing. The cross sectional dimensions of such filaments are 
typically in the micrometre range and upwards. 
 
The sacrificial material may be made from any polymer which is dissolvable in water or 
another suitable solvent which does not damage the component material. It may e.g. be 
made from poly(vinyl alcohol), PVA, which is soluble in water or from wax. Other 
examples are acrylonitrile butadiene styrene (ABS) which is soluble in acetone and 
polylactic acid or polylactide (PLA). In the embodiments involving 3D-printing, the 
material chosen should be printable with the actual printer being used. 
 
The component material may be selected from the following group: collagen, gelatine, 
polyhema, SU8, polystyrene, or silicone elastomers, such as polydimethylsiloxane 
(PDMS). SU8 is a commonly used epoxy-based negative photoresist which is found 
suitable for the present invention.  It is in principle possible to use any artificial or 
natural polymers provided that they are applicable for the precise manufacturing method 
used. Some of the embodiments of the invention relate to polymers which can be cured, 
e.g. under the influence of light, to form a cross-linked material. Other embodiments 
relate to thermoplastic polymers which are heated to become liquid before being mould-
ed around the sacrificial material and then cooled to solidify, preferably before the 
sacrificial material is removed. Gelatine is an example of a polymer which can be used 
both with and without the crosslink-forming curing step. The choice of component is 
highly dependent on the application of the component being manufactured. E.g. it is 
important for some applications that the component material is biocompatible, whereas 
for other applications it is necessary to use a material which can be pyrolyzed.  
 
In a second aspect the invention relates to a polymer component obtained by a method 
as described above. Such a component may find use in a number of applications as will 
be described in further details below. 
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In a third aspect the invention relates to the use of a component manufactured as de-
scribed above as a three-dimensional scaffold for tissue engineering. An example of 
such a use relates to the ability to fabricate a 3D tissue engineering scaffold including 
domains (the porous regions) for culturing effector cells such as hepatocytes and 
providing artificial veins, arteries and/or blood vessels (structured part) feeding these 
domains.  
 
In a fourth aspect the invention relates to the use of a component manufactured as 
described above as a medical device. Such medical devics could e.g. be artificial organs 
and tissues as well as lab-on-a-chip systems. This fourth aspect of the invention also 
relates to a medical device comprising a polymer component as described above or to a 
component manufactured as described above for use as a medical device.  
A fifth aspect of the invention is the application of these structures for cultivating a high 
cell density. This can be used for expanding different cell types or production of e.g. 
recombinant proteins. 
The first, second, third, fourth and fifth aspect of the present invention may each be 
combined with any of the other aspects. These and other aspects of the invention will be 
apparent from and elucidated with reference to the embodiments described hereinafter. 
BRIEF DESCRIPTION OF THE FIGURES 
The method according to the invention will now be described in more detail with regard 
to the accompanying figures. The figures show one way of implementing the present 
invention and is not to be construed as being limiting to other possible embodiments 
falling within the scope of the attached claim set. 
Figure 1 shows schematically the overall steps in an embodiment of the invention used 
to manufacture a component with a substantially uniform inner structure throughout the 
component. 
Figure 2 shows schematically examples of structures with pores and channels, respec-
tively. 
Figure 3 shows schematically the differences between structured and random inner 
structures in a component. 
Figure 4 shows schematically the steps in a manufacturing method including a step of 
pyrolyzing the polymer component. 
Figure 5 shows SEM images of a pyrolyzed component.  
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Figure 6 shows schematically an embodiment of the invention in which the sacrificial 
material is arranged manually.  
DETAILED DESCRIPTION OF AN EMBODIMENT 
Figure 1 shows schematically the overall steps in an embodiment of the invention used 
to manufacture a porous polymer component 1 with a substantially uniform inner 
structure throughout the component 1. In this embodiment, the inner structure of the 
component 1 is controlled to have a predefined geometrical configuration with orderly 
arranged channels. Figure 1.a shows the dissolvable, sacrificial material 2 arranged in a 
geometrical arrangement corresponding to an inner structure to be obtained in the 
polymer component 1. The upper part of figure 1.a is a three-dimensional view, and the 
lower part if figure 1.a is a cross sectional view. Figure 1.b shows the component 
material 3 which has been arranged so that it surrounds a majority of the sacrificial 
material 2. Figure 1.c shows the final polymer component 1 after the sacrificial material 
2 has been dissolved and removed from the component material 3. An important part of 
the process is that the arrangement of the sacrificial material 2 and thereby the resulting 
inner structure of the cavities, including the pores and/or channels, in the component 1 
is done in a controlled and reproducible manner. How this can be done will be explained 
in further details below. Depending on the actual polymer material used, the method 
may further comprise the step of curing the component material 3 before the sacrificial 
material 2 is removed. This will e.g. be necessary in the case of polydimethyl siloxane 
(PDMS) as a component material 3. In the case of 3D-printing two or more different 
polymers such as PLA and ABS, the curing occurs in the same moment as the polymers 
are printed. 
Figure 2 shows schematically examples of structures with pores 4 and channels 5, 
respectively. The geometries and relative sizes of the pores 4 and channels 5 in figure 2 
are examples and given for illustrative purposes only. In a real component 1, e.g. the 
walls of the channels 5 may be rough, and the overall path of the channels 5 need not be 
along a straight line. The structure of the component 1 may be so that it comprises pores 
4 and/or channels 5 of predefined dimensions through the thickness of the component 1. 
The channels 5 may also be of varying dimensions through the thickness of a compo-
nent 1, such as from an outer surface of the component 1 towards an inner region of the 
component 1. 
Figure 3 shows schematically the differences between structured (shown to the left) and 
random (shown to the right) inner structures in a component 1. It will also be possible to 
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have regions with different structures in the component, such as structured regions with 
different cross sectional dimensions of the channels 5 or with different volume fractions 
of solid material. It will also be possible to have both random and structured regions in 
one component. 
At least for some geometries and/or combinations of materials it will be advantageous 
to 3D-print both the sacrificial material 2 and the component material 3 concurrently. 
Hereby the pores 4 or channels 5 in the geometrical arrangement of the sacrificial 
material 2 are filled with the component material 3 while the component 1 is being 
formed. A typically used 3D-printing method is fused deposition technology.  
A method as described above may further comprise a subsequent step of pyrolyzing the 
component 1. This method step can e.g. be used to obtain an electrically conductive 
component which may e.g. find use in tissue engineering and sensing applications. 
Figure 4 shows schematically the steps in a process as described above including the 
step of pyrolyzing the component. 1: A sacrificial material 2 is provided e.g. by 3D-
printing. 2: The sacrificial material 2 is placed in a container 6 with component material 
3. 3: Vacuum is applied, e.g. in a vacuum chamber 7, to ensure that the component 
material 3 infiltrates the sacrificial material 2. 4: The component material 3 is then 
cured in an oven 8 at raised temperature for a predetermined time period. 5: The sacrifi-
cial material 2 is dissolved by placing the cured intermediate component in a solvent 9 
for a predetermined time period or until the sacrificial material 2 has been dissolved and 
can be removed e.g. by washing (not shown). 6: The component 1 now being constitut-
ed by component material 3 can further be pyrolized to obtain the pyrolized final 
component 1 shown as number 7. Figure 5 shows SEM images of an example of such a 
pyrolized component at two different magnifications.  
An alternative to 3D-printing which will be possible for some application is to arrange 
the sacrificial material 2 manually. Such a method can e.g. be used to manufacture a 
microfluidic device without the need for cleanroom fabrication technologies. Another 
advantage over some known methods is the possibility to form completely cylindrical 
channels 5, e.g. from arrangement of filaments having a circular cross section. An 
example of a method wherein the sacrificial material 2 is arranged manually is shown 
schematically in figure 6. Figure 6.a shows a frame 10, also referred to as a template, 
which can e.g. be made by laser ablation of a 1 mm thick PC sheet. As shown in figure 
6.b, filaments of sacrificial material 2 are arranged around the template 10, and the 
grooves 11 along the edges of the template 10 assist in holding the filaments 2 in a 
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desired arrangement during manufacturing of the component 1. Such filaments 2 can 
e.g. be 400 µm thick PVA filaments pre-made e.g. by extrusion or by 3D-printing. A 
cast and partially cured layer 12 of e.g. PDMA is arranged in a mould 13 as shown in 
figure 6.c, and the frame 10 with the filaments 2 are placed on top thereof as shown in 
figure 6.d. An upper layer of PDMS (not visible in the figure) in then is cast on top 
thereof as shown in figure 6.e, and the whole arrangement is cured, typically by applica-
tion of heat or light depending of the type of material used. In this embodiment the 
component material 3 is constituted by the two layers 12 of PDMS and the template 10 
which becomes cast into the component 1. After curing of the component material 3, it 
is removed from the mould 13, and the sacrificial filament material 2 is dissolved e.g. 
by placing the component 1 in hot water (not shown). The component may also be cut 
to a final shape as shown in figure 6.f. 
Although the present invention has been described in connection with the specified 
embodiments, it should not be construed as being in any way limited to the presented 
examples. The scope of the present invention is set out by the accompanying claim set. 
In the context of the claims, the terms “comprising” or “comprises” do not exclude 
other possible elements or steps. Also, the mentioning of references such as “a” or “an” 
etc. should not be construed as excluding a plurality. The use of reference signs in the 
claims with respect to elements indicated in the figures shall also not be construed as 
limiting the scope of the invention. Furthermore, individual features mentioned in 
different claims, may possibly be advantageously combined, and the mentioning of 
these features in different claims does not exclude that a combination of features is not 
possible and advantageous.  
9.6 OUR CLAIMS 
1. Method of manufacturing a porous polymer component (1) with structured and/or 
random pores (4) and/or channels (5), the method comprising the steps of: 
arranging a dissolvable, sacrificial material (2) in a geometrical arrangement corre-
sponding to an inner structure to be obtained in the polymer component (1),  
arranging a component material (3) so that it surrounds at least a majority of the sacrifi-
cial material (2), and 
dissolving and removing the sacrificial material (2) from the component material (3), 
wherein the step of arranging the sacrificial material (2) and thereby the resulting inner 
structure of the component (1) is done in a controlled and reproducible manner. 
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2. Method according to claim 1, further comprising the step of curing the component 
material (3) before the sacrificial material (2) is removed. 
3. Method according to claim 1 or 2, wherein the inner structure of the component (1) is 
controlled to be random.  
4. Method according to claim 1 or 2, wherein the inner structure of the component (1) is 
controlled to have a predefined geometrical configuration with orderly arranged pores 
(4) and/or channels (5). 
5. Method according to claim 4, wherein the inner structure of the component (1) is so 
that it comprises pores (4) and/or channels (5) of predefined dimensions through the 
thickness of the component (1). 
6. Method according to claim 5, wherein the pores (4) and/or channels (5) are of varying 
dimensions through the thickness of the component (1). 
7. Method according to any of the preceding claims, wherein the sacrificial material (2) 
is arranged by use of 3D-printing. 
8. Method according to claim 7, wherein both the sacrificial material (2) and the com-
ponent material (3) are arranged concurrently by a use of 3D-printing. 
9. Method according to claim 7 or 8, wherein fused deposition technology is used. 
10. Method according to any of the preceding claims, wherein two or more sacrificial 
materials (2) arranged at different regions of the component (1) being manufactured, the 
two or more sacrificial materials (2) being dissolvable by use of different solvents (9), 
the method further comprising the step of sequentially dissolving and removing the two 
or more sacrificial materials (2) from the component material (3). 
11. Method according to any of the preceding claims, further comprising a subsequent 
step of pyrolyzing the component (1). 
12. Method according to claim 11, wherein the component (1) is pyrolyzed so that an 
electrically conductive component is obtained. 
13. Method according to claim 1, wherein the sacrificial material (2) is arranged manu-
ally with respect to a template (10) adapted to assist in holding the sacrificial material 
(2) in the form of filaments in a desired arrangement during manufacturing of the 
component (1). 
14. Use of a component (1) manufactured according to any of the preceding claims as a 
three-dimensional scaffold for tissue engineering. 
15. Use of a component (1) manufactured according to any of claims 1 to 13 as a 
medical device. 
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10.  Patent Application B: A METHOD FOR 
FABRICATING A THREE-DIMENSIONAL 
CARBON STRUCTURE. 
Authors: Soumyaranjan Mohanty, Jenny Emnéus, Anders Wolff, Arto Heiskanen. 
 
Filed on: 28 August 2015. 
Application number/Patent number: 15182928.0 - 1355 
 
10.1 Abstract 
A method for fabricating a three-dimensional carbon structure (4) is disclosed. A mould 
(1) defining a three-dimensional shape is provided, and natural protein containing fibres 
are packed in the mould (1) at a predetermined density. The packed natural protein 
containing fibre structure (3) is removed from the mould (1), and undergoes pyrolysis. 
Thereby a three-dimensional porous and electrically conducting carbon structure (4) 
having a three-dimensional shape defined by the three-dimensional shape of the mould 
(1) and a porosity defined by the density of the packed natural protein containing fibre 
structure (3) is obtained. The carbon structure (4) is well suited for use as a scaffold for 
tissue engineering, or for material for batteries, fuel cells, supercapacitors, sorbents for 
separation processes, gas storage, supports for many important catalysts, etc. 
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10.2 Field of the invention 
The present invention relates to a method for fabricating a three-dimensional carbon 
structure, e.g. for use as a scaffold for tissue engineering, as electrode materials for 
batteries, fuel cells and supercapacitors, as sorbents for separation processes and gas 
storage, as supporters for many important catalysts, etc. When applying the method of 
the invention the micro-porosity of the resulting three-dimensional carbon structure can 
be controlled, and any desired three-dimensional shape of the structure can be obtained. 
Furthermore, the carbon fibres of the three-dimensional carbon structure fabricated by 
means of the method of the invention contain nitrogen, thereby making the structure 
suitable for a wide range of applications. 
10.3 Background of the invention 
For some purposes, such as tissue engineering, electrode materials for batteries, fuel 
cells and supercapacitors, sorbents for separation processes and gas storage, supports for 
many important catalysts, etc., there is a need for conductive porous scaffolds, made 
from a biocompatible material. It is, furthermore, desirable to be able to provide such 
scaffolds in various sizes and shapes, and with a scalable porosity. Finally, it is desira-
ble to be able to provide such scaffolds in an easy and cost effective manner. 
US 2008/0085648 A1 discloses a method of producing an electric conductive material 
by spirally winding a yarn composed of organic fibres on a core member. The core 
member is removed, and the yarn is carbonized. 
US 2012/0125071 A1 discloses carbon moulds for use in the fabrication of bulk metal-
lic glass parts and moulds. A master shape is patterned into a pyrolyzable material, and 
the master shape is pyrolyzed into a carbon mould. 
10.4 Description of the invention 
It is an object of embodiments of the invention to provide a method for fabricating a 
three-dimensional carbon structure in an easy and cost effective manner. 
It is a further object of embodiments of the invention to provide a method for fabricat-
ing a three-dimensional carbon structure in which the porosity of the structure can be 
controlled. 
The invention provides a method for fabricating a three-dimensional carbon structure, 
the method comprising the steps of: providing a mould defining a three-dimensional 
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shape, packing natural protein containing fibres in the mould at a predetermined density, 
thereby obtaining a packed natural protein containing fibre structure, removing the 
packed natural protein containing fibre structure from the mould, performing pyrolysis 
on the packed natural protein containing fibre structure, thereby obtaining a three-
dimensional porous and electrically conducting carbon structure having a three-
dimensional shape defined by the three-dimensional shape of the mould and a porosity 
defined by the density of the packed natural protein containing fibre structure. 
 
In the present context the term ‘three-dimensional carbon structure’ should be interpret-
ed to mean a structure which has a three-dimensional shape, and which contains carbon 
material. 
According to the method of the invention, a mould defining a three-dimensional shape 
is initially provided. The three-dimensional shape of the mould corresponds to a desired 
three-dimensional shape of the carbon structure, which is fabricated by means of the 
method. Thus, any desired shape or size of the resulting three-dimensional carbon 
structure can be obtained, simply by providing an appropriate mould, defining a corre-
sponding three-dimensional shape. 
Next, natural protein containing fibres are packed into the mould at a predetermined 
density. Thereby a structure is obtained, which comprises or consist of packed natural 
protein containing fibres, i.e. a packed natural protein containing fibre structure. Since 
the packed natural protein containing fibre structure has been obtained by packing 
protein containing fibres into the mould, the packed natural protein containing fibre 
structure has a size and a shape which corresponds to the size and shape of the mould. 
Furthermore, the density of the packed natural fibre containing structure can be con-
trolled by controlling the packing process to obtain a predetermined density. 
Then the packed natural protein containing fibre structure is removed from the mould. 
The removed structure maintains its size, shape and density, but is no longer contained 
in the mould, and is therefore ready for further processing. 
Finally, pyrolysis is performed on the packed natural protein containing fibre structure. 
Since the structure comprises protein containing fibres, the structure also comprises 
carbon. Accordingly, as a result of the pyrolysis, a porous and electrically conducting 
carbon structure is obtained. Furthermore, since the carbon structure is formed by 
performing pyrolysis on the packed natural protein containing fibre structure, the carbon 
structure has a three-dimensional shape which corresponds to the three-dimensional 
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shape of the packed natural protein containing fibre structure, and thereby to the three-
dimensional shape defined by the mould. Furthermore, the pyrolysis process results in 
nitrogen containing carbon fibres being generated, since the pyrolysis process produces 
nitrogen doped carbon. This is an advantage, because this has turned out to be important 
for catalysing hydrogen evolution and for cell adhesion for, e.g., tissue engineering and 
microbial biofilm formation. 
Furthermore, the porosity of the carbon structure is defined by the density of the packed 
natural protein containing fibre structure. Since the density of the packed natural protein 
containing fibre structure is controlled during the packing process, as described above, a 
desired porosity of the resulting porous and electrically conducting carbon structure can 
be obtained by carefully selecting a predetermined density of the packed natural protein 
containing fibres, and controlling the packing process to obtain the predetermined 
density. Furthermore, the surface area of the resulting carbon structure depends on the 
porosity of the structure. Accordingly, the surface area of the resulting carbon structure 
is controllable and scalable, and, for instance, a structure with a very high surface area 
can be obtained. 
Thus, the method according to the invention results in the fabrication of a three-
dimensional porous and electrically conducting carbon structure, having a desired and 
appropriate three-dimensional shape, and having a desired and appropriate porosity. The 
three-dimensional shape and the porosity of the carbon structure can be designed to 
meet any specific requirement, simply by designing the mould in an appropriate man-
ner, and by controlling the packing process in an appropriate manner. Accordingly, the 
method of the invention provides an easy and cost effective manner of fabricating a 
three-dimensional carbon structure having a desired three-dimensional shape and 
porosity. This makes the resulting carbon structure suitable for use as a porous carbon 
scaffold for tissue engineering, or as a porous carbon material for batteries, fuel cells, 
supercapacitors, sorbents for separation processes or gas storage, supports for many 
important catalysts, etc. 
The natural protein containing fibres may be silk fibres, and the method may further 
comprise the step of extracting the silk fibres from raw silk cocoons. Raw silk cocoons 
are readily available at reasonable costs. Therefore this embodiment provides suitable 
natural protein containing fibres in an easy and cost effective manner. Furthermore, 
pyrolysed single silk fibres have nanoporous structure, which increases the surfaced 
area of the bulk material. Thus, the method according to this embodiment of the inven-
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tion makes it possible to control the macroporosity of structures composed of multiple 
pyrolysed silk fibres. 
As an alternative, the natural protein containing fibres may be of any other suitable 
kind, including, but not limited to, spider silk, fibrin and sicrine. 
The step of packing natural protein containing fibres may further comprise packing the 
natural protein containing fibres in the mould in a predetermined pattern, and the 
porosity of the three-dimensional porous, electrically conducting carbon structure may 
further be defined by the pattern of the packed natural protein containing fibre structure. 
According to this embodiment, porosity of the resulting three-dimensional porous, 
electrically conducting carbon structure depends on the density as well as on the pattern, 
with which the natural protein containing fibres are packed. 
According to this embodiment, a three-dimensional, conductive structure, with a high 
surface area and with macro-, micro- and nanoporosity is provided. Furthermore, clean 
room facilities are not required in order to perform the method, thereby providing a very 
cost effective process. Finally, the use of protein containing fibres inherently provides 
the possibility of tuning the nitrogen content of the resulting carbon structure. 
The method may further comprise the step of using the three-dimensional porous, 
electrically conducting carbon structure as a scaffold for tissue engineering. As an 
alternative, the three-dimensional porous, electrically conducting carbon structure may 
be used for other purposes, such as for electrode materials for batteries, fuel cells and 
supercapacitors, sorbents for separation processes and gas storage, supports for many 
important catalysts, etc. 
Since the three-dimensional carbon structure resulting from the method of the invention 
is produced on the basis of natural protein containing fibres, it is biocompatible. This 
makes the three-dimensional carbon structure suitable for use for tissue engineering 
purposes. Furthermore, since the three-dimensional structure is a carbon structure, the 
structure is electrically conducting, making it further suitable for tissue engineering 
purposes, such as neuronal and cardiac tissue engineering purposes. Finally, the control-
lable size, shape and porosity of the three-dimensional structure allows the three-
dimensional structure to be designed to exactly match a required application, such as to 
exactly match a part which it is desired to provide by means of tissue engineering, 
thereby making the three-dimensional structure even further suitable for tissue engineer-
ing purposes. In summary, according to this embodiment of the invention, a suitable 
scaffold for tissue engineering is provided in an easy and cost effective manner. 
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Using the structure for other purposes than tissue engineering, the method of the inven-
tion provides suitable porous carbon structures which can be produced in an easy and 
cost effective manner, e.g. for applications such as batteries, fuel cells, supercapacitors, 
sorbents for separation processes and gas storage, supports for catalysts, etc. 
The method may further comprise the step of using the three-dimensional porous, 
electrically conducting carbon structure as an actuator and/or as a sensor during the 
tissue engineering. This is possible due to the electrical conductivity of the three-
dimensional carbon structure. This is further relevant for applications within the field of 
microbial electrosynthesis or bioremediation. 
According to this embodiment, the structure facilitates direct monitoring of cellular 
behaviour in the tissue engineering scaffold, using electrical sensing. Furthermore, the 
structure facilitates electrical stimulation of cells that can differentiate into different 
tissue specific lineages, e.g. neurons, cardiac cells and osteoblasts. Furthermore, the 
structure provides electrical stimulation of microbes to intensify biofilm formation in 
the porous carbon structure and production of chemicals. The conductive porous carbon 
can be directly used as electrode material in biofuel cells. Finally, the inherent nitrogen 
content additionally improves cell adhesion in microbial biofilm formation and tissue 
engineering. 
The step of performing pyrolysis on the packed natural protein containing fibre structure 
may comprise positioning the packed natural carbon containing fibres in a furnace and 
reducing an oxygen level inside the furnace. This may, e.g., be obtained by supplying an 
inert gas, such as nitrogen, into the furnace. 
The step of performing pyrolysis may comprise increasing the temperature inside the 
furnace to approximately 1000C or above. 
The step of packing natural protein containing fibres may comprise the steps of: 
determining a desired weight of natural protein containing fibres to be contained in the 
resulting packed natural protein containing fibre structure, 
providing an amount of natural protein containing fibres corresponding to said desired 
weight, and 
packing the provided amount of natural protein containing fibres into the mould in such 
a manner that a volume defined by the mould is filled. 
According to this embodiment, the density of the packed natural protein containing fibre 
structure, and thereby the porosity of the resulting three-dimensional porous and electri-
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cally conducting carbon structure, is controlled by determining a desired weight of 
natural protein containing fibres to be arranged in the mould during the step of packing 
the natural protein containing fibres. Since the size and shape of the mould are known, 
the volume defined by the mould is also known, and thereby the total weight of the 
natural protein containing fibres being packed into the mould defines the density of the 
packed fibres. Accordingly, the desired weight of natural protein containing fibres is 
selected in such a way that the predetermined density is obtained. 
Next, an amount of natural protein containing fibres is provided, which corresponds to 
the determined desired weight, and the provided amount of natural protein containing 
fibres is packed into the mould, in such a manner that the volume defined by the mould 
is exactly filled by the fibres. Thereby it is ensured that the natural protein containing 
fibres are packed with exactly the predetermined density. 
Thus, according to this embodiment, the density of the packed natural protein contain-
ing fibres is controlled by controlling the total weight of the fibres being packed. This is 
very simple, and thereby it is easy to perform the method and obtain a desirable porosity 
of the resulting three-dimensional porous and electrically conducting carbon structure. 
The step of packing the natural protein containing fibres may further comprise the step 
of wetting the natural protein containing fibres prior to packing the natural protein 
containing fibres into the mould. Wetting the natural protein containing fibres will 
squeeze the fibres together, thereby allowing the fibres to fit more easily into the mould. 
The step of wetting the fibres may, e.g., be performed using water. The amount of liquid 
used for wetting the fibres depends on the amount of fibres to be packed. According to 
this embodiment, the method may further comprise the step of drying the packed fibres 
before performing pyrolysis on the packed natural protein containing fibre structure, e.g. 
by means of air drying or freeze drying. 
Alternatively or additionally, the method may further comprise the step of cutting the 
natural protein containing fibres before packing the fibres into the mould. The cutting 
may be performed using mechanical or chemical methods. According to this embodi-
ment, the size of the natural protein containing fibres is controlled, and the smaller, cut 
fibres fit more easily into the mould. 
The method may further comprise the step of suspending the natural protein containing 
fibres into solution, after cutting the fibres and before packing the fibres into the mould. 
The fibres solution may further be dried, e.g. by means of air drying or freeze drying, 
before performing the pyrolysis step. 
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10.5 Brief description of the drawings 
The invention will now be described in further detail with reference to the accompany-
ing drawings in which 
Figs. 1-4 illustrate a method according to a first embodiment of the invention, and 
Figs. 5-7 illustrate a method according to a second embodiment of the invention. 
detailed description of the drawings 
Figs. 1-4 illustrate a method according to a first embodiment of the invention. Fig. 1 is a 
perspective view of a mould 1 defining a volume 2 having a substantially cylindrical 
shape. 
In Fig. 2 natural protein containing fibres, e.g. in the form of silk fibres, have been 
packed into the volume 2 of the mould 1. The fibres form a packed natural protein 
containing fibre structure 3. The fibres have been packed in such a manner that the 
packed natural protein containing fibre structure 3 has a predetermined and desired 
density. This may, e.g., be obtained by providing a weight amount of fibres which will 
result in the desired density when the weight amount of fibres exactly fills the volume 2 
defined by the mould 1, and then packing these fibres into the volume 2 defined by the 
mould 1. 
In Fig. 3 the packed natural protein containing fibre structure 3 has been removed from 
the mould 1. It can be seen that the packed natural protein containing fibre structure 3 
maintains the size and shape defined by the mould 1, i.e. the structure 3 is cylindrical. 
Accordingly, the density of the packed natural protein containing fibre structure 3 is 
also maintained, even though the structure 3 is removed from the mould 1. 
In Fig. 4 pyrolysis has been performed on the packed natural protein containing fibre 
structure 3, and thereby a three-dimensional porous and electrically conducting carbon 
structure 4 has been obtained. The carbon structure 4 has the same shape and size as the 
packed natural protein containing fibre structure 3, i.e. the size and shape of the carbon 
structure 4 is determined by the size and shape of the volume 2 defined by the mould 1. 
Furthermore, the porosity of the carbon structure 4 is defined by the density of the 
packed natural protein containing fibre structure 3. 
Accordingly, performing the method illustrated in Figs. 1-4 results in a porous and 
electrically conducting carbon structure 4 with a porosity which can be adjusted by 
adjusting the density of the packed fibres. Furthermore, the carbon structure 4 can be 
given any desired size or shape, simply by providing a suitable mould 1 which defines a 
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volume 2 having the desired size and shape. Thus, an electrically conducting carbon 
structure 4 with a desired size, shape and porosity can be provided in a simple and cost 
effective manner. Such a carbon structure 4 is well suited for use as a carbon scaffold 
for tissue engineering, or for material for batteries, fuel cells, supercapacitors, sorbents 
for separation processes, gas storage, or supports for many important catalysts. 
It should be noted that, even though the mould 1 used when performing the method 
illustrated in Figs. 1-4 has a simple cylindrical shape, the method described above could 
be performed using a mould 1 defining a volume 2 having any desired size or shape. 
Figs. 5-7 illustrate a method according to a second embodiment of the invention. Fig. 5 
shows a mould 1 having eight through-going rods 5 arranged therein. The mould 1 
further defines a substantially box-shaped volume 2, which is traversed by the through-
going rods 5. 
In Fig. 6 natural protein containing fibres have been packed in the mould, thereby 
obtaining a packed natural protein containing fibre structure 3, essentially in the manner 
described above with reference to Figs. 1-4. Since the through-going rods 5 are arranged 
inside and extend through the volume 2 defined by the mould 1, the fibres are packed 
around the through-going rods 5. As a consequence, the through-going rods 5 are 
embedded in the resulting packed natural protein containing fibre structure 3. 
Furthermore, in Fig. 6, the packed natural protein containing fibre structure 3 and the 
through-going rods 5 have been removed from the mould 1. 
In Fig. 7 the through-going rods 5 have been removed from the packed natural protein 
containing fibre structure 3, thereby leaving eight through-going channels 6 in the 
packed natural protein containing fibre structure 3. This may, e.g., be obtained by 
removing the through-going rods 6 in a mechanical manner, or by dissolving the 
through-going rods 5. 
Furthermore, in Fig. 7, pyrolysis has been performed on the packed natural protein 
containing fibre structure 3, and thereby a three-dimensional porous and electrically 
conducting carbon structure 4 has been obtained. As described above with reference to 
Figs. 1-4, the carbon structure 4 has a size and shape which is determined by the size 
and shape of the volume 2 defined by the mould 1, including the sizes, shapes and 
positions of the through-going rods 5, and a porosity which is defined by the density of 
the packed fibres. 
 
 199 
 
10.6 Our Claims 
1. A method for fabricating a three-dimensional carbon structure, the method compris-
ing the steps of: 
providing a mould defining a three-dimensional shape, 
packing natural protein containing fibres in the mould at a predetermined density, 
thereby obtaining a packed natural protein containing fibre structure, 
removing the packed natural protein containing fibre structure from the mould, 
performing pyrolysis on the packed natural protein containing fibre structure, thereby 
obtaining a three-dimensional porous and electrically conducting carbon structure 
having a three-dimensional shape defined by the three-dimensional shape of the mould 
and a porosity defined by the density of the packed natural protein containing fibre 
structure. 
2. A method according to claim 1, wherein the natural protein containing fibres are silk 
fibres, and wherein the method further comprises the step of extracting the silk fibres 
from raw silk cocoons. 
3. A method according to claim 1 or 2, wherein the step of packing natural protein 
containing fibres further comprises packing the natural protein containing fibres in the 
mould in a predetermined pattern, and wherein the porosity of the three-dimensional 
porous, electrically conducting carbon structure is further defined by the pattern of the 
packed natural protein containing fibre structure. 
4. A method according to any of the preceding claims, further comprising the step of 
using the three-dimensional porous, electrically conducting carbon structure as a 
scaffold for tissue engineering. 
5. A method according to claim 4, further comprising the step of using the three-
dimensional porous, electrically conducting carbon structure as an actuator and/or as a 
sensor for tissue engineering applications and microbial electrosynthesis or bioremedia-
tion. 
6. A method according to any of the preceding claims, wherein the step of performing 
pyrolysis on the packed natural protein containing fibre structure comprises positioning 
the packed natural carbon containing fibres in a furnace and reducing an oxygen level 
inside the furnace. 
7. A method according to any of the preceding claims, wherein the step of packing 
natural protein containing fibres comprises the steps of: 
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determining a desired weight of natural protein containing fibres to be contained in the 
resulting packed natural protein containing fibre structure, 
providing an amount of natural protein containing fibres corresponding to said desired 
weight, and 
packing the provided amount of natural protein containing fibres into the mould in such 
a manner that a volume defined by the mould is filled. 
8. A method according to claim 7, wherein the step of packing the natural protein 
containing fibres further comprises the step of wetting the natural protein containing 
fibres prior to packing the natural protein containing fibres into the mould. 
9. A method according to any of the preceding claims, further comprising the step of 
cutting the natural protein containing fibres before packing the fibres into the mould. 
10. A method according to claim 9, further comprising the step of suspending the 
natural protein containing fibres into solution, after cutting the fibres and before packing 
the fibres into the mould. 
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ABSTRACT 
We present a new scalable and general approach for manufacturing structured pores/channels in 
3D polymer based scaffolds. The method involves 3D printing of a sacrificial polyvinyl alcohol 
(PVA) mould whose geometrical features are designed according to the required vascular 
channel network. Polydimethylsiloxane (PDMS) polymer is cast around the PVA mould, cross-
linked and then the mould is dissolved, leaving behind a structured porous PDMS scaffold. The 
fabrication method described here is demonstrated with silicone elastomer but various other 
natural and synthetic polymers can also be compatible with this fabrication technique  
 
KEYWORDS: Scaffold, 3D printing, Bioreactor, Elastomeric 
 
INTRODUCTION 
In tissue engineering scaffolds play a major role to provide structural support for cell attachment 
and subsequent tissue development. For long-term culture, the scaffold material with attached 
cells has to be continuous perfused for supplying nutrient and oxygen as well as waste removal. 
It is therefore really crucial to design a proper porous scaffold with desired mechanical proper-
ties and with mass transport function to facilitate tissue regeneration
1
. 
Recently there has been a move towards employing 3D printing as a rapid prototyping technique 
to fabricate micro-scale porous structures of desired complexities, allowing a true engineering 
of the scaffold
2,3
. Processes combining 3D printing and moulding have already been used for 
making structured 3D scaffolds
3,4
. Different sacrificial printing materials such as wax
4
 and sugar 
glass lattice
3
 have been utilized to form vascular networks. However the use of wax limits the 
materials that can be cast around the mould to form the scaffold since polymers requiring higher 
temperatures for cross-linking cannot be employed and in case of sugar glass it is probably 
difficult to print large 3D structures as the sugar glass is very brittle, and the inter filament 
distance (defined by the printing process) is limited to a minimum distance of 1mm. It may 
therefore not be feasible to use this technique for creating dense vascular channels in large-scale 
structures for engineering large organs.  
In this contribution, we focus on developing a method of fabrication with the opportunity to 
control the physical, chemical and morphological characteristics of the porous scaffold material 
by indirect 3D printing of sacrificial polyvinyl alcohol (PVA)
5
.  
EXPERIMENTAL 
The method involves 3D printing of a PVA mould using a commercial 3D filament printer 
(Makerbot, USA)
5
. Geometrical features of the mould are designed according to the required 
vascular channel network. PDMS pre-polymer is cast around the PVA mould, cross-linked and 
then the mould is dissolved, leaving behind a structured porous PDMS scaffold. The fabrication 
method is shown schematically in Figure 1. (I). To render them hydrophilic, the scaffolds were 
modified with oxygen plasma using a 13.56 MHz RF generator equipped Atto Plasma System 
(Diener Electronic GmbH, Ebhausen, Germany). The plasma chamber was evacuated to a 
pressure below 15 Pa, after which oxygen was introduced (pressure stabilization at 30 Pa) and 
the plasma was ignited (power 50 W) for 2 min on each side of the scaffold.  
 
Human hepatoblastoma (HepG2) cells were obtained from the German Collection of Micro-
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organisms and Cell Cultures (DSMZ, Braunschweig, Germany). The cells were maintained in 
Roswell Park Memorial Institute (RPMI) 1640 growth medium supplemented with 10% foetal 
bovine serum (FBS, Sigma-Aldrich Chemie GmbH, Switzerland) and 100 μg/ml penicillin and 
10 μg/ml streptomycin in a humidified incubator at 37 °C and 5% CO2. Scaffolds were loaded 
with a suspension containing 250,000 cells in 20 μl of media according to the procedure 
described previously
5
 and incubated in a 24 well plate with 1 ml culture media in each well. 
Medium was refreshed every 2 days.  
RESULTS AND DISCUSSION 
Scaffolds were fabricated by casting PDMS around sacrificial moulds printed using two 
different infill patterns (fig.1.II) and four different infill densities to achieve different porosity 
(not shown here). Photographs and SEM images of the printed moulds and resulting PDMS 
scaffolds of the two different infill patterns are shown in Fig. 1.II. The high scalability of the 
method is demonstrated in Fig. 1.II (i & j) 
 
Figure 1: I) Schematic illustration of the steps involved in the fabrication of structured porous 
elastomeric scaffolds. A sacrificial 3D mould was printed in PVA (a, b). The printed PVA mould was 
transferred into a container containing pre-cured PDMS (c). Vacuum was applied to ensure complete 
filling of pre-cured PDMS into the pores of the mould (d). Following crosslinking of the PDMS, the 
sacrificial PVA mould was dissolved in water (e) leaving behind the structured PDMS scaffold (f). II) 
Photographs of moulds and scaffolds with hexagonal (a, e) and woodpile (b, f) infill patterns. SEM 
images of moulds and scaffolds with hexagonal (c, g) and woodpile (d, h) infill patterns. (i) optical image 
of a 50 layered (1 cm
3
 cube) and 150 layered (75 cm
3
 cube) 3D printed PVA mould (j) optical image of 50 
layered (1 cm
3
 cube) and 150 layered (75 cm
3
 cube) PDMS scaffolds replicated from the mould (i). Scale 
bar in (i) and (j): 1 cm 
5
.  
 
Figure 2: I) Measured porosity (a) and calculated surface to volume ratio (b) of scaffolds fabricated from 
mould with different infill density (standard deviation (n = 4)). II) Hepg2 cell morphology and attachment 
to PDMS scaffold using immunostaining (a & b) and SEM (c & e). Cell cytoskeleton beta tubulin (green) 
and nucleus (red). (a) Top surface of the scaffold. (b) Longitudinal cross section of the scaffold. Low- (c) 
and high- (d) magnified SEM images of HepG2 cells cultured on PDMS scaffolds for 4 days. Scale bar of 
image a) with 100 µm b) with 1 mm, C) with 50 µm  and d) 5 µm. III) Live/dead (green = live, red =dead) 
staining of HepG2 cells grown on top and bottom part of the PDMS scaffold for 4, 8 and 12 days. Scale 
bars represent 1 mm. 
Figure 2. I(a & b) shows physical characterization of the PDMS scaffolds. The experimentally 
determined porosity of the scaffolds varied linearly as a function of the infill density of the 
printed mould and the calculated surface areas of a 1 cm
3 
fabricated scaffolds of varying infill 
densities increases from 52.5 cm
2
/cm
3
 to 150.9 cm
2
/cm
3
. Live/dead staining of the HepG2 cell-
scaffold construct on day 12 of culture, showed a confluent layer of live cells on the scaffolds 
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and no dead cells were observed, throughout the culture period (Fig 2. III)). Immunostaining 
(fig 2. II a & b) and the SEM images (fig 2. II c & e) of the scaffold showing well-attached cell 
morphology with spread-out cell attachment onto the top as well in the centre of the scaffold 
surface. 
As a proof of concept a single scaffold integrated bioreactor was fabricated using a 40% 
porous/infilled PVA mould as shown in the figure 3. In short, after printing the mould was 
placed into a Petri dish and PDMS solution was poured into it, degassed and cured. The sacrifi-
cial PVA mould was dissolved from the cross-linked PDMS and a porous scaffold with an 
integrated reactor part was formed. The reactor was dried at 60 C overnight. The inlet and 
outlet of the reactor was punched vertically. For better visualization, the PDMS device has been 
subsequently bonded to a glass slide using O2-plasma activation. Before using the device was 
degassed and cleaned using 100% ethanol and finally cleaning with water. 
 
Figure 3. Schematics of fabrication of PDMS bioreactor with integrated scaffolds. A) 3D printed PVA 
mould using 3D filament printer. i) indicates the part designed for porous scaffolds and ii) indicated the 
design for bioreactor. The PVA mould was casted around uncured PDMS and cross-linked. The 
sacrificial PVA mould was dissolved and leaving behind the PDMS chamber with integrated porous 
scaffold (B). C) The integrated device was punched from its inlet and outlet and ready for bonding to a 
glass surface. D) Photograph of the 3D PDMS bioreactor with integrated scaffold boned to a glass slide 
(D) and for visualization red food dye loaded into it (E).  
CONCLUSION 
In this study, we have demonstrated a way for fabricating scaffolds and microfluidics chambers 
by indirect 3D printing of water dissolvable PVA, and the high scalability of the process is 
shown. Different designs of PDMS scaffolds with various porosities and surface areas were 
successfully fabricated and tested for in-vitro cell studies. High cellular viability and homoge-
neous cellular distribution across the scaffold was archived for such PDMS scaffolds. 
Furthermore, as we have demonstrated, the fabrication method can generate bioreactors with 
integrated porous scaffold materials from PDMS for perfusion. The fabrication method de-
scribed here is demonstrated with silicone elastomer but various other natural and synthetic 
polymers can also be compatible with this fabrication technique. In conclusion, the presented 
process is scalable, biocompatible, rapid, and inexpensive. 
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 This work presents the fabrication, characterization and testing of pyrolysed three-
dimensional (3D) porous carbon materials as potential novel 3D conducting scaffolds 
(3D-CS) for tissue engineering applications. 
 Due to the multifunctional nature, carbon nanomaterials are becoming increasingly 
attractive, offering numerous opportunities to design novel sensors, drug delivery systems 
and scaffolds for tissue engineering
1
. For tissue engineering, carbon nanotubes (CNT) 
have been used to mechanically stabilize commonly used “soft” scaffold materials such as 
hydrogels and fibrous scaffolds
2
. Moreover, electrically conductive hydrogel based 
scaffolds have been demonstrated using CNT composites of these otherwise 
nonconductive polymers, enabling electrical stimulation of e.g. neural stem cells, 
resulting in improved action potentials and differentiation into functional neural 
networks
3
. Very recently, graphene foam (GF) - a 3D porous carbon structure - has been 
suggested as a new promising conductive scaffold that may incorporate, in the same 
structure, topographical, chemical and electrical cues
4
. We have recently shown that it is 
possible to precisely pattern SU-8 photoresist into high aspect ratio sub-micron 3D pillar 
scaffold structures
5
 that can be pyrolysed into their corresponding electrochemically 
active 3D carbon pillar scaffold structures
6
 In this study, we will demonstrate how 
scalable both randomly and structurally controlled porous conducting 3D carbon scaffolds 
can be generated through the pyrolysis of correspondingly porous polymer scaffolds of 
various polymers and copolymers. The idea is here demonstrated for a randomly 
structured PDMS sponge generated from a sacrificial carbohydrate template
7
 (in this case 
a simple sugar cube). The biocompatibility of the 3D-CS was investigated and confirmed 
using live/dead cell imaging of cells grown on the scaffold for 3 days, and its potential 
suitability as an electrochemically active scaffold was demonstrated using electrochemical 
impedance spectroscopy (EIS).  
 The procedure for fabricating the 3D-CS from a sugar cube is shown in Fig. 1: (1) A 
randomly porous sugar cube was placed in a container, (2) pre-cured PDMS was poured 
into the container, which was (3) absorbed into the sugar cube by capillary forces in a 
vacuum desiccator for 1 hour. (4) The pre-cured PDMS was then cured in an oven at 80 
0
C for 2 hour. (5) The sacrificial sugar in the sugar cube was then dissolved in water 
overnight, whereby (6) a randomly porous PDMS sponge was obtained. (7) The porous 
PDMS sponge was thereafter pyrolyzed in a furnace at 900 
0
C for 60 min in N2 
atmosphere, resulting in a highly porous 3D-CS, as shown in Fig. 2. 
 Without any further modification, the 3D-CS was sterilized and used for culturing of 
endothelial cells (HUVEC), which were allowed to attach and grow for 3 days on and 
inside the 3D-CS. Fig. 3 depicts live/dead immunostaining  (Dapi) after 3 days of cell 
culturing, showing cytoskeleton (circle) and the nucleus (square), with no indication of 
dead cells, demonstrating that the support is biocompatible even without the normally 
necessary modification with extra cellular matrix protein coating. The EIS spectra in Fig. 
4, clearly indicates that the 3D-SC has inherent electrical conductivity, indicating its 
potential use for electrical stimulation of cells and/or as a electrochemical sensing 
scaffold. 
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Figure 1. Fabrication of a conducting 
randomly porous carbon scaffold 
from a sugar cube. 
Figure 2. SEM images of the 
fabricated porous carbon scaffold. 
 
 
Figure 3. Live/dead cell imaging after 
3 days of HUVEC cell culturing on 
3D-CS. Circles - staining of cell 
cytoplasm. Squares staining the 
nucleus.  
Figure 4. Electrochemical impedance 
spectrum (Bode plot) obtained with 
the carbon scaffold material. 
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Background. The clinical need for functional replacement tissues and physiologically 
relevant drug screening models has fuelled research into engineering in-vitro tissues. In 
conventional 2D cell cultures, cells tend to lose key specific functions that they normally 
exhibit due to the absence of complex cell-cell, cell–matrix and cell factor interactions 
that are usually present in vivo [1]. There is therefore a move towards culturing cells in 
3D scaffolds that act as a substrate for cells to attach, proliferate and differentiate [2]. 
While cells in vivo are typically no further than 100 – 200 µm away from a blood 
capillary, enabling their nutrient requirements to be met through diffusion of the neces-
sary chemical species, the absence of functional vasculature in tissue engineered 
constructs poses a significant challenge when attempting to grow tissues of clinically 
relevant sizes [3]. Therefore, in order to cultivate tissues of clinically relevant sizes in 
vitro, an enhanced mechanism for transport of oxygen and nutrients is required with a 
growing trend of using porous scaffolds to guide cell assembly into 3D constructs for 
engineering different types of tissues such as liver [4]. Mass transport in such scaffolds 
can be enhanced by integrating them into perfusion bioreactors that enable continuous 
perfusion of media through the pores of the scaffold. 
 
Work to be presented. In this work, polymer scaffolds are fabricated using either photo- 
and colloidal lithographic nano/micro patterning or by a combination of 3D printing and 
polymer casting techniques (Figure 1) [5], in some cases followed by pyrolysis to generated 
conductive carbon scaffolds [6] (Figure 2). The scaffolds are optionally designed with: (a) 
Primary structured perfusable channel network that allows flow through the material 
enabling delivery of necessary nutrients and oxygen to the interior of the scaffolds. (b) 
Secondary more arbitrary random porous network that optionally can enclose a hydrogel 
phase with a “nearby” source of important cell factors, supporting the growth and differen-
tiation of cells. (c) Ability to conduct or sense electrical currents. The application of these 
scaffolds for the development of a bioartificial liver support system based on differentiation 
of induced pluripotent stem cells into functioning hepatocytes will be presented (Fig. 3), or 
for the differentiation of neural stem cells into dopaminergic neurons (Figure 2). Moreover, 
our work toward incorporating different electrode systems for monitoring biolectrochemical 
(by bioimpedance [7] (Fig. 3) and voltammetry [5]) signals generated by cells residing on 
3D scaffolds will also be presented. 
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Figure 1. Examples of different types of polymer elastomer scaffolds incorporating 
both primary structured and secondary random porous channels. 
  
Figure 2. SEM image of 
differentiated neural stem cell on 
pyrolysed SU8 derived carbon 
nanopillars patterned by 
colloidal lithography. 
Figure 3. 8-channel perfusion based bioartificial 
liver support system for bioimpedance 
monitoring of stem cell growth and 
differentiation. Inserts: Enlargement of a single 
bioreactor in the array with two needle electrodes 
incorporated and a photo of polymer scaffolds 
that can be introduced into the bioreactor. 
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